Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001
Acerta Pharma Confidential Page 1 of 84PROTOCOL
TITLE: An Open-label, Phase 1b Study of ACP-196 i n Subjects 
withMultiple Myeloma
PROTOCOL NUMBER: ACE-MY-001
STUDY DRUG: ACP-196 (acalabrutinib)
IND NUMBER: [ADDRESS_608919] NUMBER 2014 -003587-21
SPONSOR MEDICAL 
MONITOR: Acerta Pharma BV
SPONSOR: Acerta Pharma BV
Kloosterstraat 9
5349 AB OssThe Netherlands
PROTOCOL DATE: Version 0.0 - 11 July 2014
AMENDMENT 1 DATE: Version 1.0 - 20 March 2015
AMENDMENT 2 DATE: Version 2.[ADDRESS_608920] (IRB)/independ ent ethics committee (IEC). This information 
cannot be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of Acerta Pharma BV.
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608921] positive for latent hepatitis B infection at screening (or who have a known history of hepatitis B infection), this protocol will now require monthly monitoring 
for potential hepatitis B reactivation.  The reason for this amendment is hepatitis B 
reactivation has occurred in patients treated with Btk inhibitors including [ADDRESS_608922] receiving ACP-196 (Ngoma 2015). 
Clarifying edits and typographical changes hav e been made throughout the protocol. In 
addition, the following substantive changes were made as part of this amendment:  
Change Rationale 
In various parts of the protocol, the 
nonproprietary name [CONTACT_475242] -196 was 
introduced. The nonproprietary na me of acalabrutinib 
was recently approved for use.  
Title Page 
 
Sponsor address changed from:  
 
Molenst raat 110 
5342 CC Oss  
The Netherlands  
 
to new address of:  
 
Kloosterstraat [ADDRESS_608923] changes made 
throughout the protocol. To ensure consistency between the body 
of the protocol and the  synopsis. 
Section 3.4.2 Exclusion Criteria 
Revised text as follows ( bold is new 
text):  
11. Known history of human 
immunodeficiency virus (HIV), 
serologic status reflecting active hepatitis B or C infection, or any 
uncontrolled active sy stemic infection.  
Subjects with hepatitis B core 
antibody positive who are surface 
antigen negative or  who are hepatitis 
C antibody positive wi ll need to have a 
negative polymerase chain reaction As hepatitis B virus (HBV) reactivation 
has occurred in [ADDRESS_608924]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 4 of 84 
 Change Rationale 
(PCR) result before enrollment.  Those 
who are hepatitis B surface antigen positive or hepatitis B PCR positive 
and those who are hepatitis C PCR 
positive will be excluded.
 Known 
history of human immunodeficiency virus 
(HIV) or active infe ction with hepatitis C 
virus (HCV) or hepatitis B virus (HBV) or 
any uncontrolled active syste mic 
infection.  
 
 
  
Section 3.7.2 Hepatitis B Virus 
Reactivation  
New section and corresponding language 
was added:  
 
Serious or life -threatening reactivation 
of viral hepatitis may  occur in subjects 
treated with ACP -196.  Therefore, 
subjects who are hepatitis B core 
antibody (anti- HBc) positive, or have a 
known history of hepatitis B virus 
(HBV) infection, should be monitored 
monthly with a quantitative PCR test 
for HBV DNA.  Monthly monitoring should continue unti l [ADDRESS_608925] 
with a rising viral load (above lower 
limit of detection) should discontinue 
ACP -[ADDRESS_608926] 
regar
ding the safety of resuming 
ACP -196 i n subjects who develop HBV 
reactivation.    
 
Section 4.1.16  Hepatitis B and C 
Testing  
New section and corresponding language was added:
 
 
Hepatitis serology testing must 
include hepatitis B surface antigen 
(HBsAg), hepatitis B surface antibody 
(HBsAb), anti -HBc, and hepatitis C 
(HCV) antibody.  Since intravenous 
immunoglobulins (IVIG) may cause 
false positive hepatitis serology, 
subjects who are receiving 
prophylactic IVIG and have positive As HBV reactivation has occurred in 
[ADDRESS_608927]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608928] PCR testing (see 
Appendix 5  and exclusion crit erion 
#11).  Testing will be done by [CONTACT_169617].  
 
Refer  to Section 3.7.[ADDRESS_608929]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 6 of 84 
 TABLE OF CONTENTS 
1.0 BACKGROUND INFORMATION ................................................................ 19  
1.1 Role of Btk in Lymphoid Cancers ................................................................. 19  
1.2 Preclinical Studies ....................................................................................... 20  
1.2.1  Chemistry ....................................................................................... 20  
1.2.2  Efficacy Pharmacology ................................................................... 21  
1.2.3  ACP-196 and Thrombus Formation ................................................ 22  
1.2.4  Safety Pharmacology ..................................................................... 23  
1.2.5  Drug-drug Interaction Potential....................................................... 24  
1.2.6  In Vivo General Toxicology ............................................................ 25  
1.3 Clinical Experience ...................................................................................... 25  
1.3.1  Pharmacokinetics and Pharmacodynamics of ACP-196 in Healthy 
Volunteers ...................................................................................... 27  
1.3.2  Clinical Experience of ACP-196 in CLL .......................................... 29  
1.4 Benefit/Risk .................................................................................................. 33  
1.5 Summary and Conclusions .......................................................................... 33  
2.0 STUDY OBJECTIVES ................................................................................. 34  
2.1 Primary Objective ........................................................................................ 34  
2.2 Secondary Objectives: ................................................................................. 34  
3.0 STUDY DESIGN .......................................................................................... 34  
3.1 Description of Study ..................................................................................... 34  
3.2 Study Parameters ........................................................................................ 35  
3.2.1  Safety Parameters .......................................................................... 35  
3.2.2  Efficacy Parameters ....................................................................... 35  
3.2.3  Pharmacokinetic and Pharmacodynamic Parameters .................... 36  
3.3 Rationale for Study Design and Dosing Regimen ........................................ 36  
3.4 Selection of Study Population ...................................................................... 37  
3.4.1  Inclusion Criteria ............................................................................. 37  
3.4.2  Exclusion Criteria ........................................................................... 37  
3.4.3  Replacement of Subjects ............................................................... 39  
3.4.4  Enrollment and Randomization Procedures ................................... 39  
3.5 Study Drug ................................................................................................... 39  
3.5.1  Premedications ............................................................................... 39  
3.5.2  Formulation, Packaging, and Storage ............................................ 40  
[IP_ADDRESS]  ACP-196  .................................................................................... 40  
[IP_ADDRESS]  Dexamethasone  ....................................................................... [ADDRESS_608930]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 7 of 84 
 [IP_ADDRESS]  ACP-196  .................................................................................... 40  
[IP_ADDRESS]  Dexamethasone  ....................................................................... [ADDRESS_608931] Compliance......................................................... 41  
3.5.5  Study Treatment Regimen and Dose Modifications ....................... 42  
[IP_ADDRESS]  ACP-196  .................................................................................... 42  
[IP_ADDRESS]  Dexamethasone  ....................................................................... 43  
3.6 Concomitant Therapy................................................................................... 43  
3.6.1  Permitted Concomitant Therapy ..................................................... 43  
3.6.2  Guideline for Use of CYP Inhibiting/Inducing Drugs ....................... [ADDRESS_608932] Gastric pH .......................... 43  
3.6.4  Prohibited Concomitant Therapy .................................................... 44  
3.7 Precautions .................................................................................................. 44  
3.7.1  Dietary Restrictions ........................................................................ 44  
3.7.2  Hepatitis B Virus Reactivation ........................................................ 44  
3.7.3  Surgery ........................................................................................... 45  
3.7.4  Infections ........................................................................................ 45  
3.7.5  Reproductive Toxicity ..................................................................... 45  
3.7.6  Overdose Instructions .................................................................... 45  
3.8 Stoppi[INVESTIGATOR_1869] ............................................................................................ 46  
3.9 Data and Safety Monitoring ......................................................................... 47  
4.0 STUDY ACTIVITIES AND ASSESSMENTS ............................................... 47  
4.1 Description of Procedures ............................................................................ 48  
4.1.1  Informed Consent ........................................................................... 48  
4.1.2  Medical History ............................................................................... 48  
4.1.3  Adverse Events .............................................................................. 48  
4.1.4  Concomitant Medications and Therapy .......................................... 48  
4.1.5  Confirmation of Eligibility ................................................................ 48  
4.1.6  ECOG Performance Status ............................................................ 48  
4.1.7  Physical Examination, Vital Signs, Height & Weight ....................... [ADDRESS_608933] ..................................................................... 49  
4.1.11  Hematology .................................................................................... 49  
4.1.12  Serum Chemistry ............................................................................ 49  
4.1.13  Urinalysis ........................................................................................ 50  
4.1.14  T/B/NK Cell Count .......................................................................... [ADDRESS_608934]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 8 of 84 
 4.1.18  Pharmacodynamics ........................................................................ 51  
4.1.19  Pharmacokinetics ........................................................................... 51  
4.1.20  Tumor Assessment ........................................................................ 51  
4.1.21  Study Drug Accountability .............................................................. 52  
4.2 Investigator’s Assessment of Response to Treatment  ................................. 52  
4.3 Early Termination/Safety Follow-up Visit ..................................................... 54  
4.4 Missed Evaluations ...................................................................................... 54  
5.0 STATISTICAL METHODS OF ANALYSIS .................................................. 55  
5.1 General Considerations ............................................................................... 55  
5.2 Sample Size Considerations ........................................................................ 55  
5.3 Definition of Analysis Populations ................................................................ 55  
5.4 Missing Data Handling ................................................................................. 55  
5.5 Endpoint Data Analysis ................................................................................ 56  
5.5.1  Safety Endpoint .............................................................................. 56  
5.5.2  Demographics and Baseline Characteristics .................................. 56  
5.5.3  Analysis of Efficacy Parameters ..................................................... 56  
[IP_ADDRESS]  Overall Response Rate  ........................................................... 56  
[IP_ADDRESS]  Duration of Response  ............................................................. 57  
[IP_ADDRESS]  Clinical Benefit Rate  ................................................................ 57  
[IP_ADDRESS]  Disease Control Rate  .............................................................. 57  
[IP_ADDRESS]  Progression-free Survival  ....................................................... 57  
5.5.4  Analysis of Pharmacokinetic/Pharmacodynamic Parameters ........ [ADDRESS_608935]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608936] Retention ......................................................................................... 67  
7.9 Protocol Amendments.................................................................................. 67  
7.10  Publication of Study Results ........................................................................ 68  
7.11  Clinical Trial Insurance................................................................................. 68  
7.12  General Investigator Re sponsibilities ........................................................... 68  
8.0 REFERENCES ............................................................................................ 70  
9.0 APPENDICES ............................................................................................. 72  
IN–TEXT TABLES 
Table 1-1.  Assessment of ACP- 196 Active-site Occupancy in  Fine Needle Aspi[INVESTIGATOR_475149] (N=4) .......................................................................21  
Table 1-2.  ACP-196 Clinical Stud ies as of Janu ary 2015  ..............................................26  
Table 1-3.  Btk Occupancy in Peripheral Bl ood of Subjects from ACE-CL-001 (December 
2014) .....................................................................................................................30  
Table 1-4.  Preliminary Day 8 PK Result s from ACE-CL-001 (October 2014) ................[ADDRESS_608937] Response by [CONTACT_475195]-CL-001  (23OCT2014) ........................31  
Table 3-1.  Drug Discontinuati on Actions for ACP-196 ..................................................42  
Table 4-1.  Pharmacokineti c Sample Schedule .............................................................51  
Table 4-2.  Response Criteria (derived from Rajkumar 2011 and Bladé 1998) ..............52  
 
IN–TEXT FIGURES 
Figure 1-1.  Effect of ACP-196 (1 μM) and Ibrutinib (1 μM) on Thrombus Formation .....23  
Figure 1-2.  Kaplan-Meier Curves for Progression-free Survival by [CONTACT_475196]-CL- 001 (N=75; excludes Richter’s Syndrome Co hort and 
Ibrutinib R/R Cohort) ..............................................................................................31  
Figure 1-3.  Median (95% CI) Change from Baseline in ALC/SPD Over Time ...............[ADDRESS_608938]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 10 of 84 
 ABBREVIATIONS 
 
ACP-196 acalabrutinib 
AE(s) adverse event(s) 
ALT alanine aminotransferase 
ANC absolute neutrophil count 
anti-HBc hepatitis B co re antibody 
AST aspartate aminotransferase 
AUC area under the curve 
BCR B-cell receptor 
BID twice a day (dosing) 
Btk Bruton tyrosine kinase 
BUN blood urea nitrogen 
CBC complete blood count 
CFR Code of Federal Regulations 
cGMP current Good Manufacturing Practices 
CLL chronic lymphocytic leukemia 
Cmax maximum concentration 
CR complete remission (response) 
CSSF Clinical Supplies Shippi[INVESTIGATOR_475150] P450 
DLBCL diffuse large B-cell lymphoma 
DLT dose-limiting toxicity 
ECG electrocardiogram 
ECOG Eastern Cooperative Oncology Group 
eCRF electronic case report form 
EGFR epi[INVESTIGATOR_475151]-in-human (trial) 
FLC (serum) free light chains 
GCP Good Clinical Practice 
GLP Good Laboratory Practices 
HBsAb hepatitis B surface antibody 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608939] 
IVIG intravenous immunoglobulins 
LDH lactate dehydrogenase 
MCL mantle cell lymphoma 
MedDRA Medical Dictionary for Regulatory Activities 
MM multiple myeloma 
MR minimal response 
NHL non-Hodgkin lymphoma 
NK natural killer (cells) 
ORR overall response rate 
PBMC(s) peripheral blood mononuclear cells 
PCR polymerase chain reaction 
PD pharmacodynamics 
PI3K phosphoinositide-3 kinase 
PK pharmacokinetics 
PR partial remission (response) 
QD once a day (dosing) 
QM every month 
QTc corrected QT interval 
SAE(s) serious adverse event(s) 
SD stable disease 
SFLC serum free light chains 
SIFE serum immunofixation electrophoresis 
SPD sum of the products of the perpendicular diameters (of lymph nodes) 
SPEP serum protein electrophoresis 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 12 of 84 
 S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction (report) 
Tmax time to maximum drug concentration 
UIFE urine immunofixation electrophoresis 
ULN upper limit of normal 
UPEP urine serum protein electrophoresis 
VGPR very good partial response  
WHO World Health Organization 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 13 of 84 
 STUDY SYNOPSIS  
Protocol Number: ACE-MY-001 
Study Drug:  ACP-196 (acalabrutinib) 
Protocol Title:  An Open-label, Phase 1b Study of  ACP-196 in Subjects with 
Multiple Myeloma  
Phase:  Phase 1 b 
Comp arator: None  
Background and 
Rationale for Study Clinical studies have shown that targeting the B -cell receptor 
(BCR) signaling pathway by [CONTACT_475197] (Btk) 
produces significant clinical benefit in patients with non -Hodgkin 
lymphoma ( NHL) and chronic lymphocytic leukemia (CLL). 
Preclinical studies have shown th at Btk inhibition significantly 
reduces in vivo multiple myeloma (MM) cell growth and MM cell-
induced osteolysis in a murine model (Tai 2012).  D ata on the 
utility of Btk targeted therapy in patients with MM is very 
preliminary, but suggests th ere are subsets of patients with 
malignant plasma cell clones  in which Btk is active as evidenced 
by [CONTACT_475198] (p -Btk), and that these 
cancers may be particularly responsive to Btk inhibitor therapy.  
Acerta Pharma BV (Acerta  Pharma ) has developed a novel second 
generation Btk inhibitor, ACP -196, that achieves significant oral 
bioavailability and potency in  preclinical models. ACP -196 
monotherapy  is currently in mult iple Phase 1/2 studies in subjects 
with chronic lymphocytic leukemia (CLL) and other indications .   
The purpose of this study is to evaluate the safety, 
pharmacokinetics (PK), pharmacodynamics (PD) , and activity of 
ACP-196 administration with and without dexamethasone in 
subjects with  relapsed MM.  The study will explore the concept of 
whether biomarkers may help identi fy patients with MM that are 
particularly likely to benefit from Btk inhibitor therapy.  
Study Design:  This study is a multicenter, open -label, randomized, parallel- group 
study  to be conducted at approximately 20 sites in 2 countries 
([LOCATION_008] and [LOCATION_002]) .  Forty subjects will be equally 
randomized (1:1 ratio) into 2 cohorts to receive ACP-196, with and 
without dexamethasone :  
x Cohort 1: ACP-196 100 mg twice per day (BID) continuously 
x Cohort 2: ACP-196 100 mg BID continuously and 
dexamethasone 40 mg once weekly  
Twenty -eight days of study drug ad ministration is 1 cycle.  
Treatment may be continued for > [ADDRESS_608940]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608941] ug-related toxicity occurs.  For 
subjects in Cohort 1, if docume nted disease progression occurs, 
then dexamethasone can be adde d to the treatment regimen.  
Additional dose modification prov isions are provided in the study 
protocol.  Note: temporary withholdin g of study drug for as little as 
7 days can cause a transient worsening of disease and/or of constitutional symptoms.  Refer to 
Section 3.[ADDRESS_608942] a safety follow -up 
visit 30 (±7) days after the last do se of study drug unless they have 
started another cancer therapy within that timeframe.  
All subjects will have hematology, chemistry, and urinalysis safety 
panels done at screening.  Once  dosing commences (Day 1), all 
subjects will be evaluated for safety, including serum chemistry 
and hematol ogy, once weekly for the first 4 weeks , every 2 weeks 
in Cycle 2  and monthly thereafter.  PK/PD tes ting will be  done in 
Cycle [ADDRESS_608943] on the study exits the study for any reason. 
Study Objectives: Primary Objective:  
x To characterize the safety profile of ACP-196 with and without 
dexamethasone in subjects with relapsed or refractory MM 
Secondary Objective s: 
x To characterize the PK profile of ACP-196 with and without 
dexamethasone and the PK profile of dexamethasone with 
concomitant ACP-196 administration 
x To evaluate the PD effects of ACP-196 with and without 
dexamethasone 
x To evaluate the activity of  ACP-196 with and without 
dexamethasone as measured by [CONTACT_34426], 
duration of response, clinical benefit rate, disease control rate, 
and progression-free survival 
x To explore the relationship between biological markers in MM 
cells and response to therapy 
Safety Parameters: Type, frequency, severity, timing of onset, duration, and 
relationship to study drug  (ie, ACP- 196, dexamethasone, or both) 
of any adverse events (AEs) or ab normalities of laboratory tests; 
serious adverse events (SAEs); or  AEs leading to discontinuation 
of study treatment.  
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 15 of 84 
 Efficacy Parameters: x Overall response rate (ORR) 
x Duration of response 
x Clinical benefit rate 
x Disease control rate 
x Progression-free survival 
Pharmacokinetic 
Parameters:  The plasma  PK of ACP-196 will be characterized using 
noncompartmental analysis. The following PK parameters will be 
calculated, whenever possible, from plasma concentrations of 
analytes : 
x AUC 0-t:  Area under the plasma concentration-time curve 
calculated using linear trape zoidal summation from time [ADDRESS_608944] measurable concentration 
(Ct). 
x AUC 0-12:  Area under the plasma concentration- time curve from 
0 to 12 hours, calculated using linear trapezoidal summation. 
x AUC 0-∞:  Area under the plasma concentration- time curve from 
0 to infinity, calculated using the formula: AUC 0-∞ = AUC 0-t + 
Ct / λz, where λz is the apparent terminal elimination rate 
constant. 
x AUC 0-24calc :  Area under the plasma concentration- time curve 
from 0 to 24 hours, calculated by [CONTACT_475199] 0-12. 
x Cmax:  Maximum observed plasma concentration 
x Tmax:  Time of the maximum plasma concentration (obtained 
without interpolation) 
x t½:  Terminal elimination half-life (whenever possible) 
x λz:  Terminal elimination rate constant (whenever possible) 
x CL/F:  Oral clearance 
Pharmacodynamic 
Parameters:  The occupancy of Btk by [CONTACT_408799]- 196 will be measured in peripheral 
blood mononuclear cells (PBMCs ) and in bone marrow, when 
available, with the aid of a biotin-t agged ACP-[ADDRESS_608945] of ACP -196 on biologic markers of B- cell function will 
also be evaluated.  
Sample Size:  Forty subjects with 20  subjects in each cohort. 
Inclusion Criteria: x Men and women ≥ 18 years of age . 
x A confirmed diagnosis of MM, which has relapsed after, or 
been refractory to ≥ [ADDRESS_608946] one of the following: 
o Serum M- protein ≥ 0.5 g/dL 
o Urine M- protein ≥ 200 mg/[ADDRESS_608947]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 16 of 84 
 o In subjects without detectab le serum or urine M-protein, 
serum free light chain (SFLC) > 100 mg/L (involved light 
chain) and an abnormal serum kappa/lambda ratio 
o For subjects who se disease can only be reliably measured 
by [CONTACT_346686] A (IgA), IgA 
≥ 750 mg/dL (0.75 g/dL)  
x Eastern Cooperative Oncology Group (ECOG) performance 
status of ≤ 2. 
x Agreement to use acceptable methods of contraception during 
the study and for [ADDRESS_608948] dose of study drug. 
x Willing and able to participate in all requ ired evaluations and 
procedures in this study protocol including swallowing capsules 
without difficulty. 
x Ability to understand the purpose and risks of the study and 
provide signed and dated inform ed consent and authorization 
to use protected health information (in accordance with 
national and loca l patient privacy regulations). 
Exclusion Criteria: x Plasma cell leukemia or circulating plasma cells ≥ 2 x 109/L 
x Prior malignancy, except for adequately treated basal cell or 
squamous cell skin cancer, in situ cervical cancer, or other 
cancer from which the subject has been disease free for 
≥ 2 years or which will not limit survival to < 2 years. Note: 
these cases must be discussed with the Medical Monitor. 
x A life-threatening illness, medical condition, or organ s ystem 
dysfunction which, in the investigator’s opi[INVESTIGATOR_1649], could 
compromise the subject’s safety, interfere with the absorption 
or metabolism of ACP- 196, or put the study outcomes at undue 
risk. 
x Significant cardiovascular disease such as uncontrolled or 
symptomatic arrhythmias, cong estive heart failure, or 
myocardial infarction within 6 months of screening, or any 
Class 3 or 4 cardiac disease as defined by [CONTACT_183959], or QTc > [ADDRESS_608949] dose of study drug is 
< 5 times the half- life of the previously administered agent(s). 
x  Prior exposure to a B-cell receptor (BCR) inhibitor (eg, Btk,  
phosphoinositide-3 kinase [PI3 K], or Syk inhibitors) or BCL- 2 
inhibitors (eg, ABT-199). 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 17 of 84 
 x Ongoing immunosuppressive therapy, including systemic or 
enteric corticosteroids for treatment of MM or other conditi ons. 
Note: Subjects may use topi[INVESTIGATOR_475152] . During study participation, 
subjects may receive systemic or enteric corticosteroids as 
needed for MM therapy or treatment-emergent comorbid 
conditions. 
x Grade ≥ 2 toxicity (other than alopecia ) continuing from prior 
anticancer therapy in cluding radiation. 
x Known history of human immu nodeficiency virus (HIV), 
serologic status reflecting active  hepatitis B or C infection, or 
any uncontrolled active systemic  infection.  Subjects with 
hepatitis B core anti body positive who are surface antigen 
negative or who are hepatitis C antibody positive  will need to 
have a negative polym erase chain reaction (PCR) result before 
enrollment.  Those who are hepatitis B surface antigen positive 
or hepatitis B PCR po sitive and those who are hepatitis C PCR 
positive will be excluded. 
x Major surgery within [ADDRESS_608950] dose of ACP-196. 
x Known history of a bleeding di athesis (eg, hemophilia, von 
Willebrand disease) 
x History of s troke or intracranial hemorrhage within [ADDRESS_608951] (eg, phenprocoumon) within 
[ADDRESS_608952] dose of study drug.  
x Requires treatment with long- acting proton pump inhibitors (eg, 
omeprazole, esomeprazole, lansoprazole, dexlansoprazole, 
rabeprazole, or pantoprazole) 
x ANC < 0.75 x 109/L or platelet count < 50 x 109/L.  For subjects 
with > 50% plasma cells in the marrow, ANC < 0.50 x 109/L or 
platelet count < 30 x 109/L. 
x Creatinine > 2.5 x institutional upper limit of n ormal (ULN); total 
bilirubin > 2.[ADDRESS_608953]; or aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) > 3.[ADDRESS_608954]. 
x Breastfeeding or pregnant. 
x Concurrent participation in anoth er therapeutic clinical trial. 
Dosage Form and 
Strength:  ACP-[ADDRESS_608955] phar maceutical grade excipi[INVESTIGATOR_840].  
Dose Regimen/Route 
of Administration: ACP-[ADDRESS_608956].  ACP-196 can be 
administered with or without food.  
Regimens:  
x Cohort 1 (BID): 100 mg ACP- 196 (1 x 100-mg capsule) 
administered 12 hours apar t (BID dosing = 200-mg total daily 
dose) 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 18 of 84 
 x Cohort 2 (BID + dexamethasone): 100 mg ACP-196 
(1 x 100-mg capsule) administered 12 hours apart (BID dosing 
= 200-mg total daily dose) plus 40 mg dexamethasone  
administered once weekly  (weekly dosing = 40- mg total weekly 
dose) 
Concomitant 
Medications:  The effect of agents that reduce gastric acidity (eg, proton pump 
inhibitor s, H2-receptor antagonists, or antacids) on ACP-196 
absorption is currently being eval uated in a healthy volunteer study 
(ACE -HV-004). Preliminary results from this study suggest 
subjects should avoid the use of calcium carbonate containing 
drugs or supple ments (eg, antacids or calcium supplements) and 
short -acting H2-receptor antagonist s for a period of at least 
2 hours before and after taking ACP- 196.  Use of omeprazole or 
esomeprazole or any other long -acting proton pump inhibitors 
while taking ACP -196 is not permitted due to a potential decrease 
in study drug exposure ; however, if a subject requires treatment 
with a long -acting proton pump inhibitor while on study (eg, to treat 
an ulcer), trea tment options should be discussed with the Medical 
Monitor . 
Concomitant use of strong inhibitors/inducers of CYP3A should be 
avoided when possible.  If a subject requires a strong CYP3A 
inhibitor while on study, monitor the subject closely for potential 
toxicities . 
Statistics:  Subjects meeting the stated eligibility  requirements will be enrolled 
onto the study. Subjects will be randomized  in a 1:1 ratio into the 
2 regimens (ACP-196 with and without dexamethasone).  With a 
sample size of [ADDRESS_608957] the 
difference between a null-hypot hesis response rate of 15 % and an 
alternative response rate of 40% with a 0.[ADDRESS_608958].  A 
sample size of 19 subjects per cohort will also provide a 97.5 % 
one-sided confidence interval cent ered around an expected ORR 
of 40% that excludes an ORR of 18.6% as a lower bound. 
Descriptive statistics (including means, standard deviations, and 
medians for continuous variable s and proportions for discrete 
variables) will be used to summarize data, as appropriate.   
 
 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 19 of 84 
 1.0 BACKGROUND INFORMATION 
1.1 ROLE OF BTK IN LYMPHOID CANCERS 
Bruton tyrosine kinase (Btk) is a non-recepto r enzyme of the Tec kinase family that is 
expressed among cells of hematopoietic origin , including B cells, myeloid cells, mast 
cells and platelets, where it regulates multiple cellular processes including proliferation, differentiation, apoptosis, and cell mi gration (Mohamed 2009, Bradshaw 2010). 
Functional null mutations of Btk in humans  cause the inherited disease, X-linked 
agammaglobulinemia, which is characterized by a lack of mature peripheral B cells 
(Vihinen 2000). Conversely, Btk activation is  implicated in the pathogenesis of several 
B-cell malignancies (Buggy 2012). Taken together, these findings have suggested that 
inhibition of Btk may offer an  attractive strategy for treating B-cell neoplasms.  
Ibrutinib (IMBRUVICA™), a first -generation oral, small-molecu le Btk inhibitor has been 
approved for the treatment for chronic lymp hocytic leukemia (CLL ) and mantle cell 
lymphoma (MCL) and is being evaluated for acti vity in other B-cell neoplasms including 
multiple myeloma (MM).  Preclinical studies have shown that Btk inhi bition with ibrutinib 
significantly reduces in vivo multiple myel oma (MM) cell growth and MM cell-induced 
osteolysis in a murine model (Tai 2012).   
While current therapi[INVESTIGATOR_475153] s ubstantial benefit to patients, MM remains 
incurable; for patients who experience disease relapse a fter application of existing 
therapi[INVESTIGATOR_014], the prognosis is dismal and new dr ugs and therapeutic strategies are required 
for continued disease control (Romano 2014).   Inhibition of Btk may simultaneously 
address the MM-related bone complications as well improve patient outcome in MM 
(Edwards 2012). 
While highly potent in inhibiting Btk, ibruti nib has also shown in vitro activity against 
other kinases with a cysteine in the same po sition as Cys481 in Btk to which the drug 
covalently binds.  The inhibition of epi[INVESTIGATOR_475154] (EGFR) is also 
observed in cellular assays and may be the cause of ibru tinib-related adverse events 
(AEs) of diarrhea and rash (IMBRUVICA® pack age insert). In addi tion, ibrutinib is a 
substrate for CYP3A4; inhibition of CYP3 A causes a 29-fold increase in maximum 
concentration (C
max) and 24-fold increase in area under the curve (AUC) for ibrutinib 
(IMBRUVICA® package insert).  This increases the possibility of drug-drug interactions 
in combination therapi[INVESTIGATOR_475155] y used in management of subjects with 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608959] 
led to identification of ACP-196  (also known as acalabrutinib) , an orally bioavailable, new 
chemical entity that covalently inhibits Btk and shows encouraging activity and acceptable safety in nonclinical studies. With in the class of Btk inhibitors, ACP-196 is a 
more selective inhibitor of Btk than ibrutini b.  Key nonclinical differentiators of ACP-196
versus ibrutinib are: 
xACP-[ADDRESS_608960] ibruti nib in EGFR expressing cell lines.  
Ibrutinib is a potent covalent inhibitor of EGFR (EC50 = 50 to 70 nM).  ACP-[ADDRESS_608961] concentration tested (10 μM).
xACP-[ADDRESS_608962] ibruti nib in in vitro antibody-dependent cell-
mediated cytotoxicity (ADCC) assays.  At physiologic concentrations, ibrutinib, 
but not ACP-196, reduced natural killer (NK) cell-mediated lysis of Raji and 
autologous CLL tumor cells and significantly inhibited rituximab-induced NK cell cytokine secretion (P<0.05).  
xACP-[ADDRESS_608963] ibruti nib in an in vivo thrombus formation 
model.  At physiologic concentrations, ibrutinib, but not ACP-196, significantly 
inhibited thrombus formation (P=0.001).  
The nonclinical and toxicology results of ACP-[ADDRESS_608964] an improved 
therapeutic window relative to  ibrutinib; it may be more readily combined with other 
agents for the treatment of cancer.   
1.2 PRECLINICAL STUDIES 
Summaries of preclinical studies are provided below. For more detailed information please refer to the Investigator’s Brochure.   
1.2.1 Chemistry 
 ACP-196 is 
orally bioavailable in humans and is suitab le for formulating in capsules. For clinical 
testing, ACP-196 has been manufactured and formulated according to current Good 
Manufacturing Practices (cGMP). 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 21 of 84 
 1.2.2 Efficacy Pharmacology 
Spontaneous canine B-cell lymphoma shar es many characteristics with human NHL, 
including diagnostic classifications and respon se to Btk inhibition (Honigberg 2010). The 
life expectancy in untreated animals with aggr essive disease is ~6 weeks, thus enabling 
rapid assessment of drug efficacy (Vail 2004 ). ACP-196 is currently being evaluated in 
an ongoing dose-escalation study in canine  spontaneous B-cell lymphoma.  Fourteen 
dogs, all of which had diffuse large B-cell lymphoma (DLBCL) confirmed by [CONTACT_27183], have been treated with ACP-[ADDRESS_608965] ranged from 
2.5 to 20 mg/kg once (QD) or twice (BID) per day.  To date, per Veterinary Cooperative 
Oncology Group criteria for assessment of response in peripher al nodal lymphoma 
(Vail 2010), partial responses (PRs) been observed in 4 of 14 dogs (29%) and stable 
disease has been observed in 8 of 14 dogs  (57%).  No ACP-196-related adverse events 
(AEs) have been reported to date in this study.  These findings are preliminary and 
similar to the clinical responses (ie, 1 dog wi th PR out of 5 dogs treated with suspected 
or confirmed DLBCL) observed with ibrutinib in dogs with  spontaneous B-cell lymphoma 
(Honigberg 2010). 
Preliminary results assessing Btk occupancy using a biotin -tagged analogue of ACP-196 
show near complete Btk occupancy over 24  hours with both BID and QD dosing in 
canine tumor tissue ( Table 1-1 ). 
Table 1-1.  Assessment of ACP-196 Active-site Occupancy in  
Fine Needle Aspi[INVESTIGATOR_475156] (N=4) 
Timing Dog Identification and ACP-196 Dosing Regimen 
DL-10 DL-12 DL-14 DL-16 
5 mg/kg BID 10 mg/kg QD 20 mg/kg QD 20 mg/kg QD 
Btk Occupancy (% versus predose) 
Day 1 (3 hours 
after morning 
dose) 98% 99% 98% 99% 
Day 7 (before 
morning dose) 80% 98% 77 93% 
BID = twice per day; Btk = Bruton ty rosine kinase; QD = once per day 
These canine data provide nonclinical support for the ability of ACP-196 to target Btk in 
vivo. The role of Btk expression in driving the proliferation and survival of malignant plasma cells in multiple myeloma (MM) has been less clear than among other lymphoid cancers. However, emerging, unpublished, preclinical data from the laboratory of Sagar 
Lonial (Emory University) suggest that Btk and phosphorylated Btk (p-Btk) expression is 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608966] panel of 12 myeloma cell lines, thus providing a 
basis for evaluating Btk inhi bition as a therapy for MM. 
1.2.3 ACP-196 and Thrombus Formation 
Ibrutinib is associated with an increased ri sk of bleeding (Kamel 2014). Hence, the 
effects of ACP-196 and ibrutinib were evalua ted on human platelet-mediated thrombosis 
by [CONTACT_475200] a VWFHA1 murine model, which has 
been previously described (Chen 2008).  Purified human platelets were preincubated 
with various concentrations of  ibrutinib and ACP-196 (0.1 μM, 0.5 μM, or 1 μM for each) 
or DMSO and then administered to VWFHA1 mice followed by [CONTACT_201558]-induced thrombus 
formation.  Ibrutinib- and ACP-196-treated human platelets were fluorescently labeled 
and infused continuously through a catheter inserted into the femoral artery. Thrombus 
formation in response to laser-induced vascula r injury was monitored in real time using 
2-channel confocal intravital microscopy (Furie 2005) ( Figure 1-1 ). Upon induction of 
arteriole injury, untreated pl atelets rapi[INVESTIGATOR_475157] a mean (± SEM) 
thrombus size of 6450 ± 292 mm2. Similarly, ACP- 196 (1 μM) treated platelets formed 
slightly smaller but not significantly different  thrombi, with a mean thrombus size of 
5733 ± [ADDRESS_608967], a significant reduction in thrombus size occurred in 
platelets pretreated with ibrutinib (1 μM); mean thrombus size was 2600 ± 246 mm2, 
representing in a reduction in maximal thro mbus size by [CONTACT_3450] 61% compared 
with control (P=0.001). Similar results were obtained with platel ets pretreated with 
500 nM of ACP-196 or ibrutinib: mean thrombus sizes were 5946 ± 283 mm2 and 
2710 ± 325 mm2, respectively. These preliminary results showing reduced thrombus 
formation for ibrutinib at physiologicall y relevant concentrations (0.5 to 1 μM) may 
provide some mechanistic background for the Grade ≥ 3 bleeding events (eg, subdural 
hematoma, gastrointestinal bleeding, hematuri a, and post procedural hemorrhage) that 
have been reported in ≤ 6% of patients treated with ibruti nib. In addition, bleeding events 
of any grade, including bruising and petechia e, were reported in approximately half of 
patients treated with ibrutinib (IMBRUVICA® package insert). 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608968] of ACP-196 (1 μM) and Ibrutinib (1 μM) on Thrombus Formation 
 
 
1.2.[ADDRESS_608969]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 24 of 84 
 A3 adenosine receptor; follow-up dose -response experiments indicated a IC 50 of 2.7 μM, 
suggesting a low clinical risk of off-target effects.  ACP- 196 at 10 μM showed no 
inhibition of in vitro epi[INVESTIGATOR_226792] (EGFR) phosphorylation in an A431 
human epi[INVESTIGATOR_475158], whereas ibrutinib had an IC [ADDRESS_608970] of ACP- 196 on human ether-à-go-go-related gene (hERG) channel 
activity was investigated in vitro in human em bryonic kidney cells stably transfected with 
hERG. ACP-196 inhibited hERG ch annel activity by 25% at [ADDRESS_608971] in vivo Good Labora tory Practices (GLP) studies 
of pharmacologic safety. A functional observ ation battery in rats at doses of through 
300 mg/kg (the highest dose level) revealed no adverse effects on neurobehavioral effects or body temperature at any dose level. A study of respi[INVESTIGATOR_475159]-related adverse effect s at doses through 300 mg/kg (the highest 
dose level). In a cardiovascular function stud y in awake telemeterized male beagle dogs, 
single doses of ACP-196 at dose levels through 30 mg/k g (the highest dose level) 
induced no meaningful changes in body temperature, cardiovascular, or 
electrocardiographic (ECG) (including QT inte rval) parameters.  The results suggest that 
ACP-[ADDRESS_608972] CYP-mediat ed metabolism of ACP-196 appears to be 
catalyzed predominantly by [CONTACT_097]3A4/5.  Howeve r, in elimination st udies in preclinical 
species, the metabolic fate of ACP-[ADDRESS_608973] conjugation of ACP-196 
with glutathione, providing evidence for a sign ificant non-CYP mechanism of elimination.  
In a healthy volunteer study (ACE-HV-001), the effect of coadministration of a potent 
CYP3A and P-gP inhibitor, itraconazole, on the plasma levels of ACP-[ADDRESS_608974]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608975] that ACP-196 is not anticipated to alter 
the PK of other therapeutic agents that are substrates for MDR1, OATP1B1, OATP1B3, 
OAT1, OAT3, and OCT2.  ACP-196 (100 mg BID) may alter the PK of BCRP substrates by [CONTACT_378141]. 
1.2.6 In Vivo General Toxicology 
To date, the toxicology program has included  28-day GLP evaluations in rats and dogs. 
In the 28-day study in male and female Sprague-Dawley rats, animals received oral gavage ACP-196 dosages of 30 , 100, and 300 mg/kg/day. In  the 28-day study in male 
and female beagle dogs, animals received  oral ACP-196 dosages of 3, 10, and 
30 mg/kg/day. Both studies had 28-day recovery periods. 
The no observable adverse effect level in  the dog was 30 mg/kg/day, which was the 
highest dose evaluated. In rats, 30 mg/kg/da y resulted in minimal inflammation of the 
pancreas in some animals, with reversal, in dicating the rat to be the more sensitive 
preclinical species. The pancreatic effects were minimally increased at 100 mg/kg/day in the rat though there was no clinical evidence of toxicity. Hence, 100 mg/kg/day was selected to conservatively represent the high est nonseverely toxic dose (HNSTD).  In 
dogs at 30 mg/kg/day, no adverse effects on  the pancreas were observed.  In rats and 
dogs, no adverse ECG or histopathologic cardiovascular effects were noted at the 
planned conclusion of the 28-day toxicology studies. However, in 5 of 6 rats from the 
300-mg/kg dose group that died early in the st udy, slight to moderate necrosis of the 
myocardium and/or white blood cell infiltra tion/inflammation of the myocardium were 
noted on microscopic examination of the hearts. These findings were most likely 
incidental postmortem changes. 
1.[ADDRESS_608976]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 26 of 84 
 Table 1-2.  ACP-196 Clinical Studies as of January 2015 
Protocol Design Subjects 
Enrolled Status 
ACE-CL-001 
([STUDY_ID_REMOVED]) x First-in-human 
x Open label 
x Dose escalation (ACP-196 100-
400 mg QD and 100-200 mg BID) 
x Subjects with relapsed/refractory CLL 
x Expansion cohorts: 
o treatment-naive subjects 
o subjects with Richter’s syndrome  
o subjects who are intolerant to 
ibrutinib treatment 
o subjects who are 
relapsed/refractory to ibrutinib treatment 125 x Cohort 1 (100 mg QD) 
enrolled and no DLTs 
observed.   
x Cohort 2a (175 mg QD) 
enrolled and no DLTs 
observed. 
x Cohort 3 (250 mg QD) 
enrolled and no DLTs 
observed. 
x Cohort 4a (400 mg QD) 
enrolled and no DLTs 
observed. 
x Cohort 2b (100 mg BID 
now enrolling) and no 
DLTs observed. 
x Expansion cohorts now 
enrolling. 
ACE-HV-001 x Open label 
x Single-dose escalation 
(ACP-196 2.5-50 mg BID and 100 mg 
QD) 
x Food effect (ACP-196 75 mg QD) 
x Drug-drug interaction with 
itraconazole (ACP-196 50 mg QD) 
x Healthy volunteers 59 x Enrollment completed. 
x No adverse laboratory, 
vital signs, or ECGs 
findings observed. 
x 1 event each of 
constipation, feeling 
cold, somnolence (each Grade 1) was reported 
as related to study drug. 
ACE-HV-004 x Open label 
x ACP-196 100 mg 
x Drug-drug interaction: 
o Calcium carbonate 
o Omeprazole 
o Rifampin 
x Healthy volunteers 72 x Enrollment completed. 
x No adverse laboratory, 
vital signs, or ECGs 
findings observed. 
x Other analyses 
pending. 
ACE-LY-002 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 100 mg BID 
x Activated B-cell subtype of diffuse 
large B-cell lymphoma 
 6 x Enrollment recently 
begun 
ACE-WM-001 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 100 mg BID and 200 mg QD 
x Waldenström macroglobulinemia 7 x Enrollment recently 
begun 
ACE-LY-003 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 100 mg BID and 200 mg QD 
x Follicular lymphoma 1 x Enrollment recently 
begun 
15-H-0016 
(NIH study)  x Open label 
x ACP-[ADDRESS_608977]-003 x Open label 
x ACP-196 100 mg BID ± 
pembrolizumab 200 mg IV Q3W 
x Advanced or metastatic pancreatic 
cancer 0 x Protocol in study start 
up 
 
AE = adverse event; BID = twice per day; CLL = chronic lymphocytic leukemia; DLT = dose-limiting toxicity; 
ECGs = electrocardiograms; QD = once per day 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 27 of 84 
  
Table 1-2.  ACP-196 Clinical Studie s as of January 2015 (continued) 
Protocol Design Subjects 
Enrolled Status 
ACE-ST-005 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 100 mg BID ± 
pembrolizumab 200 mg IV Q3W 
x Advanced or metastatic bladder 
cancer 
 0 x Protocol in study start 
up 
ACE-LY-004 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 100 mg BID 
x Mantle cell lymphoma 0 x Enrollment recently 
begun 
ACE-CL-002 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 50 mg BID and ACP- 319 
25 mg BID 
x CLL 8 x Enrollment recently 
begun 
ACE-LY-001 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 100 mg BID and ACP- 319 
25 to 100 mg BID 
x B-cell malignancies 1 x Enrollment recently 
begun 
ACE-CL-003 
([STUDY_ID_REMOVED]) x Open label 
x ACP-196 200 mg QD and 
Obinutuzumab per label 
x CLL 2 x Enrollment recently 
begun 
ACE-HI-001 x Hepatic impairment study 
x ACP-196 50 mg QD 18 x Enrollment ongoing 
ACE-LY-005 x Open label 
x ACP-196 100 mg BID and 
pembrolizumab 2 mg/kg IV Q3W 
x B-cell malignancies None x Protocol in study start 
up 
ACE-ST-006 x Open label 
x ACP-196 100 mg BID ± 
pembrolizumab 200 mg IV Q3W 
x Advanced or metastatic head & neck 
cancer [ADDRESS_608978]-007 x Open label 
x ACP-196 100 mg BID ± 
pembrolizumab 200 mg IV Q3W 
x Advanced or metastatic non- small cell 
lung cancer 0 x Protocol in study start 
up 
AE = adverse event; BID = twice per day; CLL = chronic lymphocytic leukemia; DLT = dose-limiting toxicity; 
ECGs = electrocardiograms; IV = intravenous; Q3 W = once every 3 weeks; QD = once per day 
 
1.3.[ADDRESS_608979] udy has been completed and no adverse 
laboratory, vital signs, or ECG findings were observed (2.5 to 50 mg BID; 50 to 100 mg 
QD). Three AEs related to ACP-[ADDRESS_608980]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 28 of 84 
 without treatment.  The AEs were constipation  (2.5 mg BID), feeling cold (75 mg QD), 
and somnolence (75 mg QD). 
In Part 1, PK properties of ACP-196 were eval uated after oral admini stration of 2 daily 
doses of 2.5 to 50 mg and a single dose of 100 mg.  Of the 30 subjects evaluated, all 
had measurable systemic concentrations of ACP-196.  ACP-19 6 plasma time to 
maximum concentration (T max) values were between 0.5 and 1.0 hour for all dose 
cohorts and independent of  the dose level.  The increase in mean maximum 
concentration (C max) values was greater than dose prop ortion based on the increases of 
Cmax from the first dose administered.  When  evaluating area under the concentration 
curve (AUC 0-12, AUC 0-24 or AUC 0-inf), the mean values increased in a dose proportional 
manner based on the increases of the to tal dose administered.  Mean half-life (t 1/2) 
values ranged from 0.97 to 2.1 hours, and appe ared to decrease as the dose increased.  
The mean calculated oral clearance (CL/F: 16 5 to 219 L/h) and volu me of distribution 
values (Vz/F: 233 to 612 L) appeared to be independent of the dose administered. 
ACP-196 was not detected in the urine of subj ects who received the 2.5- or 5.0-mg BID 
doses of ACP-196.  AC P-196 was detected in urine of other subjects (0.4% to 0.6% of 
dose) and amounts increased in a dose dependent manner. 
In Part 2, the effect of food on the PK  of ACP-196 (75 mg) after a single oral 
administration was evaluat ed in 6 men and 6 women.  Median ACP-196 plasma T max 
values were increased in the fed state (2.5 hour s) relative to the fasted state (0.5 hour).  
The mean plasma ACP-196 C max values decreased to 27.3% of the values observed in 
the fasted state.  In contrast, the relative  exposure of ACP-196 (AUC) remained mostly 
unchanged in both states. Per FDA guidance on food-effect studies (FDA 2002), this decrease in exposure is not clinically sign ificant, and therefore, ACP-196 can be taken 
with or without food. 
In Part 3, after administration of a single  dose of ACP-196 (50 mg), the effect of 
itraconazole on the PK was evaluated in 17 subjects.  No difference in ACP-196 T
max 
values was observed in the presence or absence of itraconazole. 
Mean ACP-196 exposures (as assessed by C max, AUC 0-last, AUC 0-24, and AUC 0-inf) 
increased in the presence of itraco nazole.  The mean plasma ACP-[ADDRESS_608981], AUC 0-24, 
and AUC 0-inf values also increased between 4.9-  to 5.1-fold in the presence of 
itraconazole. Mean CL/F and Vz/F values de creased in the presence of itraconazole 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 29 of 84 
 (CL/F: 217 vs 44 L/h; Vz/F: 1190 vs 184 L).  No differenc es in half-life values were 
observed (3.3 vs 2.5 hours). 
The pharmacodynamics (PD) pr ofile of ACP-196 was evaluated using a Btk occupancy 
assay and correlated with a func tional assay that determines th e level of Btk inhibition by 
[CONTACT_475201]69 and CD86 on B-cells.  A dose-dependent increase in Btk occupancy and corresponding decrease in CD69/86 expression was observed in this 
study.  Full Btk occupancy ( ≥ 90%) and complete CD86 and CD69 inhibition ( ≥ 90%) 
occurred in the 75- and 100-mg single dose cohorts 1 to 3 hours after administration.  
However, only the 100 mg cohort maintained  high Btk occupancy (91.5%) and high BCR 
functional inhibition (CD86: 86  ± 3% and CD69: 78 ± 8%) at [ADDRESS_608982] administration, full Btk target 
occupancy was observed 3 hours after the second  dose for the 50 mg dose cohort (Btk 
occupancy 97 ± 4%). 
1.3.2 Clinical Experience of ACP-196 in CLL 
ACE-CL-001 ([STUDY_ID_REMOVED]),  an ongoing Phase 1/2 study in subjects with 
relapsed/refractory or previously untreated CLL or Richter’s syndrome , has a sequential, 
dose-escalation design.  As of [ADDRESS_608983] received ACP-196 at 
dosages from 100 to 400 mg QD  or 100 to 200 mg BID.  
To date, ACP-196 has been well tolerated at all dose levels evaluated.  No dose-limiting 
toxicities (DLTs) have occurr ed at any dose level.  The MTD was not reached in this 
study; however, per the protocol, dose esca lation was stopped once a plateau in PK was 
observed (ie, between 250 and 400 mg).   
Preliminary data from ACE-CL-001 show that  Btk occupancy with AC P-196, in peripheral 
blood cells, is > 95% at 4 ho urs but decreases to < 95% at 24 hours, while with BID 
dosing complete Btk occupancy (97% to 99%) is maintained over 24 hours at steady state ( Table 1-3 ). These data suggest that synthesis of de novo Btk may occur within 
[ADDRESS_608984]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 30 of 84 
 Table 1-3.  Btk Occupancy in Peripheral  Blood of Subjects from ACE-CL-001 
(December 2014) 
Timepoint* Subjects with Relapsed/Refractory CLL  
100 mg QD 
(n=8) 175 mg QD 
(n=8) 250 mg QD 
(n=6) 100 mg BID 
(n=17) 
Day 7: 
Median % 
Occupancy 24 h 89.0 86.9 93.5 97.4 
Day 8: 
Median % 
Occupancy 4 h 98.6 98.7 100 98.8 
Abbreviations:  BID = twice per day; CLL = chronic lymphocytic leukemia; QD = once per day 
*Note: 24-h timepoint on BID regimen represents  [ADDRESS_608985] 
dose on Day 8.   
 
 
 
Preliminary PK data from Day 8 show dose  linearity from 100 to 250 mg and no 
accumulation with repeat dosing ( Table 1-4 ). 
Table 1-4.  Preliminary Day 8 PK Res ults from ACE-CL-001 (October 2014) 
Cohort Mean C max ± SD 
(ng/mL) Mean AUC 0-last ± SD 
(ng•h/mL)  
100 mg QD (N=8) 529 ± 286 634 ± 197a 
175 mg QD (N=7) 800 ± 692 1240 ± 789 
250 mg QD (N=7) 1350 ± 933 2170 ± 1180 
400 mg QD (N=6) 932 ± 576 1870 ± 1040 
100 mg BID (N=22) 716 ± 658 837 ± 485b 
Timepoints: Predose, 0.25, 0.50, 0.75, 1.0, 2.0, 4.0, and 6.0 postdose. 
a N=7 for AUC calculations in 100 mg QD dose group. 
b BID regimens were not sampled during the second daily dose interval; 0-24 h exposures are 
expected to be approx imately 2-fold the AUC 0-6 values shown. 
AUC = area under the curve; BID = twice per day; C max = maximum concentration; SD = standard 
deviation 
 
To date, [ADDRESS_608986] been evaluated for tumor response, by [CONTACT_431], based 
on International Working Group response cr iteria (Hallek 2008) as recently updated 
(Cheson 2012) to includ e partial response with  treatment-induced lymphocytosis.  Based 
on preliminary, unaudited dat a an overall response rate (ORR) of 94% (71% PR + 23% 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 31 of 84 
 PR with lymphocytosis) has been observed ( Table 1-5 ).  Of the 31 subjects assessed, 
nearly half (15 of 31) have 17p del.  Of th e 15 subjects with 17p del, 80% (12/15) have 
PR and 20% (3/15) have PR with lymphocyto sis.  The median follow-up for the ACP-196 
subjects evaluated for response is 7.3 cycles  (range 3.0 to 10.8) an d each cycle is 28 
days.  No primary disease progression  has occurred on study (N = 75; Figure 1-2 ). 
Table 1-5.  Best Response by [CONTACT_475202]-CL-001 (23OCT2014) 
n (%) All 
Cohorts 
(N=31) 100 mg QD 
(N=8) 175 mg QD 
(N=8) 250 mg QD 
(N=7) 100 mg BID 
(N=3) 400 mg QD 
(N=5) 
PR 22 (71) 7 (88) 5 (71) 4 (57) 3 (100) 2 (40) 
PR+L 7 (23) 0 (0) 3 (38) 2 (29) 0 (0) 2 (40) 
SD 2 (6) 1 (12) 1 (13) 0 (0) 0 (0) 1 (20) 
PD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Median (range) Cycles 
 7.3 (3.0-10.8) 10.0 (9.0-10.8) 8.6 (3.0-8.8) 7.0 (7.0-7.3) 5.2 (4.7-5.5) 5.0 (4.8-5.5) 
BID = twice per day; PD = progressive disease; PR = partial response; PR+L = partial response 
with lymphocytosis; QD = once per day; SD = stable disease 
 
Figure 1-2.  Kaplan-Meier Curves for Progression-free Survival by [CONTACT_475196]-CL- 001 (N=75; excludes Richte r’s Syndrome Cohort and 
Ibrutinib R/R Cohort) 
 
 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608987] generation 
Btk inhibitor, when administered at dosa ges of 420 mg QD in subjects with 
relapsed/refractory CLL (N=195).  In the ib rutinib study, By[CONTACT_475203] (2014) 
report a PR rate of 43%, a PR with lymphocytosis rate of 20% —for an ORR of 63% ─an 
SD rate of 32%, and a progressive diseas e (PD) rate of 3% (By[CONTACT_26752] 2014) based on 
independent review.  The median follow-up time reported for the ibrutinib study was 9.5 months (range 0.1 to 16.6).   
Figure 1-[ADDRESS_608988] of the diameters (SPD) 
(N=31) and in absolute lymphocyte count (A LC) (N=57) over time.  As shown in the 
figure, substantial reductions in lymphadeno pathy have been observed despi[INVESTIGATOR_475160]-quarters of the evaluable subjects  have high-risk cytogenetics (17p del, 11q 
del, or both).  As mentioned above, the ob served reductions in lymphadenopathy are 
consistent with the clinical results for ibrutinib (By[CONTACT_26752] 2013, By[CONTACT_26752] 2014).  However, the reduced drug-induced lymphocytosis and the ra pid time to resolution of lymphocytosis 
with ACP-196 treatment varies greatly from that reported for ibrutinib.  Per the IMBRUVICA package insert , 77% of patients wi th CLL treated with ibrutinib experienced 
lymphocytosis, which occurred during the fi rst month of therapy and resolved by a 
median of 23 weeks (range 1 to 104+ weeks) .  With ACP-196 treatment, the onset of 
lymphocytosis, if it occurs, is within the firs t week of treatment and resolves by a median 
of 8 weeks (range 0 to 24+ weeks). 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 33 of 84 
 Figure 1-3.  Median (95% CI) Change from Baseline in ALC/SPD Over Time 
 
 
ALC = absolute lymphocyte count; CI = confidence interval; SPD = sum of the 
products of the perpendicula r diameters (of lymph nodes). 
 
 
1.4 BENEFIT/RISK 
ACP-196 is a potent, orally av ailable small-molecule inhibito r of Btk.  A PK/PD study has 
been completed with ACP-196 in healthy volunteers (ACE-HV-001; Section1.3.1 ).  The 
safety results showed no identified safety ri sks in healthy subjects receiving 1 or 2 days 
of ACP- 196 ≤ [ADDRESS_608989] udy of ACP-196 in subjects with 
relapsed/refractory or previously untreated CLL or Richter’s syndrome, no DLTs have 
been reported at dosa ges of ≤ 400 mg QD or 100 and 200  mg BID.  The overall 
response rate in the evaluable subjects fo r this study is currently 94% with some 
subjects obtaining PRs after only [ADDRESS_608990]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608991] of this study is supported by [CONTACT_475204][INVESTIGATOR_378117]; knowledge of the efficacy and 
safety of the first-generation BCR inhibitor (e g, ibrutinib) in subjects with hematologic 
cancers; and the available nonclinical and clinical information regarding ACP-196. 
Preclinical studies are ongoing in parallel to identify biomarkers that may be evaluated in 
this clinical trial as correlates of response to Btk-directed therapy and that may permit selection of patients who are particularly likely to benefit from ACP-196 treatment for 
MM. 
2.0 STUDY OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
x To characterize the safety profile of ACP-196 with and without dexamethasone in 
subjects with relapsed or refractory MM 
2.2 SECONDARY OBJECTIVES: 
x To characterize the PK profile of ACP-196 with and without dexamethasone and the 
PK profile of dexamethasone with concomitant ACP-196 administration 
x To evaluate the PD effects of AC P-196 with and without dexamethasone 
x To evaluate the activity of ACP-196 wi th and without dexamethasone as measured 
by [CONTACT_34426], dura tion of response, clinical benefit rate, disease control 
rate, and progression-free survival 
x To explore the relationship between biological markers in MM cells and response to 
therapy 
3.0 STUDY DESIGN 
3.1 DESCRIPTION OF STUDY 
This study is a multicenter, open-label , randomized, parallel -group study to be 
conducted at approximately 20 sites in 2 coun tries ([LOCATION_008] and [LOCATION_002]).  
Forty subjects will be randomized 1:1 into the following 2 cohorts to receive ACP-196, with and without dexamethasone: 
x Cohort 1: ACP-196 100 mg BID continuously  
x Cohort 2: ACP-196 100 mg BID contin uously and 40 mg dexamethasone once 
weekly  
Twenty-eight days of study drug administration  is 1 cycle.  Treatment may be continued 
for > 28 days until disease progression or an unacceptable drug-relat ed toxicity occurs.  
For subjects in Cohort 1, if docume nted disease progression occurs, then 
dexamethasone can be added to  the treatment regimen.  Ad ditional dose modification 
provisions are provided in Section 3.5.5 .  Note: temporary withholding of study drug for 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 35 of 84 
 as little as 7 days can cause a transient worsening of dise ase and/or of constitutional 
symptoms.  Refer to Section 3.[ADDRESS_608992] a safety 
follow-up visit 30 (±7) days af ter the last dose of study dr ug unless they have started 
another cancer therapy within that timeframe.  
All subjects will have standard hematology, chemistry, and urinalysis safety panels 
performed at screening.  Once dosing commenc es (Day 1), all subjects will be evaluated 
for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, 
every 2 weeks in Cycle 2 and monthly thereafter.  PK/PD testing will be done in Cycle [ADDRESS_608993] on the study exits the study for 
any reason. 
3.2 STUDY PARAMETERS 
3.2.1 Safety Parameters 
The safety of ACP-196 with and without dexamethasone will be characterized by [CONTACT_344412], frequency, severity, timing of onset, du ration, and relationship to study drug (ie, 
ACP-196, dexamethasone, or both) of any treatment-emergent AEs or abnormalities of 
laboratory tests; serious adverse events ( SAEs); or AEs leading to  discontinuation or 
dose reduction of study treatment.  
For consistency of interpretation, AEs will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), and the seve rity of AEs and laboratory abnormalities 
will be graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Standard definitions fo r seriousness will be applied (see Section 6.1 ). 
3.2.[ADDRESS_608994] been established for MM 
(Rajkumar 2011); assessments of ACP-196 effi cacy in this study will be based on these 
criteria. Efficacy endpoints will include: 
x Overall response rate (ORR) 
x Duration of response 
x Clinical benefit rate 
x Disease control rate 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_608995] PK parameters for ACP-196 and dexamethasone in plasma will be evaluated 
in this study.  A full description of the PK parameters is provided in Section 5.5.4 . 
The occupancy of Btk by [CONTACT_408799]-196 will be measured in peripheral blood mononuclear 
cells (PBMCs) and bone marrow, when avai lable, with the aid of a biotin-tagged 
ACP-[ADDRESS_608996] of ACP-19 6 on biologic markers of B-cell function 
will also be evaluated. 
3.3 RATIONALE FOR STUDY DESIGN AND DOSING REGIMEN 
As described in Section 1.3 , preliminary data from the ongoing Phase 1/2 study in 
subjects with relapsed/refractory or previo usly untreated CLL have  shown that ACP-196 
is well tolerated at dosages of 100 to 400 mg QD and 100 to  200 mg BID.  In addition, 
preliminary PD data from AC E-CL-001 show that Btk occupancy with ACP-196, in 
peripheral blood, is > 95% at 4 hours after QD dosing but decreases to < 95% at 
24 hours with QD dosing, while with BID dosi ng complete Btk occupancy (95% to 99%) 
is maintained over 24 hours at steady state ( Table 1-3 ).  These data suggest that de 
novo synthesis of Btk can occur within 24 ho urs in peripheral blood cells.  BID dosing 
may ensure Btk inhibition for th e entire 24 hours and thus ma y be beneficial in terms of 
increasing efficacy and/or decreasing deve lopment of resistance to ACP-196.  In 
addition, having information regarding the safety and pharmacology of a BID schedule 
may support future combination studies with other drugs that are administered BID.   
Evaluation of dexamethasone as a combin ation partner for ACP-196 builds on known 
antineoplastic activity  of this drug in patients with MM. Dexamethasone therapy is 
commonly coadministered with targeted agents for MM (Ocio 2014).  The dosing 
regimen of 40 mg weekly to be used in this study has been established based on 
randomized trial data showing the superiority of this method of administration (Rajkumar 
2009). Combined use of ACP-[ADDRESS_608997] increased ef ficacy relative to administration of the 
individual agents alone. While dexamethas one can increase CYP3A4 activity and thus 
might enhance ACP-196 metabolism, it is cons idered a weak inducer of this isoenzyme 
and has not substantially altered the disposition of other CYP3A4 substrates (eg, 
bortezomib) that are commonly used in the therapy of MM (Hellmann 2011). The 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 37 of 84 
 randomized design of this pi [INVESTIGATOR_475161]-drug interactions 
between ACP-196 and dexameth asone to be assessed. 
3.4 SELECTION OF STUDY POPULATION 
3.4.1 Inclusion Criteria 
Eligible subjects will be considered for inclusion in this study if they meet all of the 
following criteria:  
1. Men and women ≥ 18 years of age . 
2. A confirmed diagnosis of MM, which has relapsed after, or been refractory to 
≥ [ADDRESS_608998] one of the 
following: 
o Serum M- protein ≥ 0.5 g/dL 
o Urine M- protein ≥ 200 mg/24 hours 
o In subjects without detectable serum or urine M-protein, serum free light 
chain (SFLC) > 100 mg/L (involved light chain) and an abnormal serum 
kappa/lambda ratio 
o For subjects whose disease can only be reliably measured by [CONTACT_475205] A (IgA), IgA ≥ 750 mg/dL (0.75 g/dL)  
4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. 
5. Agreement to use acceptable methods of  contraception during the study and for 
[ADDRESS_608999] dose of study drug. 
7. Willing and able to participate in all requ ired evaluations and procedures in this 
study protocol including swallowing capsules without difficulty. 
8. Ability to understand the purpose and ri sks of the study and provide signed and 
dated informed consent and authorization to  use protected health information (in 
accordance with national and loca l patient privacy regulations). 
3.4.2 Exclusion Criteria 
Subjects will be ineligible for this study if they meet any of the following criteria: 
1. Plasma cell leukemia or circulating plasma cells ≥ 2 x 109/L 
2. Prior malignancy, except for adequately treated basal cell or squamous cell skin 
cancer, in situ cervical cancer, or other cancer from which the subject has been 
disease free for ≥ 2 years or which will not limit su rvival to < 2 years. Note: these 
cases must be discussed with the Medical Monitor. 
3. A life-threatening illness, medical conditio n or organ syst em dysfunction which, in 
the investigator’s opi[INVESTIGATOR_1649], could compromise the subject’s safety, interfere with 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 38 of 84 
 the absorption or metabolism of ACP-196, or put the study outcomes at undue 
risk. 
4. Significant cardiovascular disease such as uncontrolled or symptomatic 
arrhythmias, congestive heart failure, or my ocardial infarction within 6 months of 
screening, or any Class 3 or 4 cardiac dise ase as defined by [CONTACT_183959], or QTc > [ADDRESS_609000] dose of study drug is  < 5 times the half-life of the previously 
administered agent(s). 
8. Prior exposure to a B-cell receptor (B CR) inhibitor (eg, Btk,  phosphoinositide-3 
kinase [PI3K], or Syk inhibitors) or BCL-2 inhibitors (eg, ABT-199). 
9. Ongoing immunosuppressive therapy, including systemic or enteric 
corticosteroids for treatment of MM or other conditions. Note: Subjects may use 
topi[INVESTIGATOR_475162]. During 
study participation, subjects may also re ceive systemic or enteric corticosteroids 
as needed for MM therapy or treatment-emergent comorbid conditions. 
10. Grade ≥ 2 toxicity (other than alopecia ) continuing from prior anticancer therapy 
including radiation. 
11. Known history of human immunodeficiency virus (HIV), serologic status reflecting 
active hepatitis B or C infect ion, or any uncontrolled active systemic infection.  
Subjects with hepatitis B core  antibody positive  who are surface antigen negative 
or who are hepatitis C antibo dy positive will need to have a negative PCR result 
before enrollment.  Those who are hepa titis B surface antigen positive or 
hepatitis B PCR posi tive and those who are hepati tis C PCR positive will be 
excluded. 
12. Major surgery within [ADDRESS_609001] dose of ACP-196. 
13. Known history of a bleeding diathesis (eg, hemophilia, von Willebrand disease) 
14. History of stroke or intracranial hemorrhage within [ADDRESS_609002] (eg, phenprocoumon) within [ADDRESS_609003] dose of study drug. 
16. Requires treatment with long-acting proton pump inhibitors (eg, omeprazole, 
esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). 
17. ANC < 0.75 x 109/L or platelet count < 50 x 109/L.  For subjects with >50% 
marrow involvement with plasma cells, ANC < 0.50 x 109/L or platelet count 
< 30 x 109/L. 
18. Creatinine > 2.5 x institutional upper limit of normal (ULN); total bilirubin 
> 2.[ADDRESS_609004]; and aspartate aminotransfera se (AST) or alanine aminotransferase 
(ALT) > 3.[ADDRESS_609005]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609006] into the study will  be performed according to the following 
procedure:  
x Notify the sponsor when a clinically eligible subject is identified and is ready to 
screen, to ensure enrollment availability on the study. 
x After the subject has signed and dated the Informed Consent Form (ICF), all 
screening procedures have been completed, and eligibility has been confirmed, the 
subject can be officially enrolled in the study.  
x To enroll a subject, the study center will fax/email a completed Enrollment 
Confirmation Form to the sponsor.  The enrollment date will be the date that the form is faxed/emailed to the sponsor. 
x An Enrollment Confirmation Form will be  completed and faxed/emailed to the study 
center by [CONTACT_86622] [ADDRESS_609007] begin within the screening window ( Section 4.1 ) and after the site has 
received the cohort allocation from the sponsor.  Study treatment is not blinded on this study. 
3.[ADDRESS_609008]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 40 of 84 
 3.5.2 Formulation, Packaging, and Storage 
[IP_ADDRESS] ACP-[ADDRESS_609009] ge latin capsules containing 100 mg drug 
substance.  ACP-196 will be provided in white, high-density polyethylene bottles. 
If a drug shipment arrives damaged, or if  there are any other drug complaints, a 
SAE/Product Complaint Form shou ld be completed and emailed or faxed to the sponsor 
or the sponsor’s represen tative.   
Refer to the Investigator’s Brochure for additional  information regarding the drug product 
to be used in this trial. 
[IP_ADDRESS] Dexamethasone 
This study will use commercially available dex amethasone tablets for oral administration.  
The Sponsor will either directly supply site s with dexamethasone or the sites will be 
reimbursed to prescribe dexamethasone ; this will be detailed separately in each site’s 
clinical trial agreement.  Per the U.S. dexamethasone package insert ( Appendix 4 ), 
tablets are to be stored at room temperatur e (20° to 25°C) and protected from moisture 
and light.  Please refer to  the appropriate dexamethason e package insert for further 
storage and handling instructions.  
3.5.3 Administration of Study Drug  
[IP_ADDRESS] ACP-[ADDRESS_609010] ensure that subjects receive ACP-196 only from personnel wh o fully understand the procedures for administering the 
drug. 
ACP-196 is intended to be administered orally  with 8 ounces (approximately 240 mL) of 
water (avoid grapefruit juice and Seville oran ge juice due to CYP3A4  inhibition).  ACP-
[ADDRESS_609011]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609012] be returned to the site at the next scheduled visit. 
[IP_ADDRESS] Dexamethasone 
This study will use commercially available de xamethasone tablets for oral administration.  
At the time of weekly dexamethasone admi nistration, the subject should take the 
dexamethasone tablets simultaneously with the ACP-196 capsules and with 8 ounces 
(approximately 240 mL) of water.  The de xamethasone tablets should be swallowed 
intact and subjects should not attempt to chew them or dissolve them in water.  
If a dexamethasone dose is missed, it can be  taken up to 3.5 days (84 hours) days after 
the scheduled time with a return to the no rmal schedule the following week.  If the 
interval of missed dosing has been > 3.5 days (84 hours), the dexamethasone dose 
should not be taken and the subject should take the next dose at the scheduled time in the following week.  The missed dexamethasone dose will not be ma de up and must be 
returned to the site at the next scheduled visit. 
3.5.[ADDRESS_609013] Compliance 
During cycle 1, subjects will receive their Day 1, 8, 15, 22, and 28 doses (for Cohort 2 this includes the dexamethasone dose) in the c linic.  For treatments that are taken in the 
clinic, subjects should take the dose from th e drug dispensed for them for that particular 
time period.  All other treatments will be taken at home.  Subjects will receive a diary to record the specific time ea ch dose was taken and to re cord reasons for any missed 
doses.   
Subject compliance will be assessed at every visit.  The subject will be instructed to 
bring the diary and any remaining ACP-[ADDRESS_609014]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 42 of 84 
 3.5.5 Study Treatment Regimen and Dose Modifications 
[IP_ADDRESS] ACP-196 
Dose Delays  
Treatment with ACP-196 should be held for any unmanageable, potentially study drug-
related toxicity that is Grade ≥ [ADDRESS_609015] be discussed with 
the Medical Monitor.  Study drug may be he ld for a maximum of 28 consecutive days 
from expected dose due to to xicity.  Study treatment should  be discontinued in the event 
of a toxicity lasting > 28 days, unless reviewed and approv ed by [CONTACT_1689]. 
Note: temporary withholding of study drug  for as little as 7 days can cause a 
transient worsening of disease and/ or of constitutional symptoms.   Refer to 
Section 3.8 for more information on assessi ng disease progression under these 
circumstances. 
Dose Modification and Discontinuation 
The actions in Table 3-1 should be taken for the following toxicities: 
x Grade 4 ANC (< 500/ μL) for > 7 days (Neutrophil growth factors are permitted 
per ASCO guidelines [Smith 2006] and use must be recorded on the electronic 
case report form [eCRF]). 
x Grade 3 platelets in the pres ence of significant bleeding 
x Grade 4 platelets  
x Grade 3 or 4 nausea, vomiting, or di arrhea, if persistent despi[INVESTIGATOR_271182]/or anti-diarrheal therapy 
x Any other Grade [ADDRESS_609016] - 2nd Hold ACP-196 until recovery to Grade ≤ 1 or baseline; may restart at 
original dose level  
3rd Hold ACP-196 until recovery to Grade ≤ 1 or baseline; rest art at [ADDRESS_609017]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 43 of 84 
 Subjects in Cohort 1 (ACP-196 monotherapy) who do not experience at least an minimal 
response (MR) after [ADDRESS_609018]  dexamethasone (40 mg once 
weekly) added to their treatment. 
Whenever possible, any dose adjustment of  ACP-196, including adding dexamethasone 
to subjects in Cohort 1, should be discu ssed between the investigator and the Acerta 
Pharma medical monitor before implementati on. The appropriate clinic staff should 
dispense the study drug for the new dose le vel and instruct the subject/caregiver about 
the change in dose level.  Any changes to the dosing regimen must be recorded in the 
appropriate eCRF.   
[IP_ADDRESS] Dexamethasone 
This study will use commercially available dexamethasone.  Dosing of dexamethasone 
will be [ADDRESS_609019] itutional standards.   
For subjects considered at risk for tumor lysis syndrome:  Administer appropriate 
hydration and allopurinol or rasburicase per institutional standards before initiating 
treatment. 
3.6.2 Guideline for Use of CYP Inhibiting/Inducing Drugs 
At the systemic exposure levels expected in this study, ACP-19 6 inhibition of CYP 
metabolism is not anticipated.  However, as discussed in Section 1.3.1 , concomitant 
administration of AC P-196 with a strong CYP3A4 in hibitor increased exposure by 
[CONTACT_3450] 5-fold.  Consequently, the concomitant use of strong inhibitors/inducers of 
CYP3A4 ( Appendix 3 ) should be avoided when possible.  If a subject requires a strong 
CYP3A4 inhibitor while on stud y, monitor the subject closel y for potential toxicities. 
3.6.[ADDRESS_609020] of agents that reduce gastric acid ity (eg, proton pump inhibitors, H2-receptor 
antagonists or antacids) on AC P-196 absorption is currently being evaluated in a healthy 
volunteer study (ACE-HV-004).  Preliminary results from this study suggest subjects 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 44 of 84 
 should avoid the use of calcium carbonate containing drugs or supplements (eg, 
antacids or calcium supplements) for a period of at least [ADDRESS_609021] 
requires treatment with a long-acting proton pu mp inhibitor while on study (eg, to treat an 
ulcer), discuss treatment option s with the Medical Monitor. 
3.6.4 Prohibited Concomitant Therapy 
Any chemotherapy, immunotherapy, kinase in hibitors, bone marro w transplantation, 
experimental therapy, and radi otherapy are prohibited (see Section 3.4.2 ).   
Administration of live or live, attenuated vacci nes is contraindicated in patients receiving 
immunosuppressive doses of corticosteroid s, per the dexamethasone package insert 
(Appendix 4 ). Killed or inactivated vaccines may be administered. However, the 
response to such vaccine s cannot be predicted. 
3.7 PRECAUTIONS 
3.7.1 Dietary Restrictions 
Because ACP-196 may be metabolized by [CONTACT_097]3A4/3A5 (see Section 1.2.4 ), subjects 
should be strongly cautioned against excessi ve consumption of grapefruit, grapefruit 
juice, Seville oranges, or Seville orange ju ice (which contain potent CYP3A4 inhibitors) 
or using herbal remedies or dietary suppleme nts (in particular, St. John’s Wort, which is 
a potent CYP3A4 inducer). 
ACP-196 may be taken with or without food. 
3.7.2 Hepatitis B Virus Reactivation 
Serious or life-threatening reactivation of viral hepatitis may occur in subjects treated 
with ACP-196.  Therefore, subjects who ar e hepatitis B core antibody (anti-HBc) 
positive, or have a known hi story of hepatitis B virus (HBV) infection, should be 
monitored monthly with a quantitative PC R test for HBV DNA.  Monthly monitoring 
should continue until [ADDRESS_609022] with a rising 
viral load (above lower limit of detection) should discontinue ACP- [ADDRESS_609023]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609024] generation Btk inhibitor, 
ibrutinib [IMBRUVICA package insert].  As a precaution, it is sugg ested that ACP-196 be 
held for 3 days before and afte r any major surgical procedure. 
3.7.4 Infections 
Patients who are on corticosteroids are more susceptible to infections than are healthy 
individuals (dexamethasone package insert, Appendix 4 ). Corticosteroids may 
exacerbate systemic fungal infections and th erefore should not be used in the presence 
of such infections unless they are needed to control life-threatening drug reactions. 
3.7.[ADDRESS_609025]’s  partner must be reported (see Section 6.2.3 ). Male subjects must agree 
to refrain from sperm donation  during the study and for [ADDRESS_609026] experienci ng an ACP-196 overdose (administration of a dose 
≥ 1.[ADDRESS_609027] intended dose level in the clinical study protocol), observation for 
any symptomatic side effects should be inst ituted, and vital sign s and biochemical and 
hematologic parameters should be followed cl osely (consistent with the protocol or more 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 46 of 84 
 frequently, as needed). Appropriate supportive  management to mitigate adverse effects 
should be initiated. If the overdose ingestion is  recent and substantial, and if there are no 
medical contraindications, use of gastric lavage or induction of emesis may be considered. 
The Acerta Pharma Medical Monitor should be contact[CONTACT_35114] a study drug overdose 
occurs.  
3.8 STOPPI[INVESTIGATOR_475163]-196 in definitely as long as they are safely 
benefitting. However: 
x Any subject has the right to withdraw from the study at any time. 
x Any subject who has objective evidence of definitive MM progression while receiving 
study treatment at the highest individual to lerable dose level allowed in the protocol 
(see Section 3.5.5 ) should be withdrawn from the study treatment.  Note: If there is 
uncertainty regarding whether there is MM progression, the subject should continue 
study treatment and remain unde r close observation (eg, evaluated at 4- to 8-week 
intervals) pending confirmation of progressi on. In particular, transient worsening of 
disease during temporary interruption of study therapy (eg, for intercurrent illness, 
drug-related toxicity, or surgery) may not indicate definitive di sease progression. In 
such circumstances, and if medically appr opriate, subjects may resume therapy and 
relevant clinical, laboratory, and/or ra diographic assessment should be done to 
document whether tumor control can be maintained or whether actual disease 
progression has occurred.  
x Any subject who is unable to tolerate re challenge at the lowest protocol-described, 
dose-modified levels (see Section 3.5.5 ) should be withdrawn from the study 
treatment unless continued therapy is permitted by [CONTACT_378147]. 
x Any subject whose medical co ndition substantially changes after entering the study 
should be carefully evaluated by [CONTACT_475206]. Such subjects should be withdrawn from study 
treatment if continuing wo uld place them at risk.  
x Any subject who becomes pregnant or begins breastfeeding should be removed from 
study treatment. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609028] from the study treatment, if, in  the investigator’s opi[INVESTIGATOR_1649], it is 
not in the subject’s best interest to continue.  
Subjects who discontinue study therapy will continue on study for safety ( Section 4.3 ) 
unless they withdraw consent for further follow- up. Thus, all subjects receiving ≥ [ADDRESS_609029] is withdrawn 
from study treatment or from the study and the reason for discontinuation will be recorded and also should be descri bed on the appropriate eCRF.   
3.9 DATA AND SAFETY MONITORING 
This trial will be monitored in accordance with the sponsor’s Pharmacovi gilance 
Committee procedures.  Adverse events and SA Es will be reviewed  internally on an 
ongoing basis to identify safety concerns .  Quarterly conference calls with the 
investigators will be conducted to discuss study progress, obtain investigator feedback 
and exchange, and discuss "significant safe ty events" (ie, AEs leading to dose 
reductions, related SAEs, and deaths).   
4.[ADDRESS_609030]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609031] read, understand and sign th e IRB/IEC approved ICF confirming his or 
her willingness to participate in this study befo re initiating any screening activity that is 
not standard of care.  Subjects must also  grant permission to use protected health 
information. 
4.1.[ADDRESS_609032]’s complete history  should be collected and recorded through review of 
medical records and by [CONTACT_30230]. Concurre nt medical signs and symptoms must be 
documented to establish baseline severities . A disease history, including the date of 
initial diagnosis and list of all prior anticanc er treatments, and resp onses and duration of 
response to these treatments, also will be recorded. 
4.1.[ADDRESS_609033] 
dose of study drug. 
4.1.6 ECOG Performance Status 
The ECOG performance index is provided in  Appendix 1 . 
4.1.7 Physical Examination, Vital Signs, Height & Weight 
The screening physical examination will includ e, at a minimum, the general appearance 
of the subject, height (screening only) an d weight, and examination of the skin, eyes, 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 49 of 84 
 ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, nervous 
system, and lymphatic system. 
Symptom-directed physical exams, including tumor assessments by [CONTACT_23302], will be 
done during the treatmen t period and at the sa fety follow-up visits. 
Vital signs (blood pressure, he art rate, respi[INVESTIGATOR_697], an d body temperature) will be 
assessed after the subject has rest ed in the sitting position.   
4.1.8 Bone Marrow Aspi[INVESTIGATOR_127843] 
A bone marrow aspi[INVESTIGATOR_475164] 30 days before the 
main screening procedures.  Per the current response criteria (Rajkumar 2011), a bone 
marrow aspi[INVESTIGATOR_337]/biopsy will also be required at any time on study to confirm a complete response (CR).  The base line bone marrow aspi[INVESTIGATOR_337] /biopsy will used for 
immunohistochemistry and/or flow cytometry, cytogenetics, and FISH.  Testing will be performed at the study center’s local laboratory or other clinical laboratory listed on the investigator’s form FDA 1572.  De -identified copi[INVESTIGATOR_475165]/aspi[INVESTIGATOR_378123].  
When available, any unused bone marrow tissu e will be used for PD testing.  PD testing 
will be done by [CONTACT_456]. 
4.1.9 Electrocardiogram 
Subjects should be in supi[INVESTIGATOR_050] p osition and resting for ≥ [ADDRESS_609034] include complete blood count (CBC) with  differential and 
platelet and reticulocyte counts.  Testin g will be done by [CONTACT_2237]. 
4.1.[ADDRESS_609035], bicarbonate, 
blood urea nitrogen (BUN), bone-specific alkaline phosphatase, calcium, chloride, 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 50 of 84 
 creatinine, C-terminal telopept ide, glucose, lactate dehydrogenase (LDH), magnesium, 
phosphate, potassium, sodium, total bilirubin , total protein, and uric acid.  If an 
unscheduled ECG is done at any time, th en an electrolyte panel (ie, calcium, 
magnesium, and potassium) must be done to coincide with the ECG testing.  Testing will 
be done by [CONTACT_2237]. 
4.1.13 Urinalysis 
Urinalysis includes pH, ketones, specific grav ity, bilirubin, protein, blood, N-terminal 
telopeptide, and glucose.  Testing will be done by [CONTACT_2237].  
4.1.14 T/B/NK Cell Count 
Flow cytometry testing will include CD3+, CD4+, CD8+, CD19+, and CD16/56+ cells.  
Testing will be done by [CONTACT_2237]. 
4.1.15 Disease Markers 
Testing for serum M-protein levels (by [CONTACT_475207] [SPEP] and serum 
immunofixation electrophoresis [SIFE]), seru m free light chains (SFLC), urine M-protein 
levels (by [CONTACT_475208] [UPEP] and urine immunofixation 
electrophoresis [U IFE]), and serum β2-microglobulin will be done by [CONTACT_11378]. 
4.1.[ADDRESS_609036] include hepat itis B surface antigen (HBsAg), hepatitis B 
surface antibody (HBsAb), an ti-HBc, and hepatitis C (HCV) antibody.  Since intravenous 
immunoglobulins (IVIG) may cause false posit ive hepatitis serology, subjects who are 
receiving prophylactic IVIG and have positiv e HBsAg or anti-HBc must have negative 
hepatitis B DNA to be eligible.  In addition, any subjects test ing positive for any hepatitis 
serology, must have PCR testing (see Appendix 5  and exclusion criterion #11).  Testing 
will be done by [CONTACT_169617].   
Refer to Section 3.7.[ADDRESS_609037] lateral radiograph of the skull, ante rioposterior and lateral views of the spi[INVESTIGATOR_050], 
and anterioposterior views of the pelvis, ri bs, femora, and humeri are required at 
screening or baseline (ie, before the first do se of study drug).  Radiographic imaging and 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 51 of 84 
 analysis will be performed at the study center’s  local laboratory or other clinical 
laboratory listed on the investigator’ s form FDA 1572.   
4.1.18 Pharmacodynamics 
Blood samples and bone marrow, when availabl e, will be used for PD testing (eg, Btk 
occupancy and B-cell activation).  Refer to the laboratory binder for instructions on 
collecting and processing these samples.  Testing will be done by [CONTACT_456]. 
4.1.19 Pharmacokinetics 
Refer to the laboratory binder for instructions on collecting and processing these 
samples. Testing will be performed at the ce ntral clinical laboratory.  Leftover plasma 
samples may be used for exploratory ACP-196 metabolite analyses.  The PK sampling 
timepoints are provided in Table 4-1 . 
Table 4-1.  Pharmacokinetic Sample Schedule 
 HOURS POSTDOSE 
Cycle Day Predose 0.5 
(±5 min) 0.75 
(±5 min) 1 
(±5 min) 2 
(±10 min) 4 
(±10 min) 6 
(±10 min) 
1 1 X X X X X X X 
 8 X   X    
 15 X   X    
 22 X X X X X X X 
 28 X   X    
Note: These timepoints are relative to the morning dose. 
 
4.1.[ADDRESS_609038] of:  
● M-protein determination using both of the following procedures: 
○ serum protein electrophoresis (SPEP) and serum immunofixation 
electrophoresis (SIFE) 
○ Urine protein electrophoresis (UPEP) and urine immunofixation 
electrophoresis (UIFE), all using th e same 24-hour urine collection  
● SFLC 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 52 of 84 
 ● Plasmacytoma evaluation 
● Bone marrow to quantify percent myeloma cell involvement (aspi[INVESTIGATOR_475166]) 
● Skeletal survey: lateral radiograph of the skull, anteriopos terior and lateral 
views of the spi[INVESTIGATOR_050], and anterioposterior  views of the pelvis, ribs, femora, and 
humeri 
● β2-microglobulin 
On-study myeloma assessments will consist of:  
● SPEP and/or UPEP (if results were meas urable at baseline); quantitative 
immunoglobulins if used to follow disease; immunofixation to confirm a 
complete response 
● SFLC 
● Plasmacytoma evaluation (if only  measurable disease at baseline) 
● Bone marrow aspi[INVESTIGATOR_6706]/or trephine  bone biopsy (to confirm a complete 
response or if clinically indicated). 
4.1.21 Study Drug Accountability 
See Section 7.7 . 
4.2 INVESTIGATOR’S ASSES SMENT OF RESPONSE TO TREATMENT 
Subjects will be evaluated by [CONTACT_475209] 1 (Rajkumar 2011) and Eu ropean Group for Blood and Marrow 
Transplant (EBMT; Bladé 1998)as listed below in .  Response categories include sCR, 
CR,  VGPR, PR, SD, and progressive disease. In addition, the number of subjects achieving the response category of MR will also be evaluated and reported.  Subjects 
will be considered evaluable for response if they have a baseline and t1 adequate on-
study myeloma assessment obtained t4 weeks from the start of therapy.   
Table 4-2.  Response Criteria (deriv ed from Rajkumar 2011 and Bladé 1998) 
Response Subcategory Response Criteriaa 
Complete response (CR) x Negative immunofixation of serum and urine and 
x Disappearance of any soft tissue plasmacytomas and 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 53 of 84 
 x < 5% plasma cells in bone marrowb. 
Stringent complete 
response (sCR)  x CR as defined above plus 
x Normal FLC ratio and 
x Absence of clonal plasma cells by [CONTACT_128756] 2- to 
4-color flow cytometry. 
Very good partial 
response (VGPR)  x Serum and urine M- component detectable by [CONTACT_237472] 
x ≥ 90% reduction in serum M-component plus urine M- component 
< 100 mg per 24 h. 
Partial response (PR) x ≥ 50% reduction of serum M-protein and reduction in 24- h urinary 
M-protein by ≥ 90% or to < 200 mg per 24 h 
x If the serum and urine M-protein are not measurable , a ≥ 50% 
decrease in the difference between involved and uninvolved FLC 
levels is required in plac e of the M-protein criteria 
x If serum and urine M-pr otein are not measurable , and serum free 
light assay is also not measurable , ≥ 50% reduction in bone 
marrow plasma cells is required in place of M- protein, provided 
baseline percentage was ≥ 30% 
x In addition to the above crit eria, if present at baseline, ≥ 50% 
reduction in the size of soft tissue plasmacytomas is also required 
Minimal response (MR) x Requires all of the following: 
o t 25% to d 49% reduction of serum M-protein and 
o 50% to 89% reduction in 24-hour urine M-protein and 
o If present at baseline, 25-49% reduction in the size of soft 
tissue plasmacytomas and 
o No increase in size or number of lytic bone lesions 
(development of compression fracture does not exclude 
response). 
Stable disease (SD)  x Not meeting criteria for CR, VGPR, MR, PR or progressive 
disease  
 
Progressive disease Any of the following: 
x Increase of ≥ 25% from lowest response valuec in: 
o Serum M-component (abs olute increase must be ≥ 0.5 g/dL )d 
o Urine M-component (absolute increase must be 
≥ 200 mg/24 h) 
o Only in subjects without measurable serum and urine 
M-protein levels: the difference between involved and 
uninvolved FLC levels (absolute increase must be 
> 10 mg/dL) 
o Only in subjects without measurable serum and urine M-
protein levels and without measurable disease by [CONTACT_475210]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 54 of 84 
 bone marrow plasma cell percentage (absolute increase must 
be ≥ 10%) 
x Definite development of new bone lesions or soft tissue 
plasmacytomas or definite increase in the size of existing bone 
lesions or soft tissue plasmacytomas 
x Development of hypercalcemia (corrected serum calcium 
> 11.5 mg/dL) that can be attributed solely to the plasma cell 
proliferative disorder 
 
Abbreviations:  FLC = (serum) free light chains Note: in subjects in whom the only measurable disease is by [CONTACT_128758], CR requires a 
normal FLC ratio of 0.26-1.65 in addition to negative serum and urine immunofixation. VGPR in 
such subjects is defined as a > 90% decrease in  the difference between involved and uninvolved 
free light chain FLC levels 
a. All response categories (CR, sCR, VGPR, PR, and PD) require 2 consecutive assessments 
made at t4 weeks after the start of study therapy and any time before the institution of any 
new therapy after study therapy; CR, sCR, VG PR, PR, and SD categories also require no 
known evidence of progressive or new bone lesions if radiographic studies were performed. 
VGPR and CR categories require serum and urine studies regardless of whether disease at 
baseline was measurable on serum, urine, both , or neither. Radiographic studies are not 
required to satisfy these response requirements. 
b. Bone marrow assessments need not be confirmed. 
c. Lowest response value does not need to be a confirmed value. 
d. For progressive disease, serum M- component increases of ≥ 1 gm/dL are sufficient to define 
relapse if starting M- component is ≥ 5 g/dL. 
 
4.3 EARLY TERMINATION/SAFETY FOLLOW-UP VISIT 
An early termination visit is required for any subjects who permanently discontinue study 
drug early for any reason including dise ase progression.  Each subject should be 
followed for 30 (±7) days after his or her last dose of study drug (ie, the “safe ty follow-up 
visit”) to monitor for resolution  or progression of AEs (see Section 6.2.5)  and to 
document the occurrence of any new even ts; unless, the subject receives a new 
anticancer therapy within this timeframe.  Subjects who withdraw consent should still be encouraged to complete the safety follow-up assessments, but these assessments cannot be mandated once consent is wi thdrawn.  The Schedule of Assessments 
(Appendix 5 ) describes the procedures required for the safety follow-up.  
4.4 MISSED EVALUATIONS 
Missed evaluations should be rescheduled an d performed as close to the original 
scheduled date as possible.  An exception is made when rescheduling becomes, in the 
investigator’s op inion, medically unnecessary or unsafe because it is too close in time to 
the next scheduled evaluation.  In that case, the missed evaluation should be 
abandoned. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 55 of 84 
 5.0 STATISTICAL METHODS OF ANALYSIS  
5.1 GENERAL CONSIDERATIONS 
Descriptive statistics (including means, standard deviations, and medians for continuous 
variables and proportions for discrete vari ables) will be used to summarize data as 
appropriate.  Analyses will be done  by [CONTACT_178359]. 
5.2 SAMPLE SIZE CONSIDERATIONS 
This study will assess safety, PK, PD, and antitumor activity of ACP-196 alone or in 
combination with dexamethasone.  Subjects will be equally randomized into 1 of the 2 dosing regimens (ACP-196 monotherapy or ACP-196 + dexamethasone) as an 
efficient method for allocating  patients into these regimens. The study is not formally 
designed to compare these regimens but rather  to obtain descriptive information that can 
be used in support of fu rther ACP-196 development. 
While the primary objective of this study is to determine the safety in each of the 
2 dosing cohorts, the sample size has been  determine to indepe ndently evaluate the 
activity of each dosing regimen. The trial seeks to exclude an uninteresting ORR of 
d 15% (ie, the response rate that might be associated with single-agent dexamethasone 
therapy [Anderson 2013]) in favo r a target response rate of t 40%.  Considering a 
sample size of [ADDRESS_609039] the difference between a null-
hypothesis response rate of 15% and an alternative-hypoth esis response rate of 40% 
with a 0.025 one-sided significance level is 69% using a one-group, exact binomial test.  A sample size of 19 subjects per cohort will also provide a 97.5% 1-sided confidence 
interval centered around an expected ORR of  40% that excludes an ORR of 18.6% as a 
lower bound
. 
5.3 DEFINITION OF ANALYSIS POPULATIONS 
The following definitions will be used for the analysis populations: 
x Safety population:  All enrolled subjects who receive ≥ 1 dose of study drug. 
x Intent-to-treat (ITT) population : All subjects who have been randomized. 
The safety population will be used for evalua ting the safety parameters in this study.  
The ITT population will be analyzed for efficacy parameters in this study. 
5.4 MISSING DATA HANDLING 
General Considerations:   Subjects lost to follow-up (or who dropped out) will be 
included in statistical analyses up to  the point of their last evaluation. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 56 of 84 
 Duration of Response and Progression-free Survival:   Data for subjects without 
disease progression or death will be censored at the date of the last tumor assessment 
and before the initiation of alternative anticancer therapy. 
Safety:   Missing or partial start and end dates for AEs and co ncomitant medications will 
be imputed according to prespecified, cons ervative imputation rules.  No other 
imputation of values for missing data will be performed. 
5.5 ENDPOINT DATA ANALYSIS 
5.5.1 Safety Endpoint 
Safety summaries will include summaries in the form of tables and listings.  The 
frequency (number and percentage) of treatment emergent AEs will be reported in each 
treatment group by [CONTACT_61121].  Summaries will also be presented by [CONTACT_475211] (per CTCAE, v4.03) and by 
[CONTACT_8792]. 
Laboratory shift tables containing counts and percentages will be prepared by [CONTACT_11512], laboratory parameter, and time.  Summary tables will be prepared for each laboratory parameter.  Figures of changes in  laboratory parameters over time will be 
generated. 
Results of vital sign assessments and physical exams will be tabulated and summarized.   
5.5.2 Demographics and Baseline Characteristics 
Additional analyses will include summaries of subjec t demographics, baseline 
characteristics, compliance, and concurrent treatments. Concomitant medications will be 
coded according to the World Health Or ganization (WHO) Drug Dictionary and 
tabulated. 
5.5.3 Analysis of Efficacy Parameters 
[IP_ADDRESS] Overall Response Rate 
Tumor control will be documented at each assessment by [CONTACT_115188] (eg, CR, 
sCR, VGPR, PR, MR, SD, and disease prog ression) as defined for each response 
parameter, date that response is first docu mented, and date of MM disease progression. 
The overall response rate (ORR) will be defined as the proportion of subjects who 
achieve a CR, sCR, VGPR, or PR. ORR will be calculated and the corresponding 
95% two-sided confidence in terval will be derived. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 57 of 84 
 [IP_ADDRESS] Duration of Response 
The duration of response (DOR) defined as the interval from the first documentation of 
CR, sCR, VGPR, or PR to the earlier of th e first documentation of definitive disease 
progression or death from any cause.  Kaplan -Meier methods will be used to estimate 
event-free curves and corresponding quant iles (including the median). Data from 
surviving, nonprogressing subjects will be censored at the earliest of the time of initiation of anticancer treatment other than the study treatment or the last time that lack of definitive MM progression was objectively documented. Data from subjects who have 
MM progression or die after ≥ [ADDRESS_609040] time before the missing assessments that lack of MM progression 
was objectively documented. 
[IP_ADDRESS] Clinical Benefit Rate 
Clinical benefit rate (CBR) will be defined as the proportion of subjects who achieve a 
CR, sCR, VGPR, PR, or MR.  CBR will be calculated and the corresponding 95% two-sided confidence interval will be derived. 
[IP_ADDRESS] Disease Control Rate 
Disease control rate (DCR) will be defined as the proportion of subjects who achieve a CR, sCR, VGPR, PR, MR, or SD.  DCR will be calculated and the corresponding 
95% two-sided confidence in terval will be derived. 
[IP_ADDRESS] Progression-free Survival 
Progression-free survival (PFS) is defined as the interval from the date of randomization 
to the earlier of the first documentation of objective MM disease progression or death from any cause.  Kaplan-Meier methods will be used to estimate the event-free curves and corresponding quantiles (including th e median).  Data from surviving, non-
progressing subjects will be censored at the earliest of the time of initiation of anticancer treatment other than the study treatment or the last time that lack of MM progression was objectively documented. Data from subjec ts who have MM progression or die after 
≥ [ADDRESS_609041] time prior to the 
missing assessments that lack of MM progression was objec tively documented. 
5.5.4 Analysis of Pharmacokinetic/Pharmacodynamic Parameters  
The plasma PK of ACP-196 and dexamethasone will be characterized using 
noncompartmental analysis. The following PK parameters will be calculated, whenever 
possible, from plasma concentrations of ACP-196: 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609042] 
measurable concentration (C t). 
x AUC 0-12 Area under the plasma concentratio n-time curve from 0 to 12 hours, 
calculated using linear trapezoidal summation. 
x AUC 0-∞ Area under the plasma concentratio n-time curve from 0 to infinity, 
calculated using the formula: AUC 0-∞ = AUC 0-t + C t / λz, where λz is the 
apparent terminal elimination rate constant. 
x AUC 0-24calc  Area under the plasma concentratio n-time curve from 0 to 24 hours, 
calculated by [CONTACT_378152] 0-12. 
x C max Maximum observed plasma concentration 
x T max Time of the maximum plasma concentration (obtained without 
interpolation) 
x t ½ Terminal elimination half -life (whenever possible)  
x λz Terminal elimination rate constant (whenever possible) 
x CL/F Oral clearance 
Missing dates or times may be  imputed for PK and PD samples if the missing values can 
be established with an acceptable level of ac curacy based on other information obtained 
during the visit in question. If PK and PD sampling for a given subject is not performed 
according to protocol instructions that su bject may be excluded from the PK and PD 
analyses. 
The PK parameters will be tabulated and su mmarized using descriptive statistics.  
For each PD variable, the concentration at each assessment will be described.  The 
change from baseline to each assessment will be summarized.  The best change from baseline during the st udy will also be summarized.  As  appropriate, the on-treatment 
values will be compared with the pretreatment  baseline values using paired t-tests.   
5.5.[ADDRESS_609043] of monitoring and recording AEs and SAEs; 
measurements of protocol-specified hematology , clinical chemistry, urinalysis, and other 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 59 of 84 
 laboratory variables; measurement of protocol-specified vital signs; and other protocol-
specified tests that are deemed critical to the safety evaluation of the study drug(s). 
6.1 DEFINITIONS 
6.1.1 Adverse Events 
An AE is any unfavorabl e and unintended sign, symptom, or disease temporally 
associated with the use of an investigatio nal (medicinal) product or other protocol-
imposed intervention, regardless of attribution. 
This includes the following: 
x AEs not previously observed in the subject that emerge during the protocol-specified 
AE reporting period, including signs or symptoms associated with MM that were not 
present before the AE reporting period (see Section 6.2.1 ) 
x Complications that occur as a result of pr otocol-mandated interven tions (eg, invasive 
procedures such as biopsies) 
x Preexisting medical conditions (other than the condition being studied) judged by [CONTACT_475212]-specified AE reporting period. 
Abnormal laboratory values should not be reported as AEs; however, any clinically 
significant laboratory values (defined as requiring treatment, discontinuation from study, or dose modification) should be reported as AEs. 
6.1.2 Serious Adverse Event 
The terms “ severe ” and “serious” are not synonymous.  Severity (or intensity) r efers to 
the grade of an AE (see below).  “Serious” is  a regulatory definition and is based on 
subject or event outcome or action criteria usually associated with events that pose a 
threat to a subject’s life or function ing.  Seriousness (not severity) ser ves as the guide 
for defining regulatory reporting obligations from the Sponsor to applicable regulatory 
authorities. 
An AE should be classified as an SAE if it meets any 1 of the following criteria: 
x It results in death (ie, the AE actually causes or leads to death). 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 60 of 84 
 x It is life-threatening (ie, the AE, in the vi ew of the investigator, places the subject at 
immediate risk of death.  It  does not include an AE tha t, had it occurred in a more 
severe form, might ha ve caused death). 
x It requires or prolongs in-patient hospi[INVESTIGATOR_059]. 
x It results in persistent or significant disability/incapacity (ie, the AE results in 
substantial disruption of the subject’s ability to conduct normal life functions).  
x It results in a congenital anomaly/birth de fect in a neonate/infant born to a mother 
exposed to the investigational product. 
x It is considered a significant medical ev ent by [CONTACT_188212] (eg, may jeopardize the subj ect or may require medical/surgical 
intervention to prevent 1 of the outcomes listed above). 
6.1.3 Severity 
Definitions found in the CTCAE version 4.03 or higher will be used for grading the 
severity (intensity) of AEs. The CTCAE displays Grades [ADDRESS_609044] experience any AE not 
listed in the CTCAE, the following grading system should be used to assess severity: 
x Grade 1 (Mild AE) – experiences which are usually transient, requiring no special 
treatment, and not interfering with the subject’s daily activi ties 
x Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience 
or concern to the subject, and which may interfere with daily activities, but are 
usually ameliorated by [CONTACT_475213] 
x Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, 
significantly interrupt the subject’s usual daily activity, and require systemic drug 
therapy or other treatment 
x Grade 4 (Life-threatening or disabling AE) – experiences which cause the subject to 
be in imminent danger of death 
x Grade 5 (Death related to AE) – experiences which resu lt in subject death 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609045] be reported on the SAE/Product Complaint form (see Section 6.2.4 ). 
6.2.[ADDRESS_609046] dose of 
study medication and ends with the safety foll ow-up visit (or last on-treatment visit if the 
safety follow-up visit is not done), or wh en the subject receives a new anticancer 
therapy.  An exception to this reporting pe riod is any AE occurring due to a protocol-
defined screening procedure.  Fatal AEs occurring within [ADDRESS_609047]’s medical record and on the 
AE eCRF and, when applicable, on an SAE/Product Complaint form. 
Disease progression itself is not considered an adverse event; however, signs and 
symptoms of disease progression may be recorded as AEs or SAEs. 
Each recorded AE or SAE will be described by  [CONTACT_13662] (ie, start and end dates), 
severity, regulatory seriousness criteria, if ap plicable, suspected relationship to the study 
drug (ie, ACP-196, dexameth asone, or both; see following guidance), and any actions 
taken.  The relationship of AEs to the study drug will be assessed by [CONTACT_7859]: ‘Is there a reasonab le possibility that the event may have been caused by [CONTACT_50463]?’  Answer Yes o r No.  
See Appendix [ADDRESS_609048]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 62 of 84 
 reported using the SAE report form, according to the usual timelines and directions for 
SAE reporting ( Section 6.2.4 ). 
Any uncomplicated pregnancy that occurs in a subject or a partner of a treated subject 
during this study will be reported for tracking purposes only, if agreed to by [CONTACT_475214]. A ll pregnancies and partner pregnancies that are 
identified during or after this study, wherein the estimated date of conception is determined to have occurred from the time of consent to [ADDRESS_609049] interfered with the effectiveness of a 
contraceptive medication. Likewise, elective abortions without complications are not considered AEs. Any SAEs associated with pregnancy (eg, congenital 
abnormalities/birth defects/spontaneous misca rriages or any other serious events) must 
additionally be reported  as such using the SAE/Product Complaint form.  
Subjects should be instructed to immediately no tify the investigator of any pregnancies.  
Any female subjects receiving ACP-[ADDRESS_609050] be reported within 24 hours of  discover.  All initial SAE reports and follow-
up information will be reported using the protocol-specific electronic data capture 
system.  If electronic SAE reporting is no t available, paper SAE/Product Complaint forms 
must be emailed or faxed to Acerta Pharma Drug Safety, or designee.  Acerta Pharma may request follow-up and other additional info rmation from the investigator (eg, hospi[INVESTIGATOR_15517]/discharge notes and laboratory results).  
All deaths should be reported with the prim ary cause of death as the AE term, as death 
is typi[INVESTIGATOR_36069], not th e event itself. The primary cause of death on 
the autopsy report should be the term reported.  Autopsy and postmortem reports must be forwarded to Acerta Pharma Drug Safe ty, or designee, as outlined above. 
If study drug is discontinued because of an SAE,  this information must be included in the 
SAE report. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609051] and is not listed in the current 
Investigator’s Brochure (ie, an unexpecte d event). In this case, Acerta Pharma Drug 
Safety/Designee will forward a formal notifica tion describing the SAE to all investigators. 
Each investigator must then notify his or her IRB/IEC of the SAE. 
Drug Safety Contact [CONTACT_475215]:
Email:
6.2.[ADDRESS_609052] to follow-up or withdraws 
consent. 
7.0 STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS 
Acerta Pharma retains the right to terminate  the study and remove all study materials 
from a study site at any time. Specific circumstances that may precipi[INVESTIGATOR_475167]: 
x Unsatisfactory subject enrollment wi th regard to quality or quantity 
x Significant or numerous deviations from  study protocol requirements, such as 
failure to perform required  evaluations on subjects and maintain adequate study 
records 
x Inaccurate, incomplete or late data recording on a recurrent basis 
x The incidence and/or severity of AEs in this or other studies indicating a potential 
health hazard caused by [CONTACT_104841] 
7.1 REGULATORY AND ETHICAL COMPLIANCE 
This clinical study was designed and will be implemented in accordance with the 
protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practices, 
applicable local regulations (including US Code of Federal Regulations Title [ADDRESS_609053]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 64 of 84 
 European Directive 2001/20/EC), and the ethica l principles laid down in the Declaration 
of Helsinki. 
7.[ADDRESS_609054] AND INDEPENDENT ETHICS 
COMMITTEE 
The investigator will submit this protocol, the ICF , Investigator’s Brochure, and any other 
relevant supporting information (eg, all advertising materials) to the appropriate IRB/IEC for review and approval before study initiation.  A signed protocol approval page; a letter 
confirming IRB/IEC appr oval of the protocol and informed consent;  and a statement that 
the IRB/IEC is organized and operates according to GCP an d the applicable laws and 
regulations;  must  be forwarded to Acerta Pharma before  screening subjects for the 
study.  Additionally, sites must forward a signed FDA 1572 form (Statement of 
Investigator form) to Acerta Pharma before  screening subjects for study enrollment.  
Amendments to the protocol must also be ap proved by [CONTACT_1201]/IEC and local regulatory 
agencies, as appropriate, before the impl ementation of changes in this study. 
7.[ADDRESS_609055] HEALTH 
INFORMATION AUTHORIZATION 
A copy of the IRB/IEC-approved ICF must be forwarded to Acerta Pharma for regulatory 
purposes.  The investigator, or designee (designee must be listed on the Study 
Personnel Responsibility/Signature [CONTACT_94618], see Section 7.12 ), must  explain to each subject 
the purpose and nature of the study, the st udy procedures, the possible adverse effects, 
and all other elements of consent as define d in § 21CFR Part 50, and other applicable 
national and local regulations governing inform ed consent.  Each subject must provide a 
signed and dated informed consent before enrollment into this study.  In the case of a subject who is incapable of providing informed consent, the investigator (or designee) must obtain a signed and dated informed cons ent form from the subject’s legal guardian.  
Signed consent forms must remain in each subject’s study file a nd be available for 
verification by [CONTACT_9534]. 
In accordance with individual local and national patient privacy regulations, the 
investigator or designee must  explain to each subject that  for the evaluation of study 
results, the subject’s protected health information obta ined during the study may be 
shared with Acerta Pharma an d its designees, regulatory agencies, and IRBs/IECs.  As 
the study Sponsor, Acerta Pharma will not use the subject’s protected health information 
or disclose it to a third party without appl icable subject authorization.  It is the 
investigator’s or designee’s responsibility to  obtain written permissi on to use protected 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609056]’s legal guardian.  If a 
subject or subject’s legal guardian withdraws permission to use protected health 
information, it is the investigator’s respon sibility to obtain the withdrawal request in 
writing from the subject or subject’s legal guardian and to ensure that no further data will 
be collected from the subject.  Any data coll ected on the subject before withdrawal will 
be used in the analysis of study results. 
7.[ADDRESS_609057] that lists all subjects considered for enrollment 
(including those who did not undergo screen ing) in the study.  For those subjects 
subsequently excluded from enrollment , record the reason(s) for exclusion. 
7.5 CASE REPORT FORMS 
Authorized study site personnel (see Section 7.12 ) will complete eCRFs designed for 
this study according to the completion guidelin es that will be provided.  The investigator 
will ensure that the eCRFs are accurate, complete, legible, and completed within [ADDRESS_609058]’s visit  (unless required earlier for SAE re porting).  The investigator will 
ensure that source documents that are requir ed to verify the validity and completeness 
of data transcribed on the e CRFs are never obliterated or destroyed, in accordance with 
the record retention policies in Section 7.[ADDRESS_609059] to reviews or audits by [CONTACT_103], regulatory authorit ies, or ethics committees. 
Every effort will be made to maintain the anonymity and confidentiality of all subjects 
during this clinical study.  However, be cause of the experimental nature of this 
treatment, the investigator agrees to allo w the IRB/IEC, representatives of Acerta 
Pharma, its designated agents, and authorized  employees of the appropriate regulatory 
agencies to inspect the facilitie s used in this study and, for purposes of verification, allow 
direct access to the hospi[INVESTIGATOR_475168].  This 
includes providing by [CONTACT_6791], email, or regular mail de-identified copi[INVESTIGATOR_134464], 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 66 of 84 
 pathology, and/or laboratory results when requ ested by [CONTACT_456].  A statement to this 
effect will be included in the informed cons ent and permission form authorizing the use 
of protected health information. 
7.[ADDRESS_609060] be  maintained and readily available for 
inspection by [CONTACT_475216].  
Each shipment of study drug will contain a Clinical Supplies Sh ippi[INVESTIGATOR_378128] 
(CSSF) that must be appended to the site’s drug accountability records. If it is used, the 
Drug Re-order Form (provided in the pharmacy binder) must also be included in the 
site’s drug accountability records.    
Contents of each shipment must be visual ly inspected to verify the quantity and 
document the condition of study drug capsules.  Then the designated recipi[INVESTIGATOR_475169]. A copy of the signed CSSF must be faxed or emailed to 
Acerta Pharma at the fax number/emailing address listed on the form. 
An Investigational Drug Accountability Log mu st be used for drug accountability.  For 
accurate accountability, the following information must be noted when drug supplies are used during the study: 
1. study identification number (ACE-MY-001) 
2. subject identification number 
3. lot number(s) of ACP-[ADDRESS_609061] 
At study initiation, the monitor will evalua te and approve the site’s procedure for 
investigational product disposal/destruction to ensure that it complies with Acerta Pharma ’s requirements. If the site cannot meet Acerta Pharma ’s requirements for 
disposal/destruction, arrangements will be ma de between the site and Acerta Pharma or 
its representative, for return of unused investigational product.  Before 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 67 of 84 
 disposal/destruction, final drug accountability and reconciliation must be performed by 
[CONTACT_2037]. 
All study supplies and associ ated documentation will be regularly reviewed and verified 
by [CONTACT_2037]. 
7.[ADDRESS_609062] RETENTION 
The investigator and other appropriate stud y staff are responsible for maintaining all 
documentation relevant to the study. Mandat ory documentation includes copi[INVESTIGATOR_475170], each FDA Form 1572, IRB/IEC approval letters, signed 
ICFs, drug accountability records, SAE forms tr ansmitted to Acerta Pharma, subject files 
(source documentation) that substantiate entries in eCRFs, and all relevant 
correspondence and other documents pertaining to the conduct of the study. 
An investigator shall retain records for a period  of at least [ADDRESS_609063] 
marketing application is approved for the drug  for the indication for which it is being 
investigated; or, if no application is to be f iled or if the application is not approved for 
such indication, until [ADDRESS_609064] from th e study site so that they can be returned 
sealed to the investigator for audit purposes. 
7.9 PROTOCOL AMENDMENTS 
Acerta Pharma will initiate any change to  the protocol in a protocol amendment 
document. The amendment will be submitted to the IRB/IEC together with, if applicable, 
a revised model ICF. If the change in any way increases the risk to the subject or 
changes the scope of the study, then writte n documentation of IRB/IEC approval must 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609065]. Additionally 
under this circumstance, informa tion on the increased risk an d/or change in scope must 
be provided to subjects already actively part icipating in the study, and they must read, 
understand, and sign any revised ICF confirming willingness to remain in the trial. 
7.[ADDRESS_609066]. The results may also be used for 
papers, abstracts, posters or other material pr esented at scientific meetings or published 
in professional journals or as part of an ac ademic thesis by [CONTACT_2413]. The study is 
being conducted as part of a multicenter clinical  trial. Data from all study centers shall be 
pooled and analyzed for publication in a fi nal report (Primary Publication). The 
investigator agrees that the Primary Public ation, which will be coordinated by [CONTACT_475217], will be the first publication to presen t the pooled study results. After the Primary 
Publication, or if the Primary Publication is not published within [ADDRESS_609067] matter and/or any 
inadvertent disclosure of its confidential information, which must be redacted from any final publication or presentation. If necessary, to permit the preparation and filing of patent applications, Acerta Pharma may elect an additional review period not to exceed 
60 days. 
Authorship, in general, will follow the recomm endations of the International Committee of 
Medical Journal Editors (International Commit tee of Medical Journal Editors 2014).   
7.[ADDRESS_609068] ensure that: 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609069] of the study clearly 
understand their responsibilities and hav e their names includ ed in the Study 
Personnel Responsibility/Signature [CONTACT_94618]. 
3. The study is conducted according to the protocol and all applicable regulations. 
4. The protection of each subject’s rights and welfare is maintained.  
5. Signed and dated informed consent an d, when applicable, permission to use 
protected health information are obtained  from each subject before conducting 
nonstandard of care study procedures.  If a subject or subject’s legal guardian 
withdraws permission to use protected health information, the investigator will 
obtain a written request from t he subject or subject’s legal guardian and will 
ensure that no further data be  collected from the subject. 
6. The consent process is conducted in co mpliance with all applicable regulations 
and privacy acts. 
7. The IRB/IEC complies with applicable  regulations and co nducts initial and 
ongoing reviews and approvals of the study. 
8. Any amendment to the protocol is submitted promptly to the IRB/IEC. 
9. Any significant protocol deviations are reported to Acerta Pharma and the 
IRB/IEC according to the guidelines at each study site. 
10. Electronic CRF pages are completed within [ADDRESS_609070]’s visit  (unless 
required earlier for SAE reporting). 
11. All IND Safety Reports/ Suspected Unexpected Serious Adverse Reaction 
(S[LOCATION_003]R) Reports are submitted promptly to the IRB/IEC. 
12. All SAEs are reported to Acerta Pharma  Drug Safety/Designee within 24 hours of 
knowledge and to the IRB/IEC per their requirements. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 70 of 84 
 8.0 REFERENCES 
Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma, version 1.2013. J Natl 
Compr Canc Netw 2013;11:11-17.  
Bladé J, Samson D, Reece D, et al.  Cr iteria for evaluating disease response and 
progression in patients with multiple myeloma treated by [CONTACT_5019]-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European 
Group for Blood and Marrow Transplant.  Br J Haematol 1998;102:1115-1123. 
Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular 
switches. Cell Signal 2010;22:1175-1184.  
Buggy JJ, Elias L. Bruton tyrosine kinase (Btk ) and its role in B-cell malignancy. Int Rev 
Immunol 2012;31:119-132. Erratum in: Int Rev Immunol 2012;31:428. 
By[CONTACT_9063], Furman RR, Coutre SE, Flinn IW, et al . Targeting Btk with ibrutinib in relapsed 
chronic lymphocytic leukemia. NEJM 2013;369:32-42. 
By[CONTACT_9063], Brown JR, O’Brien S, et al.  Ibruti nib versus ofatumumab in previously treated 
chronic lymphoid leukemia.  NEJM 20 14 May 31 [Epub ahead of print] 
Cheson BD, By[CONTACT_9063], Rai KR, et al. Novel target ed agents and the need to refine clinical 
end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820-2820. 
Cheson BD, By[CONTACT_9063], Rai KR, et al. Novel target ed agents and the need to refine clinical 
end points in chronic lymphocytic leukemia. J Clin Oncol 2012 30:2820-2822. 
Edwards CM, BTK inhibition in myeloma:  targeting the seed and soil.  Blood 
2012;120:1757-1759.   
FDA (US Food and Drug Ad ministration). Guidance for industry. Food-Effect 
Bioavailability and Fed Bioequivalence Studies. 2002 Dec. Available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guida
nces/ucm070241.pdf.  A ccessed January 19, 2015. 
Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism 
by [CONTACT_475218]. Metabolite identifica tion and inhibi tion of 6-hydroxylation. J 
Pharmacol Exp Ther 1996;277:105-12. 
Hallek M, Cheson BD, Catovsky D, et al.  Guidelines for the diagnosis and treatment of 
chronic lymphocytic leukemia: a report from  the International Workshop on Chronic 
Lymphocytic Leukemia updating the Nation al Cancer Institute-Working Group 1996 
guidelines. Blood 2008;111:5446-5456. 
Hellmann A, Rule S, Walewski J, et al. Effect of cytochrome P450 3A4 inducers on the 
pharmacokinetic, pharmacodyna mic and safety profiles of bo rtezomib in patients with 
multiple myeloma or non-Hodgkin's lymp homa. Clin Pharmacokinet 2011;50:781-791. 
Honigberg LA, Smith AM, Sirisawad M, et al .  The Bruton tyrosine kinase inhibitor 
PCI-[ZIP_CODE] blocks B-cell activation and is e fficacious in models of autoimmune disease 
and B-cell malignancy. PNAS 2010;107:[ZIP_CODE]-[ZIP_CODE]. 
IMBRUVICA [package insert].  Horsham, PA: Janssen Biotech, Inc; 2014. 
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Schola rly Work in Medical Journals. 2014 Dec.  
Available from: http://www.ICMJE.org.  Accessed February 04, 2015. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 71 of 84 
 Mohamed AJ, Yu L, Bäckesjö CM, et al. Br uton's tyrosine kina se (Btk): function, 
regulation, and transformation with specia l emphasis on the PH domain. Immunol Rev 
2009;228:58-73. 
Ngoma PD, Kabamba B, Da hlgbist G, et al.  Occult HBV re activation induced by [CONTACT_475219]: a case report. Acta Gastroenterol Belg. 2015;78:424-426. 
Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of 
action in multiple myeloma in 2013: a report from the International Myeloma Working 
Group (IMWG). Leukemia 2014;28:525-542.   
Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop 
Consensus Panel 1. Consensus recommendation s for the uniform reporting of clinical 
trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 
May 5;117(18):4691-5.  
Rajkumar SV, Jacobus S, Callander NS, et a; Eastern Cooperative Oncology Group. 
Lenalidomide plus high-dose dexamethason e versus lenalidomide plus low-dose 
dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label 
randomised controlled trial. Lancet Oncol 2010;11:29-37. Erratum in: Lancet Oncol 2010;11:14. 
Romano A, Conticello C, Cavalli M, et al. Sa lvage therapy of multiple myeloma: the new 
generation drugs. Biomed Res Int 20 14;2014:456037. Epub 2014 May 19. 
Tai YT, Chang, BY, Kong SY, et al.  Bruton  tyrosine kinase in hibition is a novel 
therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple 
myeloma.  Blood 2012:120:1877-1887. 
Vail DM, Thamm DH. Spontaneously occurring tumors in companion animals as models 
for drug development. In: Teicher BA, Anders  PA, eds. Anticancer Drug Development 
Guide: Preclinical Screening, Clinical Tria ls, and Approval. 2nd Ed. Totowa, NJ: Human 
Press; 2004:259-284. 
Vail DM, Michels GM, Khanna C, Selting KA, London CA; Veterinary Cooperative 
Oncology Group. Response eval uation criteria for peripher al nodal lymphoma in dogs 
(v1.0) —a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet 
Comp Oncol 2010;8:28-37. 
Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (Btk) in X-linked 
agammaglobulinemia (XLA). Front Biosci 2000;5:D917-D928. 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609071]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 73 of 84 
  
Appendix 1. Performance Status Scores  
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuou s activity but ambulatory and able 
to carry out work of a light or sedentary nature, eg, light house work, office work 
2 Ambulatory and capable of all self -care but unable to carry out any 
work activities. Up and about mo re than 50% of waking hours 
3 Capable of only limited self-care,  confined to bed or chair more 
than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair 
5 Dead 
As published in Am J Clin Oncol: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, 
P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982. 
Credit: Eastern Cooperative Oncology Group Chair: Robert Comis, MD 
Available at: http://www.ecog.org/general/perf_stat.html .  Accessed [ADDRESS_609072]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609073] been caused by [CONTACT_5349]?  
No___ Yes___ 
The descriptions provided below will help guide the principal investigator [INVESTIGATOR_378132] “yes” or “no”:  
No = There is no reasonable possibility that  the event may have been caused by [CONTACT_378159]. 
The adverse event: 
x may be judged to be due to extraneous causes such as disease or environment 
or toxic factors 
x may be judged to be due to  the subject’s clinical state or other therapy being 
administered 
x is not biologically plausible 
x does not reappear or worsen when study drug is re-administered 
x does not follow a temporal sequence  from administration of study drug 
Yes = There is a reasonable possibility that  the event may have been caused by [CONTACT_378159]. 
The adverse event: 
x follows a temporal sequence from  administration of study drug 
x is a known response to the study drug based on clinical or preclinical data 
x could not be explained by [CONTACT_475220]’s clinical state, 
environmental or toxic factors, or othe r therapy administered to the subject 
x disappears or decreases upon cessation or reduction of dose of study drug 
x reappears or worsens when study drug is re-administered 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609074] John's wortf  
indinavir  
itraconazoleb  
ketoconazoleb  
lopi[INVESTIGATOR_054]/ritonavirb (combination drug)  
mibefradild  
nefazodone  
nelfinavir  
posaconazole  
ritonavirb  
saquinavir  
telaprevir  
telithromycin  
voriconazole  
  
a. A strong inhibitor for CYP3A is defined as an inhi bitor that increases the AUC of a substrate for CYP3A 
by ≥ 5-fold. 
b. In vivo inhibitor of P-glycoprotein. 
c. The effect of grapefruit juice varies widely amo ng brands and is concentration-, dose-, and preparation-
dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a c ertain 
preparation was used (eg , high dose, double strength) or as a “moderate CYP3A inhibitor” when 
another preparation was used (eg, low dose, single strength). 
d. Withdrawn from the [LOCATION_002] market because of safety reasons. 
e. A strong inducer for CYP3A is defined as an inducer that results in ≥ 80% decrease in the AUC of a 
substrate for CYP3A. 
f. In vivo inducer of P-glycoprotein.   
 
Note: The list of drugs in these tables is not ex haustive.  Any questions about drugs not on this list 
should be addressed to the Medical Monitor of the protocol. 
 
Source: FDA Drug Development and Drug Interactions: Table of  Substrates, Inhibitors and Inducers.  Web link 
Accessed 21 January 2015: http://www.fda.gov/Drugs/DevelopmentApprovalPr ocess/DevelopmentResources/DrugInteractionsLabe
ling/ucm093664.htm#inVivo 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 76 of 84 
 Appendix 4.  Dexamethaso ne Prescribing Information 
 
The [LOCATION_002] label for dexamethason e tablets (Roxane Labo ratories 2007) is 
provided for reference.  The [LOCATION_002] label will also serve as the Reference Safety 
Information for dexamethasone for this study.  Country-specific labels will be provided to 
investigative sites as appropriate. 
 
Product: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609075]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609076]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609077]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609078]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609079]: ACP-196 (acalabrutinib) 
Date: 13 January 2016 
Protocol: ACE-MY-[ADDRESS_609080]: ACP-196 (acalabrutinib)  
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 83 of 84 
 Appendix 5.  Schedule of Assessments 
 Screeninga Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycles 5-12b ET/Safety 
Follow Upc 
  Days (± 2) Days (± 2) Days (± 2) Days (± 2) Days (± 2)  
1 8 15 22 28 15 28 28 28 28  
Informed consent x            
Confirm eligibility x            
Medical history x            
PEd/Vital signse/Weight x x x x x x x x x x x x 
ECOG status x x x x x x x x x x x x 
ECGf x x x 
Lab assessments:             
 Urine pregnancy 
testg x           x 
 Hematologyh x xq x x x x x x x x x x 
 Serum chemistryi x xq x x x x x x x x x x 
 Urinalysisj x     x  x x x Every 2 mos  
 T/B/NK cell countk  xq x x  x  x   Every 6 mos  
 Disease markersl x  x  x  x x x Every 2 mos x 
Bone marrow 
(aspi[INVESTIGATOR_337]/biopsy) 
/Skeletal surveyp x        As 
clinically 
indicated 
or to 
confirm a 
CR As 
clinically 
indicated 
or to 
confirm a 
CR As clinically 
indicated or 
to confirm a 
CR  
Hepatitis serologyr x            
HBV PCRs      x  x x x QM QM 
 Pharmacodynamics  xm xm   xn  xn    x 
 Pharmacokineticso  x x x x x       
ACP-196/ 
dexamethasone  
dispensed  x x x x x x x x x x  
Study drug compliance  x x x x x x x x x x  
Tumor assessmentp x     x  x x x x  
Concomitant 
medications x x x x x x x x x x x x 
Adverse events x x x x x x x x x x x 
Product: ACP-196 (acalabrutinib)  
Date: 13 January 2016 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 84 of 84 
 Abbreviations: anti-HBc = hepatitis B core antibody; CR = comple te remission; ECG = electrocardiogram; ECOG = Eastern Cooperati ve Oncology Group; ET = 
early termination; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B surface antigen; H BV = hepatitis B virus; HCV = he patitis C virus; Ig = 
immunoglobulin; IVIG = intravenous immunoglobulins; mos = months; PCR = polymerase chain reaction; PE = physical exam; QM = eve ry month. 
Footnotes for ACE-MY-001 Schedule of Study Activities : 
a.  Screening tests should be performed within [ADDRESS_609081] not progressed while receiving study drug treatment, may be eligible to enroll into a long-term follow  up study and continue to receive ACP-
196. 
c. An early termination visit is required for any subjects who permanently discontinue study drug early for any reason includin g disease progression.  A 30-day (± 7 days) 
safety follow-up visit is required when subjects discontinue study drug unless they start another anticancer therapy within tha t timeframe. 
d. The screening physical examin ation will include, at a minimum,  the general appearance of t he subject, height (screening only ) and weight, and examination of the 
skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous syste m.  Symptom-directed physical exams 
are done thereafter.   
e. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and temperature)  will be assessed after the subject has rested in the sitting position.   
f. Subjects should be in supi[INVESTIGATOR_475171] ≥ [ADDRESS_609082] be ruled out by [CONTACT_375842]. 
h. Hematology includes complete blood count with differential and platelet and reticulocyte counts. Cycle 1 Day 1 hematology do es not need to be repeated if screening 
hematology was within 5 days. 
i. Serum chemistry: albumin, alkaline phosphatase, bone-specific alkaline phosphatase, alanine transaminase (ALT), aspartate am inotransferase (AST), bicarbonate, 
blood urea nitrogen (BUN), calcium, chloride, creatinine, C-terminal telopeptide, glucose, lactate dehydrogenase (LDH), magnesi um, phosphate, potassium, sodium, 
total bilirubin, total protein, and uric acid. Cycle 1 Day 1 serum chemistry d oes not need to be repeated if screening serum ch emistry was within 5 days. 
j. Urinalysis: pH, ketones, specific gr avity, bilirubin , protein, blood, N- terminal telopeptide, and glucose.  
k. T/B/NK cell count (ie, CD3, CD4, CD8, CD19, CD16/56).  During Cycle 5-12, only done at end of Cycle [ADDRESS_609083] of myeloma disease markers. 
m. Pharmacodynamic samples are drawn predose and 4 hours (±10 minutes) postdose on the days indicated. Note: These timepoints a re relative to the morning dose. 
n. Pharmacodynamic samples are drawn predose on the days indicated. 
o. Pharmacokinetic samples are drawn per Table 4-1 . 
p Refer to Section 4-2.  Bone marrow aspi[INVESTIGATOR_337]/biopsy and skeletal survey are required at baseline (ie, before the first dose of  study drug).  Thereafter they are required 
as indicated in the table above. 
q. The indicated samples at this timepoint (Cycle 1 Day 1) must be drawn predose. 
r. Hepatitis serology must include hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (anti-HBc), and hepatitis C (HCV) 
antibody.  Subjects who are receiving prophylactic intravenous immunoglobulins (IVIG) and have positive HBsAg or anti-HBc must have negative hepatitis B DNA to 
be eligible.  In addition, any subjects testing positive for any hepatitis serology, must have PCR testing (see exclusion crite rion #11). 
s. Subjects who are anti-HBc positive (or have a known history of HBV infection) should be monitored monthly with a quantitativ e PCR test for HBV DNA.  Monthly 
monitoring should continue until [ADDRESS_609084] with a rising viral load (above lower limit  of detection) should discontinue 
ACP-[ADDRESS_609085]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
PROTOCOL
TITLE: An Open-label, Phase 1b Study of ACP-196 in Subjects 
with Multiple Myeloma
PROTOCOL NUMBER: ACE-MY-001
STUDY DRUG: ACP-196
IND NUMBER: [ADDRESS_609086] NUMBER 2014-003587-21
SPONSOR MEDICAL 
MONITOR: Acerta Pharma BV
SPONSOR: Acerta Pharma BV
Molenstraat 1105342 CC Oss
The Netherlands
PROTOCOL DATE: Version 0.0 - 11 July 2014
AMENDMENT 1 DATE: Version 1.[ADDRESS_609087] (IRB)/independent ethics committee (IEC). This information 
cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Acerta Pharma BV.
Acerta Pharma Confidential Page [ADDRESS_609088]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609089] been made throughout the protocol. In 
addition, the following substantive changes were made as part of this amendment:
Change Rationale
Title Page:  changed Medical Monitor Sandeep Inamdar, MBBS, is now the Acerta 
Pharma Medical Monitor for the study.
Synopsis:
Revised textThe synopsis was updated to reflect the 
changes made throughout the protocol.
Section 1.1 Role of BTK in Lymphoid Cancers:  
Added background information on ibrutinibInformation added to provide context of 
ACP-196 development compared with other 
BTK inhibitors such as ibrutinib.
Section 1.2.2 Efficacy Pharmacology:
Revised Table 1-1Table updated to reflect new preclinical data.
Section 1.2.4 ACP-196 and Thrombus 
Formation:
New section added.An in vivo murine model of human thrombus 
formation showed that the thrombi formed by 
[CONTACT_475221]-[ADDRESS_609090], ibrutinib-treated platelets showed 
reduced thrombus formation, which may provide some mechanistic background for the 
bleeding events seen in patients treated with 
ibrutinib.  
Section 1.2.6 Drug-drug Interaction Potential:
Revised text throughout sectionSection updated to reflect new clinical data.
Section 1.3 Clinical Experience:
Revised Table 1-2; updated text and added 
new subsections 1.3.[ADDRESS_609091] current clinical data
from ACE-CL-001.
Section 1.4 Benefit/Risk:New section added.  Section added to summarize the risk/benefit 
to subjects in this study.  
Section 2.2 Secondary Objective:
Added endpoints of clinical benefit rate (CBR) 
and disease control rate (DCR), and deleted 
time-to-next treatment.  In addition to the endpoint of overall response
rate (ORR), which includes complete 
responses and partial responses, the activity 
of ACP-196 will be evaluated by [CONTACT_475222] (overall response plus minimal responses) and disease control rate 
(clinical benefit plus stable disease).  
Time-to-next treatment analysis was 
removed, as subjects who experience 
disease progression on study are expected to 
move quickly on to a new anticancer regimen.  
Section 3.1 Description of Study: Added Sites/countries added to clarify study 
Acerta Pharma Confidential Page [ADDRESS_609092]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Change Rationale
number of planned sites and countries and
defined end of trial.  structure. End of trial defined for reporting 
purposes
Section 3.2.2 Efficacy Parameters:  Added 
clinical benefit rate and disease control rate,deleted time-to-next treatment.  Revised to reflect changes in Section 2.2 
Secondary Objectives, as noted above.  
Section 3.3 Rationale for Study Design and 
Dosing Regimen:  updated Btk occupancy 
data.Updated to reflect current data from ACE-CL-
001.
Section 3.4.1 Inclusion Criteria:  
Added new inclusion criteria:
xEvaluable myeloma at screening, 
defined as the presence of at least 
one of the following:
oSerum M-p URWHLQ 0.5 g/dL
oUrine M-protein 
200 mg/24 hours
oIn subjects without detectable 
serum or urine M-protein, 
serum free light chain (SFLC) > 100 mg/L (involved light 
chain) andan abnormal 
serum kappa/lambda ratio
oFor subjects whose disease 
can only be reliably 
measured by [CONTACT_475205] A,J$,J$ 750 mg/dL 
(0.75 g/dL) Subjects must have measurable disease at 
screening to allow adequate evaluation of 
response on study.  
Section 3.4.2 Exclusion Criteria:
Added 3 new criteria:
xPlasma cell leukemia or circulating 
plasma cells 2x1 09/L
xKnown history of a bleeding diathesis 
(eg, hemophilia, von Willebrand disease)
xRequires treatment with long-acting 
proton pump inhibitors (eg, omeprazole, esomeprazole, 
lansoprazole, dexlansoprazole,
rabeprazole, or pantoprazole)
Revised exclusion criteria as follows:
xRemoved ECG exclusion criteria, 
except that QTc > 480 msec was 
moved to cardiovascular disease 
exclusion criteria
xAdded gastric by[CONTACT_475223]-3 kinase 
[PI3K], Syk, and BCL-[ADDRESS_609093] 
(phenprocoumon) within [ADDRESS_609094] generation Btk inhibitor, ibrutinib 
[IMBRUVICA package insert]; therefore, 
subjects with a known history of a bleeding diathesis will be excluded from this study.  
Preliminary results from a healthy volunteer 
study suggest subjects should avoid the use 
of calcium carbonate containing drugs or supplements (eg, antacids and calcium 
supplements) and short-acting H2 receptor 
antagonists for a period of at least [ADDRESS_609095]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Change Rationale
neutrophil count (ANC) and platelet 
count in subjects with bone marrow 
involvement:  ANC < 0.50 x 109/L or 
platelet count < 30 x 109/L 
xChanged aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) limits from > 2.5 x upper limit of 
normal (ULN) to > 3.[ADDRESS_609096] and 
removed exception for disease-related abnormalities for bilirubin and
ALT/ASTa long-acting proton pump inhibitor while on 
study (eg, to treat an ulcer), treatment options 
should be discussed with the Medical Monitor.
Based on the safety results observed in the 
ongoing first-in-human study of ACP-196, the 
ECG exclusion criteria have been narrowed to 
exclude QTc > 480 msec at screening.
Section [IP_ADDRESS] ACP-196:
Removed 25-mg capsule information; deleted 
inactive excipi[INVESTIGATOR_475172] 25-mg strength capsule.
Section [IP_ADDRESS] Dexamethasone:Added information about supply and storage of dexamethasone.Acerta Pharma will either directly s upply sites 
with dexamethasone or the sites will be reimbursed to prescribe dexamethasone; this 
will be detailed separately in each site’s 
clinical trial agreement.  
Per the US dexamethasone package insert 
(Appendix 4), tablets are to be stored at room 
temperature (20° to 25°C) and protected from 
moisture and light.  
Section [IP_ADDRESS] Study Treatment Regimen 
and Dose Modifications, ACP-196:Revised text and Table 3-1:  
New Section Dose Delays states:
Treatment with ACP-196 should be held for 
any unmanageable, potentially study drug-
related toxicity that is Grade [ADDRESS_609097] be discussed with 
the Medical Monitor.  Study drug may be held 
for a maximum of 28 consecutive days from 
expected dose due to toxicity.  Study 
treatment should be discontinued in the event 
of a toxicity lasting > 28 days, unless 
reviewed and approved by [CONTACT_22955].
Note: temporary withholding of study drug for 
as little as 7 days can cause a transient 
worsening of disease and/or of constitutional 
symptoms.  Refer to Section 3.9 for more 
information on assessing disease progression 
under these circumstances.
New Section Dose Modification and 
Discontinuation states:
The actions in Table 3-1 should be taken for This section is now 2 sections.  
Data from the ongoing study of ACP-196 in 
subjects with CLL (Section1.3.2) suggest full 
Btk occupancy (> 90%) over [ADDRESS_609098]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Change Rationale
the following toxicities:
xGrade 4 absolute neutrophil count 
$1&ȝ/IRU!GD\V
(Neutrophil growth factors are 
permitted per ASCO guidelines 
[Smith 2006] and use must be 
recorded on the electronic case 
report form [eCRF]).
xGrade 3 platelets in the presence of
significant bleeding
xGrade 4 platelets 
xGrade 3 or 4 nausea, vomiting, or 
diarrhea, if persistent despi[INVESTIGATOR_271182]/or anti-diarrheal 
therapy
xAny other Grade 4 toxicity or 
unmanageable Grade 3 toxicity.
Table 3-1 states:
Occurrence ÆAction
1st - 2ndÆHold ACP-196 until recovery to 
*UDGHRUEDVHOLQHPD\UHVWDUWDWRULJLQDO
dose level 
3rdÆHold ACP- XQWLOUHFRYHU\WR*UDGH
1 or baseline; restart at 100 mg once daily
4thÆDiscontinue ACP-196
Specified that subjects in Cohort 1 (ACP-196
monotherapy) who do not experience at least 
an minimal response (MR) after [ADDRESS_609099] dexamethasone 
(40 mg once weekly) added to their 
treatment.  
Section 3.6.2 Guideline for Use of CYP 
Inhibiting/Inducing Drugs:
New section added Language regarding monitoring of subjects on 
CYP3A inhibitors/inducers was moved 
(formerly appeared under Precautions/Drug-
drug Interactions) and revised for clarity and 
consistency with other studies.  At the systemic exposure levels expected in this 
study, ACP-196 inhibition of CYP metabolism 
is not anticipated.  However, as discussed in Section 1.3.1, concomitant administration of 
ACP-196 with a strong CYP3A4 inhibitor 
increased exposure by [CONTACT_3450] 5-fold.  
Consequently, the concomitant use of strong 
inhibitors/inducers of CYP3A4 (Appendix 3) should be avoided when possible.  If a subject 
requires a strong CYP3A4 inhibitor while on 
Acerta Pharma Confidential Page [ADDRESS_609100]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609101] Gastric pH:New section addedLanguage regarding the use of drugs that 
affect gastric pH was added to reflect current findings on the effect of agents that reduce 
gastric acidity (eg, proton pump inhibitors, H2-
receptor antagonists or antacids) on ACP-196 absorption in a healthy volunteer study (ACE-
HV-004).  Preliminary results from this study 
suggest subjects should avoid the use of 
calcium carbonate containing drugs or 
supplements (eg, antacids or calcium supplements) for a period of at least [ADDRESS_609102] requires 
treatment with a long-acting proton pump inhibitor while on study (eg, to treat an ulcer), 
discuss treatment options with the Medical 
Monitor.
Section 3.6.4 Prohibited Concomitant 
Therapy:  Added live or live attenuated 
vac c ines .   Per the dexamethasone package insert, 
administration of live or live, attenuated 
vaccines is contraindicated in patients receiving immunosuppressive doses of 
corticosteroids. Killed or inactivated vaccines 
may be administered. However, the response 
to such vaccines cannot be predicted.
Section 3.7.1 Dietary Restrictions:
xAdded caution against excessive 
consumption of grapefruit or Seville oranges or use of herbal remedies 
such as St. John’s Wort.  
xAdded that ACP-196 can be taken
with or without food.Because ACP-196 may be metabolized by 
[CONTACT_097]3A4/3A5, subjects are cautioned against 
ingesting these known CYP3A inhibitors and 
inducers.  
Section 3.7.2 Drug-drug Interactions:  Section 
removed.Information about drug-drug interactions with 
CYP inhibitors/inducers was moved to the 
Concomitant Medications section of the 
protocol (Section 3.6.2).  
Section 3.7.2 Surgery:New section added.Susceptibility to bleeding has been observed 
with the first generation Btk inhibitor, ibrutinib 
[IMBRUVICA package insert].  As a 
precaution, it is suggested that ACP-196 be 
held for 3 days before and after any major surgical procedure.
Section 3.7.3 Infections:New section added.Per the dexamethasone package insert, 
patients who are on corticosteroids are more susceptible to infections than are healthy 
individuals. Corticosteroids may exacerbate 
systemic fungal infections and therefore 
Acerta Pharma Confidential Page [ADDRESS_609103]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Change Rationale
should not be used in the presence of such 
infections unless they are needed to control 
life-threatening drug reactions.
Section 3.8 Stoppi[INVESTIGATOR_475173]:
Any subject who is unable to tolerate a
second rechallenge with at the lowest 
protocol-described, dose-modified levels (see 
Section 3.5.5) should be withdrawn from the 
study treatment unless continued therapy is 
permitted by [CONTACT_475224].Clarified disease assessment in the event that 
transient worsening of disease is observed 
during temporary interruption of study therapy.  
Revised instructions for study discontinuation 
to be consistent with the dose modification 
instructions in Section 3.5.5.  
Section 4.1 Description of Procedures:
Revised as noted: 
- Electrocardiograms (ECGs) – changed 
screening ECG from triplicate to single, and added a single ECG to 30-day 
Safety Follow-up visit
- Tumor Assessments – text added
- Routine Clinical Assessments – new text 
section added- ECG criteria were revised for 
consistency with other protocols
- Tumor assessment requirements were 
further clarified.
- Routine Clinical Assessments section 
added to clarify non-radiology 
assessments needed to support overall response.
Section 4.2 Investigator’s Assessment of Response:  Updated Table 4-1.Response criteria updated to reflect the latest 
criteria (Rajkumar 2011), including removal of near complete response (nCR) category.
Section 4.3 Early Termination/Safety Follow-
up Visit:  Specified that an early termination 
visit is required for any subjects who 
permanently discontinue study drug early for 
any reason including disease progression.  Clarifying edit.  
Section 5.2 Sample Size Considerations:  
Deleted power calculation based on chi 
square test (no change in power based on 
exact binomial test).  Clarifying edits; no substantive change in 
sample size calculations.  
Section 5.3 Definition of Analysis Populations:
Replaced per-protocol analysis set with
intent-to-treat ITT population for efficacy 
endpoints.Efficacy analyses will be done on randomized 
subjects (ie, the ITT population) for this study.
PK/PD analyses will be further defined in a 
separate statistical analysis plan.  
Section 5.4 Missing Data Handling:
Revised textClarified and specified missing data handling 
procedures for response and safety 
parameters.
Section [IP_ADDRESS] Overall Response Rate:  
removed nCR and MR from this endpoint;
replaced 97.5% one-sided confidence interval 
with 95% two-sided confidence interval.  Per the current guidelines (Rajkumar 2011), 
nCR is not defined, and minimal response 
rate should be considered separately from 
ORR.  
Section [IP_ADDRESS] Duration of Response:  
removed nCR and MR from this endpoint.  Per the current guidelines (Rajkumar 2011), 
nCR is not defined, and minimal response 
Acerta Pharma Confidential Page [ADDRESS_609104]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Change Rationale
rate should be considered separately from 
overall response.  
Section [IP_ADDRESS] Clinical Benefit Rate:  Added 
new section.Added endpoint of CBR, defined as the 
proportion of subjects who achieve a CR, sCR, VGPR, PR, or MR.
Section [IP_ADDRESS] Disease Control Rate:  Added 
new section.Added endpoint of DCR, defined as the 
proportion of subjects who achieve a CR, 
sCR, VGPR, PR, MR, or SD.
Section [IP_ADDRESS] Progression-free Survival:  defined start of PFS interval as the date of 
randomization, rather than the start of ACP-
196 therapy.  As the PFS analysis will be performed on the 
ITT population, the start randomization is a 
more appropriate timepoint for the PFS 
interv al.  
Section [IP_ADDRESS] Time-to-Next Treatment:  
Section deleted; long-term follow-up visits are 
no longer required.  Time-to-next treatment analysis was 
removed, as subjects who experience 
disease progression on study are expected to 
move quickly on to a new anticancer regimen.  
Section 5.5.4 Analysis of 
Pharmacokinetic/Pharmacodynamic 
Parameters:  Added AUC 0-12analysis and 
defined AUC 0-24calc (calculated by [CONTACT_475225] A UC 0-12)PK parameters revised to be consistent with 
other studies that use BID dosing.
Section 6.2.1 Adverse Event Reporting 
Period:
Added underlined text:  The AE reporting 
period for this study begins when the subject receives the first dose of study and ends with 
the safety follow-up visit (or last on-treatment 
v isit if the safety follow-up v isit is not done) or 
if the subject receives a new anticancer 
therapy.Added text to clarify the end of the AE 
reporting period.  
Section 6.2.3 Pregnancy:  Revised reporting procedures to reflect single-part formClarifying edits 
Section 6.2.4 Expedited Reporting 
Requirements for Serious Adverse Events:  
Instructions clarified to emphasize use of the electronic reporting system (no substantive 
change in reporting procedures).  Clarifying edits
Section 7.1 Regulatory and Ethical 
Compliance: New section added (with subsequent re-
numbering of sections 7.2-7.12).  New text 
reads:
This clinical study was designed and will be 
implemented in accordance with the protocol, 
the ICH Harmonized Tripartite Guidelines for 
Good Clinical Practices, applicable local 
regulations (including US Code of Federal 
Regulations Title 21 and European Directive 
2001/20/EC), and the ethical principles laid 
down in the Declaration of Helsinki.Added explicit statement that the study will be 
implemented in accordance with appropriate regulatory guidelines.  
Section 7.10 Publication of Study Results:  
Revised text to specify that authorship will 
follow ICMJE recommendations.  Clarifying edits
Section 8.[ADDRESS_609105]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Change Rationale
Appendix 3 Known Strong in Vivo Inhibitors 
and Inducers of CYP3A4:  Replaced tableReplaced with current FDA list of strong 
CYP3A inhibitors/inducers
Appendix 4:  Dexamethasone Prescribing 
Information:  Added new appendix.  The [LOCATION_002] label for dexamethasone 
tablets (Roxane Laboratories 2007) is provided for reference.  The [LOCATION_002] 
label will also serve as the Reference Safety 
Information for dexamethasone for this study.  Country-specific labels w ill be provided to 
investigative sites as appropriate
Appendix 5: Schedule of Assessments:
Revised throughout, including deletion of 
bone marrow requirement at Cycle 2Schedule updated to reflect changes as 
described above, including deletion of long-
term follow-up visit.  Bone marrow 
assessments were corrected to match the existing text (ie, required only at screening 
and as clinically indicated/to confirm a CR).
Acerta Pharma Confidential Page [ADDRESS_609106]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
TABLE OF CONTENTS
1.0 BACKGROUND INFORMATION .....................................................................23  
1.1 Role of Btk in Lymphoid Cancers .....................................................................23  
1.2 Preclinical Studies .............................................................................................24  
1.2.1  Chemistry ............................................................................................24  
1.2.2  Efficacy Pharmacology .......................................................................25  
1.2.3  ACP-196 and Thrombus Formation ...................................................26  
1.2.4  Safety Pharmacology..........................................................................27  
1.2.5  Drug-drug Interaction Potential ..........................................................28  
1.2.6  In Vivo General Toxicology.................................................................29  
1.3 Clinical Experience............................................................................................29  
1.3.1  Pharmacokinetics and Pharmacodynamics of ACP-196 in Healthy 
Volunteers ...........................................................................................31  
1.3.2  Clinical Experience of ACP-196 in CLL .............................................33  
1.4 Benefit/Risk ........................................................................................................37  
1.5 Summary and Conclusions...............................................................................37  
2.0 STUDY OBJECTIVES ......................................................................................38  
2.1 Primary Objective ..............................................................................................38  
2.2 Secondary Objectives: ......................................................................................38  
3.0 STUDY DESIGN ...............................................................................................38  
3.1 Description of Study ..........................................................................................38  
3.2 Study Parameters..............................................................................................39  
3.2.1  Safety Parameters ..............................................................................39  
3.2.2  Efficacy Parameters............................................................................39  
3.2.3  Pharmacokinetic and Pharmacodynamic Parameters......................40  
3.3 Rationale for Study Design and Dosing Regimen...........................................40  
3.4 Selection of Study Population...........................................................................41  
3.4.1  Inclusion Criteria .................................................................................41  
3.4.2  Exclusion Criteria ................................................................................41  
3.4.3  Replacement of Subjects....................................................................43  
3.4.4  Enrollment and Randomization Procedures ......................................43  
3.5 Study Drug.........................................................................................................43  
3.5.1  Premedications....................................................................................43  
3.5.2  Formulation, Packaging, and Storage ...............................................43  
[IP_ADDRESS]  ACP-196 ...............................................................................43  
[IP_ADDRESS]  Dexamethasone ...................................................................[ADDRESS_609107]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
[IP_ADDRESS]  ACP-196 ...............................................................................44  
[IP_ADDRESS]  Dexamethasone ...................................................................[ADDRESS_609108] Compliance ............................................................45  
3.5.5  Study Treatment Regimen and Dose Modifications ..........................45  
[IP_ADDRESS]  ACP-196 ...............................................................................45  
[IP_ADDRESS]  Dexamethasone ...................................................................47  
3.6 Concomitant Therapy........................................................................................47  
3.6.1  Permitted Concomitant Therapy ........................................................47  
3.6.2  Guideline for Use of CYP Inhibiting/Inducing Drugs .........................[ADDRESS_609109] Gastric pH.............................47  
3.6.4  Prohibited Concomitant Therapy........................................................48  
3.7 Precautions........................................................................................................48  
3.7.1  Dietary Restrictions.............................................................................48  
3.7.2  Surgery ................................................................................................48  
3.7.3  Infections .............................................................................................48  
3.7.4  Reproductive Toxicity..........................................................................48  
3.7.5  Overdose Instructions .........................................................................49  
3.8 Stoppi[INVESTIGATOR_1869] ..................................................................................................49  
3.9 Data and Safety Monitoring ..............................................................................50  
4.0 STUDY ACTIVITIES AND ASSESSMENTS ...................................................51  
4.1 Description of Procedures ................................................................................51  
4.1.1  Informed Consent................................................................................51  
4.1.2  Medical History....................................................................................51  
4.1.3  Adverse Events ...................................................................................51  
4.1.4  Concomitant Medications and Therapy .............................................52  
4.1.5  Confirmation of Eligibility ....................................................................52  
4.1.6  ECOG Performance Status ................................................................52  
4.1.7  Physical Examination, Vital Signs, Height & Weight.........................[ADDRESS_609110] .........................................................................53  
4.1.11  Hematology .........................................................................................53  
4.1.12  Serum Chemistry ................................................................................53  
4.1.13  Urinalysis .............................................................................................53  
4.1.14  T/B/NK Cell Count...............................................................................[ADDRESS_609111]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
4.1.19  Tumor Assessment.............................................................................54  
4.1.20  Study Drug Accountability ..................................................................55  
4.2 Investigator’s Assessment of Response to Treatment....................................55  
4.3 Early Termination/Safety Follow-up Visit .........................................................57  
4.4 Missed Evaluations ...........................................................................................57  
5.0 STATISTICAL METHODS OF ANALYSIS .....................................................58  
5.1 General Considerations ....................................................................................58  
5.2 Sample Size Considerations.............................................................................58  
5.3 Definition of Analysis Populations ....................................................................58  
5.4 Missing Data Handling ......................................................................................59  
5.5 Endpoint Data Analysis .....................................................................................59  
5.5.1  Safety Endpoint...................................................................................59  
5.5.2  Demographics and Baseline Characteristics .....................................59  
5.5.3  Analysis of Efficacy Parameters.........................................................59  
[IP_ADDRESS]  Overall Response Rate .......................................................59  
[IP_ADDRESS]  Duration of Response ..........................................................60  
[IP_ADDRESS]  Clinical Benefit Rate ............................................................60  
[IP_ADDRESS]  Disease Control Rate ..........................................................60  
[IP_ADDRESS]  Progression-free Survival ....................................................60  
5.5.4  Analysis of Pharmacokinetic/Pharmacodynamic Parameters ..........[ADDRESS_609112]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609113] Retention ..............................................................................................70  
7.9 Protocol Amendments.......................................................................................70  
7.10  Publication of Study Results .............................................................................71  
7.11  Clinical Trial Insurance......................................................................................71  
7.12  General Investigator Responsibilities...............................................................71  
8.0 REFERENCES..................................................................................................73  
9.0 APPENDICES ...................................................................................................75  
IN–TEXT TABLES
Table 1-1.  Assessment of ACP-196 Active-site Occupancy in  Fine Needle Aspi[INVESTIGATOR_475174] (N=4).....................................................................25  
Table 1-2.  ACP-196 Clinical Studies as of January 2015............................................30  
Table 1-3.  Btk Occupancy in Peripheral Blood of Subjects from ACE-CL-001 (December 
2014) ..................................................................................................................34  
Table 1-4.  Preliminary Day 8 PK Results from ACE-CL-001 (October 2014)............... [ADDRESS_609114] Response by [CONTACT_475202]-CL-001 (23OCT2014).......................35  
Table 3-1.  Drug Discontinuation Actions for ACP-196 ................................................46  
Table 4-1.  Pharmacokinetic Sample Schedule...........................................................54  
IN–TEXT FIGURES
Figure 1-1.  Effect of ACP-196 (1 ȝM) and Ibrutinib (1 ȝM) on Thrombus Formation .... 27  
Figure 1-2.  Kaplan-Meier Curves for Progression-free Survival by [CONTACT_475196]-CL-001 (N=75; excludes Richter’s Syndrome Cohort and 
Ibrutinib R/R Cohort)...........................................................................................35  
Figure 1-3.  Median (95% CI) Change from Baseline in ALC/SPD Over Time .............. [ADDRESS_609115]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
ABBREVIATIONS
AE(s) adverse event(s)
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
AUC area under the curve
BCR B-cell receptorBID twice a day (dosing)
Btk Bruton tyrosine kinase
BUN blood urea nitrogenCBC complete blood count
CFR Code of Federal Regulations
cGMP current Good Manufacturing PracticesCLL chronic lymphocytic leukemiaC
max maximum concentration
CR complete remission (response)
CSSF Clinical Supplies Shippi[INVESTIGATOR_475175] P450DLBCL diffuse large B-cell lymphoma
DLT dose-limiting toxicity
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EGFR epi[INVESTIGATOR_395474]-in-human (trial)
FLC (serum) free light chainsGCP Good Clinical PracticeGLP Good Laboratory Practices
HBV hepatitis B virus
HCV hepatitis C virus
hERG human ether-à-go-go-related gene
Acerta Pharma Confidential Page [ADDRESS_609116]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609117]
LDH lactate dehydrogenase
MCL mantle cell lymphomaMedDRA Medical Dictionary for Regulatory Activities
MM multiple myeloma
MR minimal response
NHL non-Hodgkin lymphoma
NK natural killer (cells)
ORR overall response ratePBMC(s) peripheral blood mononuclear cells
PD pharmacodynamics
PI3K phosphoinositide-3 kinase
PK pharmacokinetics
PR partial remission (response)
QD once a day (dosing)QTc corrected QT interval
SAE(s) serious adverse event(s)
SD stable disease
SFLC serum free light chainsSIFE serum immunofixation electrophoresis
SPD sum of the products of the perpendicular diameters (of lymph nodes)
SPEP serum protein electrophoresisS[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction (report)
T
max time to maximum drug concentration
UIFE urine immunofixation electrophoresis
ULN upper limit of normal
UPEP urine serum protein electrophoresis
VGPR very good partial response 
WHO World Health Organization
Acerta Pharma Confidential Page [ADDRESS_609118]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
STUDY SYNOPSIS
Protocol Number: ACE-MY-001
Study Drug: ACP-196
Protocol Title: An Open-label, Phase 1b Study of ACP-196 in Subjects with
Multiple Myeloma
Phase: Phase 1b
Comparator: None
Background and 
Rationale for StudyClinical studies have shown that targeting the B-cell receptor 
(BCR) signaling pathway by [CONTACT_378135] (Btk) produces significant clinical benefit in patients with non-Hodgkin 
lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Preclinical studies have shown that Btk inhibition significantly reduces in vivo multiple myeloma (MM) cell growth and MM cell-induced osteolysis in a murine model (Tai 2012).  Data on the utility of Btk targeted therapy in patients with MM is very 
preliminary, but suggests there are subsets of patients with
malignant plasma cell clones in which Btk is active as evidenced 
by [CONTACT_475198] (p-Btk), and that these cancers may be particularly responsive to Btk inhibitor therapy.
Acerta Pharma BV (Acerta Pharma) has developed a novel second 
generation Btk inhibitor, ACP-196, that achieves significant oral 
bioavailability and potency in preclinical models. ACP-196
monotherapy is currently in multiple Phase 1/2 studiesin subjects 
with chronic lymphocytic leukemia (CLL) and other indications.
The purpose of this study is to evaluate the safety, 
pharmacokinetics (PK), pharmacodynamics (PD), and activity of 
ACP-196 administration with and without dexamethasone in
subjects with relapsed MM. The study will explore the concept of whether biomarkers may help identify patients with MM that are particularly likely to benefit from Btk inhibitor therapy.
Study Design: This study is a multicenter, open-label, randomized, parallel-group 
study to be conducted at approximately 20 sites in 2 countries ([LOCATION_008] and [LOCATION_002]).  Forty subjects will be equally 
randomized (1:1 ratio) into 2 cohorts to receive ACP-196, with and
without dexamethasone:
xCohort 1: ACP-196 100 mg twice per day (BID) continuously
xCohort 2: ACP-196 100 mg BID continuously and
dexamethasone 40 mg once weekly 
Twenty-eight days of study drug administration is 1 cycle.  
Treatment may be continued for > [ADDRESS_609119]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
progression or an unacceptable drug-related toxicity occurs. For 
subjects in Cohort 1, if documented disease progression occurs, then dexamethasone can be added to the treatment regimen.  
Additional dose modification provisions are provided in the study 
protocol.  Note: temporary withholding of study drug for as little as 
7 days can cause a transient worsening of disease and/or of constitutional symptoms.  Refer to Section 3.8for more information 
on assessing disease progression under these circumstances.  All subjects who discontinue study drug will have a safety follow-up
visit 30 (±7) days after the last dose of study drug unless they have 
started another cancer therapy within that timeframe. 
All subjects will have hematology, chemistry, and urinalysis safety 
panels done at screening.  Once dosing commences (Day 1), all subjects will be evaluated for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, every 2 weeks 
in Cycle 2 and monthly thereafter.  PK/PD testing w ill be done in 
Cycle [ADDRESS_609120] on the study exits the study for any reason.
Study Objectives: Primary Objective:
xTo characterize the safety profile of ACP-196 with and without 
dexamethasone in subjects with relapsed or refractory MM
Se condary Objectives:
xTo characterize the PK profile of ACP-196 with and without 
dexamethasone and the PK profile of dexamethasone with concomitant ACP-196 administration
xTo evaluate the PD effects of ACP-196 with and without 
dexamethasone
xTo evaluate the activity of ACP-196 with and without 
dexamethasone as measured by [CONTACT_34426],duration of response, clinical benefit rate, disease control rate,and progression-free survival
xTo explore the relationship between biological markers in MM 
cells and response to therapy
Safety Parameters: Type, frequency, severity, timing of onset, duration, and 
relationship to study drug (ie, ACP-196, dexamethasone, or both)
of any adverse events (AEs) or abnormalities of laboratory tests; serious adverse events (SAEs); or AEs leading to discontinuation of study treatment.
Acerta Pharma Confidential Page [ADDRESS_609121]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Efficacy Parameters: xOverall response rate (ORR)
xDuration of response
xClinical benefit rate
xDisease control rate
xProgression-free survival
Pharmacokinetic 
Parameters:The plasma PK of ACP-196 will be characterized using 
noncompartmental analysis. The following PK parameters w ill be 
calculated, whenever possible, from plasma concentrations of 
analytes:
xAUC 0-t:  Area under the plasma concentration-time curve 
calculated using linear trapezoidal summation from time [ADDRESS_609122] measurable concentration 
(Ct).
xAUC 0-12:  Area under the plasma concentration-time curve from 
0 to 12 hours, calculated using linear trapezoidal summation.
xAUC 0-:  Area under the plasma concentration-time curve from 
0 to infinity, calculated using the formula: AUC 0-= AUC 0-t+ 
Ct/ȜzZKHUHȜ zis the apparent terminal elimination rate 
constant.
xAUC 0-24calc : Area under the plasma concentration-time curve 
from 0 to 24 hours, calculated by [CONTACT_475199] 0-12.
xCmax:  Maximum observed plasma concentration
xTmax:  Time of the maximum plasma concentration (obtained 
without interpolation)
xt½:  Terminal elimination half-life (whenever possible)
xȜz: Terminal elimination rate constant (whenever possible)
xCL/F:  Oral clearance
Pharmacodynamic 
Parameters:The occupancy of Btk by [CONTACT_408799]-196 w ill be measured in peripheral 
blood mononuclear cells (PBMCs) and in bone marrow, when available, with the aid of a biotin-tagged ACP- [ADDRESS_609123] of ACP-196 on biologic markers of B-cell function w ill 
also be evaluated.
Sample Size: Forty subjects with 20 subjects in each cohort.
Inclusion Criteria: x0HQDQGZRPHQ\HDUVRIDJH .
xA confirmed diagnosis of MM, which has relapsed after, or 
been refractory to [ADDRESS_609124] one of the following:
oSerum M- SURWHLQ 0.5 g/dL
oUrine M- SURWHLQ 200 mg/[ADDRESS_609125]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
oIn subjects without detectable serum or urine M-protein, 
serum free light chain (SFLC) > 100 mg/L (involved light chain) andan abnormal serum kappa/lambda ratio
oFor subjects whose disease can only be reliably measured 
by [CONTACT_346686] A (IgA), IgA 
750 mg/dL (0.75 g/dL) 
xEastern Cooperative Oncology Group (ECOG) performance 
status of 2.
xAgreement to use acceptable methods of contraception during 
the study and for [ADDRESS_609126] dose of study drug.
xWilling and able to participate in all required evaluations and 
procedures in this study protocol including swallowing capsules without difficulty.
xAbility to understand the purpose and ri sks of the study and 
provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).
Exclusion Criteria: xPlasma cell leukemia or circulating plasma cells 2x1 09/L
xPrior malignancy, except for adequately treated basal cell or 
squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for 2 years or which will not limit survival to < 2 years. Note: 
these cases must be discussed with the Medical Monitor.
xA life-threatening illness, medical condition, or organ system 
dysfunction which, in the investigator’s opi[INVESTIGATOR_1649], could 
compromise the subject’s safety, interfere with the absorption 
or metabolism of ACP-196, or put the study outcomes at undue 
risk.
xSignificant cardiovascular disease such as uncontrolled or 
symptomatic arrhythmias, congestive heart failure, or 
myocardial infarction within 6 months of screening, or any 
Class 3 or 4 cardiac disease as defined by [CONTACT_183959], or QTc > [ADDRESS_609127] dose of study drug is 
< 5 times the half-life of the previously administered agent(s).
xPrior exposure to a B-cell receptor (BCR) inhibitor (eg, Btk,
phosphoinositide-3 kinase [PI3K], or Syk inhibitors) or BCL-2
inhibitors (eg, ABT-199).
Acerta Pharma Confidential Page [ADDRESS_609128]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
xOngoing immunosuppressive therapy, including systemic or 
enteric corticosteroids for treatment of MM or other conditions. Note: Subjects may use topi[INVESTIGATOR_475176]. During study participation, 
subjects may receive systemic or enteric corticosteroids as 
needed for MM therapy or treatment-emergent comorbid conditions.
x*UDGHWR[LFLW\RWKHUWKDQDORSHFLD ) continuing from prior 
anticancer therapy including radiation.
xKnown history of human immunodeficiency virus (HIV) or 
active infection with hepatitis C virus (HCV) or hepatitis B virus 
(HBV) or any uncontrolled active systemic infection.
xMajor surgery within [ADDRESS_609129] dose of ACP-196.
xKnown history of a bleeding diathesis (eg, hemophilia, von 
Willebrand disease)
xHistory of stroke or intracranial hemorrhage within [ADDRESS_609130] (eg, phenprocoumon) within 
[ADDRESS_609131] dose of study drug.
xRequires treatment with long-acting proton pump inhibitors (eg, 
omeprazole, esomeprazole, lansoprazole, dexlansoprazole, 
rabeprazole, or pantoprazole)
xANC < 0.75 x 10
9/L or platelet count < 50 x 109/L.  For subjects 
with > 50% plasma cells in the marrow, ANC < 0.50 x 109/L or 
platelet count < 30 x 109/L.
xCreatinine > 2.5 x institutional upper limit of normal (ULN); total 
bilirubin > 2.[ADDRESS_609132]; or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.[ADDRESS_609133].
xBreastfeeding or pregnant.
xConcurrent participation in another therapeutic clinical trial.
Dosage Form and 
Strength:ACP-[ADDRESS_609134] pharmaceutical grade excipi[INVESTIGATOR_840]. 
Dose Regimen/Route of Administration:ACP-[ADDRESS_609135].  ACP-196 can be
administered with or without food.
Regimens:
xCohort 1 (BID): 100 mg ACP-196 (1 x 100-mg capsule)
administered 12 hours apart (BID dosing = 200-mg total daily 
dose)
xCohort 2 (BID + dexamethasone): 100 mg ACP-196
(1 x 100-mg capsule) administered 12 hours apart (BID dosing 
= 200-mg total daily dose) plus 40 mg dexamethasone
administered once weekly (weekly dosing = 40-mg total weekly dose)
Acerta Pharma Confidential Page [ADDRESS_609136]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Concomitant Medications:The effect of agents that reduce gastric acidity (eg, proton pump 
inhibitors, H2-receptor antagonists, or antacids) on ACP-196absorption is currently being ev aluated in a healthy volunteer study 
(ACE-HV-004). Preliminary results from this study suggest 
subjects should avoid the use of calcium carbonate containing 
drugs or supplements (eg, antacids or calcium supplements) and 
short-acting H2-receptor antagonistsfor a period of at least 2 hours before and after taking ACP-196.  Use of omeprazole or 
esomeprazole or any other long-acting proton pump inhibitors while taking ACP-196 is not permitted due to a potential decrease 
in study drug exposure; however, if a subject requires treatment 
with a long-acting proton pump inhibitor while on study (eg, to treat 
an ulcer), treatment options should be discussed with the Medical Monitor.
Concomitant use of strong inhibitors/inducers of CYP3A should be 
avoided when possible.  If a subject requires a strong CYP3A 
inhibitor while on study, monitor the subject closely for potential toxicities.
Statistics: Subjects meeting the stated eligibility requirements will be enrolled 
onto the study. Subjects will be r andomized in a 1:1 ratio into the
2 regimens (ACP-196 with and without dexamethasone). With a 
sample size of [ADDRESS_609137] the difference between a null-hypothesis response rate of 15% and an 
alternative response rate of 40% with a 0.[ADDRESS_609138].  A
sample size of 19 subjects per cohort will also provide a 97.5%one-sided confidence interval centered around an expected ORR of 40% that excludes an ORR of 18.6% as a lower bound.
Descriptive statistics (including means, standard deviations, and 
medians for continuous variables and proportions for discrete 
variables) will be used to summarize data, as appropriate.
Acerta Pharma Confidential Page [ADDRESS_609139]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
1.0 BACKGROUND INFORMATION
1.1 ROLE OF BTK IN LYMPHOID CANCERS
Bruton tyrosine kinase (Btk) is a non-receptor enzyme of the Tec kinase family that is 
expressed among cells of hematopoietic origin, including B cells, myeloid cells, mast cells and platelets, where it regulates multiple cellular processes including proliferation, 
differentiation, apoptosis, and cell migration (Mohamed 2009, Bradshaw 2010).
Functional null mutations of Btk in humans cause the inherited disease, X-linked agammaglobulinemia, which is characterized by a lack of mature peripheral B cells 
(Vihinen 2000). Conversely, Btk activation is implicated in the pathogenesis of several 
B-cell malignancies (Buggy 2012). Taken together, these findings have suggested that inhibition of Btk may offer an attractive strategy for treating B-cell neoplasms.
Ibrutinib (IMBRUVICA™), a first-generation oral, small-molecule Btk inhibitor has been 
approved for the treatment for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) and is being evaluated for activity in other B-cell neoplasms including 
multiple myeloma (MM). Preclinical studies have shown that Btk inhibition with ibrutinib 
significantly reduces in vivo multiple myeloma (MM) cell growth and MM cell-induced osteolysis in a murine model (Tai 2012).  
While current therapi[INVESTIGATOR_475177], MM remains 
incurable; for patients who experience disease relapse after application of existing 
therapi[INVESTIGATOR_014], the prognosis is dismal and new drugs and therapeutic strategies are required 
for continued disease control (Romano 2014). Inhibition of Btk may simultaneously 
address the MM-related bone complications as well improve patient outcome in MM 
(Edwards 2012).
While highly potent in inhibiting Btk, ibrutinib has also shown in vitro activity against 
other kinases with a cysteine in the same position as Cys 481 in Btk to which the drug 
covalently binds.  The inhibition of epi[INVESTIGATOR_3506] (EGFR) is also observed in cellular assays and may be the cause of ibrutinib-related adverse events (AEs) of diarrhea and rash (IMBRUVICA® package insert). In addition, ibrutinib is a 
substrate for CYP3A4; inhibition of CYP3A causes a 29-fold increase in maximum 
concentration (C
max) and 24-fold increase in area under the curve (AUC) for ibrutinib 
(IMBRUVICA® package insert).  This increases the possibility of drug-drug interactions 
in combination therapi[INVESTIGATOR_475178] [ADDRESS_609140]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609141] 
led to identification of ACP-196, an orally bioavailable, new chemical entity that 
covalently inhibits Btk and shows encouraging activity and acceptable safety in nonclinical studies. Within the class of Btk inhibitors, ACP-196 is a more selective 
inhibitor of Btk than ibrutinib.  Key nonclinical differentiators of ACP-196 versus ibrutinib 
are:
xACP-[ADDRESS_609142] ibrutinib in EGFR expressing cell lines.  
Ibrutinib is a potent covalent inhibitor of EGFR (EC50 = 50 to 70 nM).  ACP-196GRHVQRWLQKLELW(*)5HYHQDWWKHKLJKHVWFRQFHQWUDWLRQWHVWHG ȝ0
xACP-[ADDRESS_609143] ibrutinib in in vitro antibody-dependent cell-
mediated cytotoxicity (ADCC) assays.  At physiologic concentrations, ibrutinib, 
but not ACP-196, reduced natural killer (NK) cell-mediated lysis of Raji and 
autologous CLL tumor cells and significantly inhibited rituximab-induced NK cell cytokine secretion (P<0.05). 
xACP-[ADDRESS_609144] ibrutinib in an in vivo thrombus formation 
model.  At physiologic concentrations, ibrutinib, but not ACP-196, significantly 
inhibited thrombus formation (P=0.001). 
The nonclinical and toxicology results of ACP-[ADDRESS_609145] an improved 
therapeutic window relative to ibrutinib; it may be more readily combined with other 
agents for the treatment of cancer.  
1.2 PRECLINICAL STUDIES
Summaries of preclinical studies are provided below. For more detailed information please refer to the Investigator’s Brochure.  
1.2.1 Chemistry
 ACP-196 is 
orally bioavailable in humans and is suitable for formulating in capsules. For clinical testing, ACP-196 has been manufactured and formulated according to current Good 
Manufacturing Practices (cGMP).
Acerta Pharma Confidential Page [ADDRESS_609146]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
1.2.2 Efficacy Pharmacology
Spontaneous canine B-cell lymphoma shares many characteristics with human NHL, 
including diagnostic classifications and response to Btk inhibition (Honigberg 2010). The life expectancy in untreated animals with aggressive disease is ~6 weeks, thus enabling rapid assessment of drug efficacy (Vail 2004). ACP-196 is currently being evaluated in 
an ongoing dose-escalation study in canine spontaneous B-cell lymphoma.  Fourteen 
dogs, all of which had diffuse large B-cell lymphoma (DLBCL) confirmed by [CONTACT_27183],
have been treated with ACP-[ADDRESS_609147] ranged from 
2.5 to 20 mg/kg once (QD) or twice (BID) per day.  To date, per Veterinary Cooperative 
Oncology Group criteria for assessment of response in peripheral nodal lymphoma (Vail 2010), partial responses (PRs) been observed in 4 of 14 dogs (29%) and stable 
disease has been observed in 8 of 14 dogs (57%).  No ACP-196-related adverse events 
(AEs) have been reported to date in this study.  These findings are preliminary and 
similar to the clinical responses (ie, 1 dog with PR out of 5 dogs treated with suspected or confirmed DLBCL) observed with ibrutinib in dogs with spontaneous B-cell lymphoma 
(Honigberg 2010).
Preliminary results assessing Btk occupancy using a biotin-tagged analogue of ACP-196 
show near complete Btk occupancy over 24 hours with both BID and QD dosing in 
canine tumor tissue ( Table 1-1 ).
Table 1-1.  Assessment of ACP-196 Active-site Occupancy in 
Fine Needle Aspi[INVESTIGATOR_378106] (N=4)
TimingDog Identification and ACP-196 Dosing Regimen
DL-10 DL-12 DL-14 DL-16
5 mg/kg BID 10 mg/kg QD 20 mg/kg QD 20 mg/kg QD
Btk Occupancy (%  versus predose)
Day 1 (3 hours 
after morning 
dose) 98% 99% 98% 99%
Day 7 (before 
morning dose) 80% 98% 77 93%
BID = twice per day; Btk = Bruton tyrosine kinase; QD = once per day
These canine data provide nonclinical support for the ab ility of ACP-196 to target Btk in 
vivo. The role of Btk expression in driving the proliferation and survival of malignant 
plasma cells in multiple myeloma (MM) has been less clear than among other lymphoid 
cancers. However, emerging, unpublished, preclinical data from the laboratory of Sagar Lonial (Emory University) suggest that Btk and phosphorylated Btk (p-Btk) expression is 
Acerta Pharma Confidential Page [ADDRESS_609148]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609149] panel of 12 myeloma cell lines, thus providing a 
basis for evaluating Btk inhibition as a therapy for MM.
1.2.3 ACP-196 and Thrombus Formation
Ibrutinib is associated with an increased risk of bleeding (Kamel 2014). Hence, the 
effects of ACP-196 and ibrutinib were evaluated on human platelet-mediated thrombosis 
by [CONTACT_475200] a VWFHA1murine model, which has 
been previously described (Chen 2008). Purified human platelets were preincubated 
with various concentrations of ibrutinib and ACP-196 (0.1 μM, 0.5μM, or 1μM for each) 
or DMSO and then administered to VWFHA1mice followed by [CONTACT_201558]-induced thrombus 
formation.  Ibrutinib- and ACP-196-treated human platelets were fluorescently labeled and infused continuously through a catheter inserted into the femoral artery. Thrombus formation in response to laser-induced vascular injury was monitored in real time using 
2-channel confocal intravital microscopy (Furie 2005) ( Figure 1-1 ). Upon induction of 
arteriole injury, untreated platelets rapi[INVESTIGATOR_475157] a mean (± SEM) 
thrombus size of 6450 ± 292 mm
2. Similarly, ACP- ȝ0WUHDWHGSODWHOHWVIRUPHG
slightly smaller but not significantly different thrombi, with a mean thrombus size of 
5733 ± [ADDRESS_609150], a significant reduction in thrombus size occurred in 
SODWHOHWVSUHWUHDWHGZLWKLEUXWLQLEȝ0 ; mean thrombus size was 2600 ± 246 mm2,
representing in a reduction in maximal thrombus size by [CONTACT_3450] 61% compared 
with control (P=0.001). Similar results were obtained with platelets pretreated with 
500 nM of ACP-196 or ibrutinib: mean thrombus sizes were 5946 ± 283 mm2and
2710 ± 325 mm2, respectively. These preliminary results showing reduced thrombus 
formation for ibrutinib at physiologically relevant concentrations (0.5 to 1 ȝM) may 
provide some mechanistic background for the Grade 3 bleeding events (eg, subdural 
hematoma, gastrointestinal bleeding, hematuria, and post procedural hemorrhage) that 
have been reported in 6% of patients treated with ibrutinib. In addition, bleeding events 
of any grade, including bruising and petechiae, were reported in approximately half of 
patients treated with ibrutinib (IMBRUVICA®package insert).
Acerta Pharma Confidential Page [ADDRESS_609151]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609152] of ACP-196 (1 ȝM) and Ibrutinib (1 ȝM) on Thrombus Formation
1.2.[ADDRESS_609153] demonstrated a 
favorable nonclinical safety profile. 
:KHQVFUHHQHGDWȝ0LQELQGLQJDVVD\VHYDOXDWLQJLQWHUDFWLRQ VZLWKNQRZQ
pharmacologic targets such as G-protein-coupled receptors, nuclear receptors, proteases, and ion channels, ACP-[ADDRESS_609154]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
A3 adenosine receptor; follow-up dose-response experiments indicated a IC 50of 2.7μM, 
suggesting a low clinical risk of off-target effects.  ACP- DWȝ0VKRZHGQR
inhibition of in vitro epi[INVESTIGATOR_3506] (EGFR) phosphorylation in an A431 
human epi[INVESTIGATOR_475158], whereas ibrutinib had an IC 50of [ADDRESS_609155] of ACP-196 on human ether-à-go-go-related gene (hERG) channel 
activity was investigated in vitro in human embryonic kidney cells stably transfected with 
hERG. ACP-196 inhibited hERG channel activity by 25% at 10 ȝ0VXJJHVWLQJDORZ
clinical risk that ACP-[ADDRESS_609156] in vivo Good Laboratory Practices (GLP) studies 
of pharmacologic safety. A functional observation battery in rats at doses of through 300 mg/kg (the highest dose level) revealed no adverse effects on neurobehavioral 
effects or body temperature at any dose level. A study of respi[INVESTIGATOR_475159]-related adverse effects at doses through 300 mg/kg (the highest dose level). In a cardiovascular function study in awake telemeterized male beagle dogs, 
single doses of ACP-196 at dose levels through 30 mg/kg (the highest dose level) 
induced no meaningful changes in body temperature, cardiovascular, or electrocardiographic (ECG) (including QT interval) parameters.  The results suggest that ACP-[ADDRESS_609157] CYP-mediated metabolism of ACP-196 appears to be 
catalyzed predominantly by [CONTACT_097]3A4/5.  However, in elimination studies in preclinical 
species, the metabolic fate of ACP-[ADDRESS_609158] conjugation of ACP-196
with glutathione, providing evidence for a significant non-CYP mechanism of elimination.  In a healthy volunteer study (ACE-HV-001), the effect of coadministration of a potent 
CYP3A and P-gP inhibitor, itraconazole, on the plasma levels of ACP-[ADDRESS_609159]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609160] that ACP-196 is not anticipated to alter 
the PK of other therapeutic agents that are substrates for MDR1, OATP1B1, OATP1B3, 
OAT1, OAT3, and OCT2.  ACP-196 (100 mg BID) may alter the PK of BCRP substrates by [CONTACT_378141].
1.2.6 In Vivo General Toxicology
To date, the toxicology program has included 28-day GLP evaluations in rats and dogs. In the 28-day study in male and female Sprague-Dawley rats, animals received oral 
gavage ACP-196 dosages of 30, 100, and 300 mg/kg/day. In the 28-day study in male 
and female beagle dogs, animals received oral ACP-196 dosages of 3, 10, and 
30 mg/kg/day. Both studies had 28-day recovery periods.
The no observable adverse effect level in the dog was 30 mg/kg/day, which was the 
highest dose evaluated. In rats, 30 mg/kg/day resulted in minimal inflammation of the pancreas in some animals, with reversal, indicating the rat to be the more sensitive 
preclinical species. The pancreatic effects were minimally increased at 100 mg/kg/day in 
the rat though there was no clinical evidence of toxicity. Hence, 100 mg/kg/day was selected to conservatively represent the highest nonseverely toxic dose (HNSTD).  In dogs at 30 mg/kg/day, no adverse effects on the pancreas were observed.  In rats and 
dogs, no adverse ECG or histopathologic cardiovascular effects were noted at the 
planned conclusion of the 28-day toxicology studies. However, in 5 of 6 rats from the 300-mg/kg dose group that died early in the study, slight to moderate necrosis of the 
myocardium and/or white blood cell infiltration/inflammation of the myocardium were 
noted on microscopic examination of the hearts. These findings were most likely incidental postmortem changes.
1.[ADDRESS_609161]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Table 1-2.  ACP-196 Clinical Studies as of January 2015
Protocol DesignSubjects 
E nrolled Status
AC E -C L-001
([STUDY_ID_REMOVED])xFirst-in-human
xOpen label
xDose escalation (ACP-196 100-
400 mg QD and 100-200 mg BID)
xSubjects w ith relapsed/refractory CLL
xExpansion cohorts:
otreatment-naive subjects
osubjects w ith Richter’s syndrome
osubjects w ho are intolerant to 
ibrutinib treatment
osubjects w ho are 
relapsed/refractory to ibrutinib treatment125 xCohort 1 (100 mg QD) 
enrolled and no DLTs 
observed.  
xCohort 2a (175 mg QD) 
enrolled and no DLTs 
observed.
xCohort 3 (250 mg QD) 
enrolled and no DLTs observed.
xCohort 4a (400 mg QD) 
enrolled and no DLTs 
observed.
xCohort 2b (100 mg BID 
now  enrolling) and no DLTs observed.
xExpansion cohorts now  
enrolling.
AC E -H V-001 xOpen label
xSingle-dose escalation
(ACP-196 2.5-50 mg BID and 100 mg 
QD)
xFood effect (ACP-196 75 mg QD)
xDrug-drug interaction w ith 
itraconazole (ACP-196 50 mg QD)
xHealthy volunteers59 x Enrollment completed.
x No adverse laboratory, 
vital signs, or ECGs 
findings observed.
x 1 event each of 
constipation, feeling cold, somnolence (each Grade 1) w as reported as related to study drug.
AC E -H V-004 xOpen label
xACP-196 100 mg
xDrug-drug interaction:
oCalcium carbonate
oOmeprazole
oRif ampin
xHealthy volunteers72 x Enrollment completed.
x No adverse laboratory, 
vital signs, or ECGs findings observed.
x Other analyses 
pending.
ACE-LY-002
([STUDY_ID_REMOVED])xOpen label
xACP-196 100 mg BID
xActivated B-cell subtype of diffuse 
large B-cell lymphoma6 x Enrollment recently 
begun
ACE-WM-001
([STUDY_ID_REMOVED])xOpen label
xACP-196 100 mg BID and 200 mg QD
xWaldenström macroglobulinemia7 x Enrollment recently 
begun
ACE-LY-003([STUDY_ID_REMOVED])xOpen label
xACP-196 100 mg BID and 200 mg QD
xFollicular lymphoma1 x Enrollment recently 
begun
15-H-0016(NI H study)xOpen label
xACP-[ADDRESS_609162]-003 xOpen label
xACP-196 100 mg BID ±
pembrolizumab 200 mg IV Q3W
xAdvanced or metastatic pancreatic 
cancer0 x Protocol in study start 
up
AE = adverse event; BID = tw ice per day; CLL = chronic lymphocytic leukemia; DLT = dose-limiting toxicity; 
ECGs = electrocardiograms; QD = once per day
Acerta Pharma Confidential Page [ADDRESS_609163]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Table 1-2. ACP-196 Clinical Studies as of January 2015 (continued)
Protocol DesignSubjects 
E nrolled Status
AC E -ST-005([STUDY_ID_REMOVED])xOpen label
xACP-196 100 mg BID ±
pembrolizumab 200 mg IV Q3W
xAdvanced or metastatic bladder 
cancer0 x Protocol in study start 
up
ACE-LY-004([STUDY_ID_REMOVED])xOpen label
xACP-196 100 mg BID
xMantle cell lymphoma0 x Enrollment recently 
begun
AC E -C L-002([STUDY_ID_REMOVED])xOpen label
xACP-196 50 mg BID and ACP-319
25 mg BID
xCLL8 x Enrollment recently 
begun
ACE-LY-001
([STUDY_ID_REMOVED])xOpen label
xACP-196 100 mg BID and ACP-319
25 to 100 mg BID
xB-cell malignancies1 x Enrollment recently 
begun
AC E -C L-003
([STUDY_ID_REMOVED])xOpen label
xACP-196 200 mg QD and 
Obinutuzumab per label
xCLL2 x Enrollment recently 
begun
ACE-HI-001 xHepatic impairment study
xACP-196 50 mg QD18 x Enrollment ongoing
ACE-LY-005 xOpen label
xACP-196 100 mg BID and 
pembrolizumab 2 mg/kg IV Q3W
xB-cell malignanciesNone x Protocol in study start 
up
AC E -ST-006 xOpen label
xACP-196 100 mg BID ±
pembrolizumab 200 mg IV Q3W
xAdvanced or metastatic head & neck 
cancer0 x Protocol in study start 
up
AC E -ST-007 xOpen label
xACP-196 100 mg BID ±
pembrolizumab 200 mg IV Q3W
xAdvanced or metastatic non-small cell 
lung cancer0 x Protocol in study start 
up
AE = adverse event; BID = tw ice per day; CLL = chronic lymphocytic leukemia; DLT = dose-limiting toxicity; 
ECGs = electrocardiograms; IV = intravenous; Q3W = once every 3 w eeks; QD = once per day
1.3.[ADDRESS_609164], and drug-drug interaction study 
evaluating BID and QD dosing for 1 or 2 days in healthy volunteers.  The starting dose 
for ACP-196 was 2.5 mg BID.  This study has been completed and no adverse 
laboratory, vital signs, or ECG findings were observed (2.5 to 50 mg BID; 50 to 100 mg QD). Three AEs related to ACP-[ADDRESS_609165]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
without treatment.  The AEs were constipation (2.5 mg BID), feeling cold (75 mg QD), 
and somnolence (75 mg QD).
In Part 1, PK properties of ACP-196 were evaluated after oral administration of 2 daily 
doses of 2.5 to 50 mg and a single dose of 100 mg.  Of the 30 subjects evaluated, all 
had measurable systemic concentrations of ACP- 196.  ACP-196 plasma time to 
maximum concentration (T max) values were between 0.5 and 1.0 hour for all dose 
cohorts and independent of the dose level.  The increase in mean maximum 
concentration (C max) values was greater than dose proportion based on the increases of 
Cmaxfrom the first dose administered.  When evaluating area under the concentration 
curve (AUC 0-12, AUC 0-24or AUC 0-inf), the mean values increased in a dose proportional 
manner based on the increases of the total dose administered.  Mean half-life (t 1/2)
values ranged from 0.97 to 2.1 hours, and appeared to decrease as the dose increased.  The mean calculated oral clearance (CL/F: 165 to 219 L/h) and volume of distribution 
values (Vz/F: 233 to 612 L) appeared to be independent of the dose administered.
ACP-196 was not detected in the urine of subjects who received the 2.5- or 5.0-mg BID 
doses of ACP-196.  ACP-196 was detected in urine of other subjects (0.4% to 0.6% of 
dose) and amounts increased in a dose dependent manner.
In Part 2, the effect of food on the PK of ACP-196 (75 mg) after a single oral 
administration was evaluated in 6 men and 6 women.  Median ACP-196 plasma T
max
values were increased in the fed state (2.5 hours) relative to the fasted state (0.5 hour).  
The mean plasma ACP-196 C maxvalues decreased to 27.3% of the values observed in 
the fasted state.  In contrast, the relative exposure of ACP-196 (AUC) remained mostly unchanged in both states. Per FDA guidance on food-effect studies (FDA 2002), this decrease in exposure is not clinically significant, and therefore, ACP-196 can be taken 
with or without food.
In Part 3, after administration of a single dose of ACP-196 (50 mg), the effect of 
itraconazole on the PK was evaluated in 17 subjects.  No difference in ACP-196 T
max
values was observed in the presence or absence of itraconazole.
Mean ACP-196 exposures (as assessed by C max, AUC 0-last, AUC 0-24, and AUC 0-inf)
increased in the presence of itraconazole.  The mean plasma ACP-[ADDRESS_609166], AUC 0-24,
and AUC 0-inf  values also increased between 4.9- to 5.1-fold in the presence of 
itraconazole. Mean CL/F and Vz/F values decreased in the presence of itraconazole 
Acerta Pharma Confidential Page [ADDRESS_609167]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
(CL/F: 217 vs 44 L/h; Vz/F: 1190 vs 184 L).  No differences in half-life values were 
observed (3.3 vs 2.5 hours).
The pharmacodynamics (PD) profile of ACP-196 was evaluated using a Btk occupancy 
assay and correlated with a functional assay that determines the level of Btk inhibition by 
[CONTACT_475201]69 and CD86 on B-cells.  A dose-dependent increase in Btk occupancy and corresponding decrease in CD69/86 expression was observed in this 
VWXG\)XOO%WNRFFXSDQF\DQGFRPSOHWH&'DQG&'L QKLELWLRQ 90%) 
occurred in the 75- and 100-mg single dose cohorts 1 to 3 hours after administration.  However, only the 100 mg cohort maintained high Btk occupancy (91.5%) and high BCR functional inhibition (CD86: 86 ± 3% and CD69: 78 ± 8%) at [ADDRESS_609168] administration, full Btk target 
occupancy was observed 3 hours after the second dose for the 50 mg dose cohort (Btk occupancy 97 ± 4%).
1.3.2 Clinical Experience of ACP- 196 in CLL
ACE-CL-001 ([STUDY_ID_REMOVED]), an ongoing Phase 1/2 study in subjects with 
relapsed/refractory or previously untreated CLL or Richter’s syndrome, has a sequential, 
dose-escalation design. As of [ADDRESS_609169] received ACP-196 at 
dosages from 100 to 400 mg QD or 100 to 200 mg BID. 
To date, ACP-196 has been well tolerated at all dose levels evaluated.  No dose-limiting 
toxicities (DLTs) have occurred at any dose level.  The MTD was not reached in this 
study; however, per the protocol, dose escalation was stopped once a plateau in PK was observed (ie, between 250 and 400 mg).  
Preliminary data from ACE-CL-001 show that Btk occupancy with ACP-196, in peripheral 
blood cells, is > 95% at 4 hours but decreases to < 95% at 24 hours, while with BID 
dosing complete Btk occupancy (97% to 99%) is maintained over 24 hours at steady 
state ( Table 1-3 ). These data suggest that synthesis of de novo Btk may occur within 
[ADDRESS_609170]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Table 1-3.  Btk Occupancy in Peripheral Blood of Subjects from ACE-CL-001
(December 2014)
Timepoint*Subjects with Relapsed/Refractory CLL
100 mg QD
(n=8)175 mg QD
(n=8)250 mg QD
(n=6)100 mg BID
(n=17)
Day 7:
Median %
Occupancy 24 h89.0 86.9 93.5 97.4
Day 8:
Median %
Occupancy 4 h98.6 98.7 100 98.8
Abbreviations:  BID = twice per day; CLL = chronic lymphocytic leukemia; QD = once per day
*Note: 24-h timepoint on BID regimen represents [ADDRESS_609171] dose on Day 8.  
Preliminary PK data from Day 8 show dose linearity from 100 to 250 mg and no 
accumulation with repeat dosing ( Table 1-4 ).
Table 1-4.  Preliminary Day 8 PK Results from ACE-CL-001 (October 2014)
CohortMean C max ±S D
(ng/mL)Mean A UC 0-last±S D
(ng•h/mL)
100 mg QD (N=8) 529 ± 286 634 ± 197a
175 mg QD (N=7) 800 ± 692 1240 ± 789
250 mg QD (N=7) 1350 ± 933 2170 ± 1180
400 mg QD (N=6) 932 ± 576 1870 ± 1040
100 mg BID (N=22) 716 ± 658 837 ± 485b
Timepoints: Predose, 0.25, 0.50, 0.75, 1.0, 2.0, 4.0, and 6.0 postdose.
aN=7 for AUC calculations in 100 mg QD dose group.
bBID regimens were not sampled during the second daily dose interval; 0-24 h exposures are 
expected to be approximately 2-fold the AUC 0-6values shown.
AUC = area under the curve; BID = twice per day; C max= maximum concentration; SD = standard 
deviation
To date, [ADDRESS_609172] been evaluated for tumor response, by [CONTACT_431], based 
on International Working Group response criteria (Hallek 2008) as recently updated 
(Cheson 2012) to include partial response with treatment-induced lymphocytosis.  Based on preliminary, unaudited data an overall response rate (ORR) of 94% (71% PR + 23% 
Acerta Pharma Confidential Page [ADDRESS_609173]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
PR with lymphocytosis) has been observed ( Table 1-5 ). Of the 31 subjects assessed, 
nearly half (15 of 31) have 17p del.  Of the 15 subjects with 17p del, 80% (12/15) have 
PR and 20% (3/15) have PR with lymphocytosis.  The median follow-up for the ACP-196 subjects evaluated for response is 7.3 cycles (r ange 3.0 to 10.8) and each cycle is 28 
days. No primary disease progression has occurred on study (N = 75; Figure 1-2).
Table 1-5.  Best Response by [CONTACT_475202]-CL-001 (23OCT2014)
n (%)All
Cohorts
(N=31)100 mg QD
(N=8)175 mg QD
(N=8)250 mg QD
(N=7)100 mg BID
(N=3)400 mg QD
(N=5)
PR 22 (71) 7 (88) 5 (71) 4 (57) 3 (100) 2 (40)
PR+L 7 (23) 0 (0) 3 (38) 2 (29) 0 (0) 2 (40)
SD 2 (6) 1 (12) 1 (13) 0 (0) 0 (0) 1 (20)
PD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Median (range) Cycles
7.3 (3.0-10.8) 10.0 (9.0-10.8) 8.6 (3.0-8.8) 7.0 (7.0-7.3) 5.2 (4.7-5.5) 5.0 (4.8-5.5)
BID = twice per day; PD = progressive disease; PR = partial response; PR+L = partial response 
with lymphocytosis; QD = once per day; SD = stable disease
Figure 1-2. Kaplan-Meier Curves for Progression-free Survival by [CONTACT_475196]-CL-001 (N=75; excludes Richter’s Syndrome Cohort and 
Ibrutinib R/R Cohort)
Acerta Pharma Confidential Page [ADDRESS_609174]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609175] generation 
Btk inhibitor, when administered at dosages of 420 mg QD in subjects with 
relapsed/refractory CLL (N=195).  In the ibrutinib study, By[CONTACT_475203] (2014)report a PR rate of 43%, a PR with lymphocytosis rate of 20%—for an ORR of 63% ņan
SD rate of 32%, and a progressive disease (PD) rate of 3% (By[CONTACT_26752] 2014) based on 
independent review.  The median follow-up time reported for the ibrutinib study was 9.5 months (range 0.1 to 16.6).  
Figure 1-[ADDRESS_609176] of the diameters (SPD) 
(N=31) and in absolute lymphocyte count (ALC) (N=57) over time.  As shown in the figure, substantial reductions in lymphadenopathy have been observed despi[INVESTIGATOR_475160]-quarters of the evaluable subjects have high-risk cytogenetics (17p del, 11q 
del, or both). As mentioned above, the observed reductions in lymphadenopathy are consistent with the clinical results for ibrutinib (By[CONTACT_26752] 2013, By[CONTACT_26752] 2014).  However, the 
reduced drug-induced lymphocytosis and the rapid time to resolution of lymphocytosis 
with ACP-196 treatment varies greatly from that reported for ibrutinib.  Per the IMBRUVICA package insert, 77% of patients with CLL treated with ibrutinib experienced lymphocytosis, which occurred during the first month of therapy and resolved by a 
median of 23 weeks (range 1 to 104+ weeks).  With ACP-[ADDRESS_609177] week of treatment and resolves by a median of 8 weeks (range 0 to 24+ weeks).
Acerta Pharma Confidential Page [ADDRESS_609178]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Figure 1-3. Median (95%  CI) Change from Baseline in ALC/SPD Over Time
ALC = absolute lymphocyte count; CI = confidence interval; SPD = sum of the 
products of the perpendicular diameters (of lymph nodes).
1.4 BENEFIT/RISK
ACP-196 is a potent, orally available small-molecule inhibitor of Btk.  A PK/PD study has 
been completed with ACP-196 in healthy volunteers (ACE-HV-001; Section1.3.1 ).  The 
safety results showed no identified safety ri sks in healthy subjects receiving 1 or 2 days 
of ACP- 100 mg.  In study ACE-CL-001, a study of ACP-196 in subjects with 
relapsed/refractory or previously untreated CLL or Richter’s syndrome, no DLTs have 
EHHQUHSRUWHGDWGRVDJHVRI 400 mg QD or 100 and 200 mg BID.  The overall 
response rate in the evaluable subjects for this study is currently 94% with some subjects obtaining PRs after only [ADDRESS_609179]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609180] of this study is supported by [CONTACT_475204][INVESTIGATOR_378117]; knowledge of the efficacy and
safety of the first-generation BCR inhibitor (eg, ibrutinib) in subjects with hematologic 
cancers; and the available nonclinical and clinical information regarding ACP-196. 
Preclinical studies are ongoing in parallel to identify biomarkers that may be evaluated in 
this clinical trial as correlates of response to Btk-directed therapy and that may permit 
selection of patients who are particularly likely to benefit from ACP-196 treatment for MM.
2.0 STUDY OBJECTIVES
2.1 PRIMARY OBJECTIVE
xTo characterize the safety profile of ACP-196 with and without dexamethasone in 
subjects with relapsed or refractory MM
2.2 SECONDARY OBJECTIVES:
xTo characterize the PK profile of ACP-196 with and without dexamethasone and the 
PK profile of dexamethasone with concomitant ACP-196 administration
xTo evaluate the PD effects of ACP-196 with and without dexamethasone
xTo evaluate the activity of ACP-196 with and without dexamethasone as measured 
by [CONTACT_34426], duration of response, clinical benefit rate, disease control 
rate, and progression-free survival
xTo explore the relationship between biological markers in MM cells and response to 
therapy
3.0 STUDY DESIGN
3.1 DESCRIPTION OF STUDY
This study is a multicenter, open-label, randomized, parallel-group study to be 
conducted at approximately 20 sites in 2 countries ([LOCATION_008] and [LOCATION_002]).Forty subjects will be r andomized 1:1 into the following 2 cohorts to receive ACP-196, 
with and without dexamethasone:
xCohort 1: ACP-196 100 mg BID continuously 
xCohort 2: ACP-196 100 mg BID continuously and 40 mg dexamethasone once 
weekly 
Twenty-eight days of study drug administration is 1 cycle.  Treatment may be conti nued 
for > 28 days until disease progression or an unacceptable drug-related toxicity occurs.  
For subjects in Cohort 1, if documented disease progression occurs, then 
dexamethasone can be added to the treatment regimen.  Additional dose modification provisions are provided in Section 3.5.5 . Note: temporary withholding of study drug for 
Acerta Pharma Confidential Page [ADDRESS_609181]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
as little as 7 days can cause a transient worsening of disease and/or of constitutional
symptoms.  Refer to Section 3.[ADDRESS_609182] a safety 
follow-up visit 30 (±7) days after the last dose of study drug unless they have started 
another cancer therapy within that timeframe. 
All subjects will have standard hematology, chemistry, and urinalysis safety panels 
performed at screening.  Once dosing commences (Day 1), all subjects will be evaluated 
for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, every 2 weeks in Cycle 2 and monthly thereafter.  PK/PD testing will be done in Cycle 1and Cycle 2. Tumor assessments will be done at 8- to 12-week intervals during the trial.
Refer to Appendix [ADDRESS_609183] on the study exits the study for 
any reason.
3.2 STUDY PARAMETERS
3.2.1 Safety Parameters
The safety of ACP-196 with and without dexamethasone w ill be characterized by [CONTACT_344412], frequency, severity, timing of onset, duration, and relationship to study drug (ie, 
ACP-196, dexamethasone, or both) of any treatment-emergent AEs or abnormalities of 
laboratory tests; serious adverse events (SAEs); or AEs leading to discontinuation or dose reduction of study treatment. 
For consistency of interpretation, AEs will be c oded using the Medical Dictionary for 
Regulatory Activities (MedDRA), and the severity of AEs and laboratory abnormalities 
will be graded using the Common Terminology Criteria for Adverse Events (CTCAE), 
Version 4.03. Standard definitions for seriousness w ill be applied (see Section 6.1 ).
3.2.[ADDRESS_609184] been established for MM
(Rajkumar 2011); assessments of ACP-196 efficacy in this study will be based on these 
criteria. Efficacy endpoints w ill incl ude:
xOverall response rate (ORR)
xDuration of response
xClinical b enefit rate
xDisease control rate
Acerta Pharma Confidential Page [ADDRESS_609185]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609186] PK parameters for ACP-196 and dexamethasone in plasma w ill be evaluated 
in this study.  A full description of the PK parameters is provided in Section 5.5.4 .
The occupancy of Btk by [CONTACT_408799]-196 w ill be measured in peri pheral blood mononuclear 
cells (PBMCs) and bone marrow, when available, with the aid of a biotin-tagged 
ACP-[ADDRESS_609187] of ACP-196 on biologic markers of B-cell function 
will also be evaluated.
3.3 RATIONALE FOR STUDY DESIGN AND DOSING REGIMEN
As described in Section 1.3 , preliminary data from the ongoing Phase 1/2 study in 
subjects with relapsed/refractory or previously untreated CLL have shown that ACP-196 
is well tolerated at dosages of 100 to 400 mg QD and 100 to 200 mg BID.  In addition, 
preliminary PD data from ACE-CL-001 show that Btk occupancy with ACP-196, inperipheral blood, is > 95% at 4 hours after QD dosing but decreases to < 95% at 
24 hours with QD dosing, while with BID dosing complete Btk occupancy (95% to 99%) 
is maintained over 24 hours at steady state (Table 1-3).  These data suggest that de 
novo synthesis of Btk can occur within 24 hours in peripheral blood cells.  BID dosing 
may ensure Btk inhibition for the entire 24 hours and thus may be beneficial in terms of 
increasing efficacy and/or decreasing development of resistance to ACP-196.  In addition, having information regarding the safety and pharmacology of a BID schedule may support future combination studies with other drugs that are administered BID.  
Evaluation of dexamethasone as a combination partner for ACP-196 builds on known 
antineoplastic activity of this drug in patients with MM. Dexamethasone therapy is
commonly coadministered with targeted agents for MM (Ocio 2014). The dosing 
regimen of 40 mg weekly to be used in this study has been established based on randomized trial data showing the superiority of this method of administration (Rajkumar 
2009). Combined use of ACP-[ADDRESS_609188] increased efficacy relative to administration of the individual agents alone. While dexamethasone can increase CYP3A4 activity and thus 
might enhance ACP-196 metabolism, it is considered a weak inducer of this isoenzyme
and has not substantially altered the disposition of other CYP3A4 substrates (eg, bortezomib) that are commonly used in the therapy of MM (Hellmann 2011). The 
Acerta Pharma Confidential Page [ADDRESS_609189]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
randomized design of this pi[INVESTIGATOR_475161]-drug interactions 
between ACP-196 and dexamethasone to be assessed.
3.4 SELECTION OF STUDY POPULA TION
3.4.1 Inclusion Criteria
Eligible subjects will be considered for inclusion in this study if they meet allof the 
following criteria: 
1.0HQDQGZRPHQ\HDUVRIDJH .
2. A confirmed diagnosis of MM, which has relapsed after, or been refractory to 
[ADDRESS_609190] one of the 
following:
oSerum M- SURWHLQ 0.5 g/dL
oUrine M- SURWHLQ 200 mg/24 hours
oIn subjects without detectable serum or urine M-protein, serum free light 
chain (SFLC) > 100 mg/L (involved light chain) andan abnormal serum 
kappa/lambda ratio
oFor subjects whose disease can only be reliably measured by [CONTACT_475205] A ,J$,J$ 750 mg/dL (0.75 g/dL) 
4. Eastern Cooperative Oncology Group (ECOG) performance status of 2.
5. Agreement to use acceptable methods of contraception during the study and for 
[ADDRESS_609191] dose of study drug.
7. Willing and able to participate in all required evaluations and procedures in this 
study protocol including swallowing capsules without difficulty.
8. Ability to understand the purpose and risks of the study and provide signed and 
dated informed consent and authorization to use protected health information (in 
accordance with national and local subject privacy regulations).
3.4.2 Exclusion Criteria
Subjects will be ineligible for this study if they meet anyof the following criteria:
1.3ODVPDFHOOOHXNHPLDRUFLUFXODWLQJSODVPDFHOOV 2x1 09/L
2. Prior malignancy, except for adequately treated basal cell or squamous cell skin 
cancer, in situ cervical cancer, or other cancer from which the subject has been GLVHDVHIUHHIRU\HDUVRUZKLFKZLOOQRWOLPLWVXUYLYDOWR \HDUV1RWHWKHVH
cases must be discussed with the Medical Monitor.
3. A life-threatening illness, medical condition or organ system dysfunction which, in
the investigator’s opi[INVESTIGATOR_1649], could compromise the subject’s safety, interfere with 
Acerta Pharma Confidential Page [ADDRESS_609192]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
the absorption or metabolism of ACP-196, or put the study outcomes at undue 
risk.
4. Significant cardiovascular disease such as uncontrolled or symptomatic 
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of 
screening, or any Class 3 or 4 cardiac disease as defined by [CONTACT_183959], or QTc > [ADDRESS_609193] dose of study drug is < 5 times the half-life of the previously 
administered agent(s).
8. Prior exposure to a B-cell receptor (BCR) inhibitor (eg, Btk, phosphoinositide-3
kinase [PI3K], or Syk inhibitors) or BCL-2 inhibitors (eg, ABT-199).
9. Ongoing immunosuppressive therapy, including systemic or enteric 
corticosteroids for treatment of MM or other conditions. Note: Subjects may use
topi[INVESTIGATOR_475179]. During 
study participation, subjects may also receive systemic or enteric corticosteroids as needed for MM therapy or treatment-emergent comorbid conditions.
10.*UDGHWR[LFLW\RWKHUWKDQDORSHFLD ) continuing from prior anticancer therapy 
including radiation.
11.Known history of human immunodeficiency virus (HIV) or active infection with 
hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled activesystemic infection.
12.Major surgery within [ADDRESS_609194] dose of ACP-196.
13.Known history of a bleeding diathesis (eg, hemophilia, von Willebrand disease)
14.History of stroke or intracranial hemorrhage within [ADDRESS_609195] (eg, phenprocoumon) within [ADDRESS_609196] dose of study drug.
16.Requires treatment with long-acting proton pump inhibitors (eg, omeprazole, 
esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
17.ANC < 0.75 x 10
9/L or platelet count < 50 x 109/L.  For subjects with >50% 
marrow involvement with plasma cells, ANC < 0.50 x 109/L or platelet count 
<3 0x1 09/L.
18.Creatinine > 2.5 x institutional upper limit of normal (ULN); total bilirubin 
> 2.[ADDRESS_609197]; and aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) > 3.[ADDRESS_609198]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609199] into the study will be performed according to the following 
procedure: 
xNotify the sponsor when a clinically eligible subject is identified and is ready to 
screen, to ensure enrollment availab ility on the study.
xAfter the subject has signed and dated the Informed Consent Form (ICF), all 
screening procedures have been completed, and eligibility has been confirmed, the subject can be officially enrolled in the study. 
xTo enroll a subject, the study center will fax/email a completed Enrollment 
Confirmation Form to the sponsor.  The enrollment date w ill be the date that the form 
is faxed/emailed to the sponsor.
xAn Enrollment Confirmation Form will be completed and faxed/emailed to the study 
center by [CONTACT_86622] [ADDRESS_609200] begin within the screening window ( Section 4.1 ) and after the site has 
received the cohort allocation from the sponsor.  Study treatment is not blinded on this study.
3.5 STUDY DRUG
3.5.1 Premedications
No specific premedications or supporting medications are required in conjunction with
ACP-196 administration. 
3.5.2 Formulation, Packaging, and Storage
[IP_ADDRESS] ACP-[ADDRESS_609201]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609202] gelatin capsules containing 100 mg drug 
substance. ACP-196 will be provided in white, high-density polyethylene bottles.
If a drug shipment arrives damaged, or if there are any other drug complaints, a 
SAE/Pr oduct Complaint Form should be completed and emailed or faxed to the sponsor 
or the sponsor’s representative.  
Refer to the Investigator’s Brochure for additional information regarding the drug product 
to be used in this trial.
[IP_ADDRESS] Dexamethasone
This study will use commercially available dexamethasone tablets for oral administration.The Sponsor will either directly supply sites with dexamethasone or the sites will be 
reimbursed to prescribe dexamethasone; this will be detailed separately in each site’s 
clinical trial agreement.  Per the U.S. dexamethasone package insert (Appendix4), 
tablets are to be stored at room temperature (20° to 25°C) and protected from moisture 
and light.  Please refer to the appropriate dexamethasone package insert for further 
storage and handling instructions.
3.5.3 Administration of Study Drug
[IP_ADDRESS] ACP-[ADDRESS_609203] ensure that subjects receive ACP-196 only from personnel who fully understand the procedures for administering the 
drug.
ACP-196 is intended to be administered orally with 8 ounces (approximately 240 mL) of 
water (avoid grapefruit juice and Sev ille orange juice due to CYP3A4 inhibition). ACP-
[ADDRESS_609204]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
[IP_ADDRESS] Dexamethasone
This study will use commercially available dexamethasone tablets for oral administration.
At the time of weekly dexamethasone administration, the subject should take the dexamethasone tablets simultaneously with the ACP-196 capsules and with 8 ounces (approximately 240 mL) of water.  The dexamethasone tablets should be swallowed 
intact and subjects should not attempt to chew them or dissolve them in water. 
If a dexamethasone dose is missed, it can be taken up to 3.5 days (84 hours) days after 
the scheduled time with a return to the normal schedule the following week.  If the 
interval of missed dosing has been > 3.5 days (84 hours), the dexamethasone dose 
should not be taken and the subject should take the next dose at the scheduled time in 
the following week. The missed dexamethasone dose w ill not be made up and must be 
returned to the site at the next scheduled visit.
3.5.[ADDRESS_609205] Compliance
During cycle 1, subjects will receive their Day 1, 8, 15, 22, and 28 doses (for Cohort 2 
this includes the dexamethasone dose) in the clinic.  For treatments that are taken in the 
clinic, subjects should take the dose from the drug dispensed for them for that particular time period.  All other treatments will be taken at home.  Subjects will receive a diary to 
record the specific time each dose was taken and to record reasons for any missed 
doses.  
Subject compliance will be assessed at every visit.  The subject will be instructed to 
bring the diary and any remaining ACP-[ADDRESS_609206] number of ACP-196 capsules and dexamethasone tablets 
needed for use until the next visit.
3.5.5 Study Treatment Regimen and Dose Modifications
[IP_ADDRESS] ACP-196
Dose Delays
Treatment with ACP-196 should be held for any unmanageable, potentially study drug-
related toxicity that is Grade [ADDRESS_609207]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609208] be discussed with 
the Medical Monitor.  Study drug may be held for a maximum of 28 consecutive days 
from expected dose due to toxicity.  Study treatment should be discontinued in the event of a toxicity lasting > 28 days, unless reviewed and approved by [CONTACT_1689].
Note: temporary withholding of study drug for as little as 7 days can cause a 
transient worsening of disease and/or of constitutional symptoms. Refer to 
Section 3.8 for more information on assessing disease progression under these 
circumstances.
Dose Modification and Discontinuation
The actions in Table 3-1 should be taken for the following toxicities:
x*UDGH$1&ȝ/IRU!GD\V1HXWURSKLOJURZWKIDFWRUV DUHSHUPLWWHG
per ASCO guidelines [Smith 2006] and use must be recorded on the electronic 
case report form [eCRF]).
xGrade 3 platelets in the presence of significant bleeding
xGrade 4 platelets 
xGrade 3 or 4 nausea, vomiting, or diarrhea, if persistent despi[INVESTIGATOR_271182]/or anti-diarrheal therapy
xAny other Grade [ADDRESS_609209] - 2nd Hold ACP-196 XQWLOUHFRYHU\WR*UDGHRUEDVHOLQHPD\UHVWDUWDW
original dose level
3rd Hold ACP-196 XQWLOUHFRYHU\WR*UDGHRUEDVHOLQHUHVW art at 100 mg 
once daily
4th Discontinue ACP-196
Subjects in Cohort 1 (ACP-196 monotherapy) who do not experience at least an minimal
response (MR) after [ADDRESS_609210] dexamethasone (40 mg once 
weekly) added to their treatment.
Whenever possible, any dose adjustment of ACP-196, including adding dexamethasone 
to subjects in Cohort 1, should be discussed between the investigator and the Acerta 
Pharma medical monitor before implementation. The appropriate clinic staff should 
Acerta Pharma Confidential Page [ADDRESS_609211]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609212]/caregiver about 
the change in dose level. Any changes to the dosing regimen must be recorded in the 
appropriate eCRF.  
[IP_ADDRESS] Dexamethasone
This study will use commercially available dexamethasone.  Dosing of dexamethasone will be [ADDRESS_609213] supportive care medications 
are permitted as per institutional standards.  
For subjects considered at risk for tumor lysis syndrome: Administer appropriate 
hydration and allopurinol or rasburicase per institutional standards before initiating 
treatment.
3.6.2 Guideline for Use of CYP Inhibiting/Inducing Drugs
At the systemic exposure levels expected in this study, ACP- 196 inhibition of CYP 
metabolism is not anticipated.  However, as discussed in Section 1.3.1 , concomitant 
administration of ACP-196 with a strong CYP3A4 inhibitor increased exposure by 
[CONTACT_3450] 5-fold.  Consequently, the concomitant use of strong inhibitors/inducers of CYP3A4 (Appendix 3) should be avoided when possible.  If a subject requires a strong CYP3A4 inhibitor while on study, monitor the subject closely for potential toxicities.
3.6.[ADDRESS_609214] of agents that reduce gastric acidity (eg, proton pump inhibitors, H2-receptor antagonists or antacids) on ACP-196 absorption is currently being evaluated in a healthy 
volunteer study (ACE-HV-004). Preliminary results from this study suggest subjects 
should avoid the use of calcium carbonate containing drugs or supplements (eg, antacids or calcium supplements) for a period of at least [ADDRESS_609215]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609216] 
requires treatment with a long-acting proton pump inhibitor while on study (eg, to treat an 
ulcer), discuss treatment options with the Medical Monitor.
3.6.4 Prohibited Concomitant Therapy
Any chemotherapy,immunotherapy, kinase inhibitors, bone marrow transplantation,
experimental therapy, and radiotherapy are prohibited (see Section 3.4.2 ).
Administration of live or live, attenuated vaccines is contraindicated in patients receiving 
immunosuppressive doses of corticosteroids, per the dexamethasone package insert (Appendix 4). Killed or inactivated vaccines may be administered. However, the 
response to such vaccines cannot be predicted.
3.7 PRECAUTIONS
3.7.1 Dietary Restrictions
Because ACP-196 may be metabolized by [CONTACT_097]3A4/3A5 (see Section 1.2.4 ), subjects 
should be strongly cautioned against excessive consumption of grapefruit, grapefruit juice, Seville oranges, or Sev ille or ange juice (which contain potent CYP3A4 inhibitors) 
or using herbal remedies or dietary supplements (in particular, St. John’s Wort, which is 
a potent CYP3A4 inducer).
ACP-[ADDRESS_609217] generation Btk inhibitor,
ibrutinib [IMBRUVICA package insert].  As a precaution, it is suggested that ACP-196 be 
held for 3 days before and after any major surgical procedure.
3.7.3 Infections
Patients who are on corticosteroids are more susceptible to infections than are healthy individuals (dexamethasone package insert, Appendix 4). Corticosteroids may 
exacerbate systemic f ungal infections and therefore should not be used in the presence 
of such infections unless they are needed to control life-threatening drug reactions.
3.7.[ADDRESS_609218]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609219]’s partner must be reported (see Section 6.2.3 ).Male subjects must agree 
to refrain from sperm donation during the study and for [ADDRESS_609220] experiencing an ACP-196 overdose (administration of a dose 1.[ADDRESS_609221] intended dose level in the clinical study protocol), observation for 
any symptomatic side effects should be instituted, and vital signs and biochemical and hematologic parameters should be followed closely (consistent with the protocol or more 
frequently, as needed). Appropriate supportive management to mitigate adverse effects 
should be initiated. If the overdose ingestion is recent and substantial, and if there are no medical contraindications, use of gastric lavage or induction of emesis may be 
considered.
The Acerta Pharma Medical Monitor should be contact[CONTACT_35114] a study drug overdose 
occurs. 
3.8 STOPPI[INVESTIGATOR_475180]-196 indefinitely as long as they are safely 
benefitting. However:
xAny subject has the right to withdraw from the study at any time.
xAny subject who has objective evidence of definitive MM progression while receiving 
study treatment at the highest individual tolerable dose level allowed in the protocol (see Section 3.5.5 ) should be withdrawn from the study treatment.  Note: If there is 
uncertainty regarding whether there is MM progression, the subject should continue 
study treatment and remain under close observation (eg, evaluated at 4- to 8-week 
Acerta Pharma Confidential Page [ADDRESS_609222]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
intervals) pending confirmation of progression. In particular, transient worsening of 
disease during temporary interruption of study therapy (eg, for intercurrent illness,
drug-related toxicity, or surgery) may not indicate definitive disease progression. In such circumstances, and if medically appropriate, subjects may resume therapy and 
relevant clinical, laboratory, and/or radiographic assessment should be done to 
document whether tumor control can be maintained or whether actual disease progression has occurred. 
xAny subject who is unable to tolerate rechallenge at the lowest protocol-described, 
dose-modified levels (see Section 3.5.5 ) should be withdrawn from the study 
treatment unless continued therapy is permitted by [CONTACT_475224].
xAny subject whose medical condition substantially changes after entering the study 
should be carefully evaluated by [CONTACT_475206]. Such subjects should be withdrawn from study 
treatment if continuing would place them at risk. 
xAny subject who becomes pregnant or begins breastfeeding should be removed from 
study treatment.
xAny subject who becomes significantly noncompliant with study drug administration, 
study procedures, or study requirements should be withdrawn from study treatment 
in circumstances that increase risk or substantially compromise the interpretation of study results.
xThe investigator, in consultation with the Acerta Pharma medical monitor, may 
withdraw any subject from the study treatment, if, in the investigator’s opi[INVESTIGATOR_1649], it is 
not in the subject’s best interest to continue. 
Subjects who discontinue study therapy w ill conti nue on study for safety ( Section 4.3 )
unless they withdraw consent for further follow- XS7KXVDOOVXEMHFWVUHFHLYLQJ [ADDRESS_609223] is withdrawn 
from study treatment or from the study and the reason for discontinuation w ill be 
recorded and also should be described on the appropriate eCRF.
3.9 DAT A AND SAFET Y M O NIT O RING
This trial will be monitored in accordance with the sponsor’s Pharmacovigilance Committee procedures.  Adverse events and SAEs w ill be reviewed internally on an 
Acerta Pharma Confidential Page [ADDRESS_609224]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
ongoing basis to identify safety concerns.  Quarterly conference calls with the 
investigators will be conducted to discuss study progress, obtain investigator feedback 
and exchange, and discuss "significant safety events" (ie, AEs leading to dose reductions, related SAEs, and deaths).  
4.[ADDRESS_609225] read, understand and sign the IRB/IEC approved ICF confirming his or 
her willi ngness to participate in this study before initiating any screening activity that is 
not standard of care.  Subjects must also grant permission to use protected health information.
4.1.[ADDRESS_609226]’s complete history should be collected and recorded through review of medical records and by [CONTACT_30230]. Concurrent medical signs and symptoms must be documented to establish baseline severities. A disease history, including the date of 
initial diagnosis and list of all prior anticancer treatments, and responses and duration of 
response to these treatments, also w ill be recor ded.
4.1.[ADDRESS_609227]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609228] dose of study drug.
4.1.6 ECOG Performance Status
The ECOG performance index is provided in Appendix 1 .
4.1.7 Physical Examination, Vital Signs, Height & Weight
The screening physical examination will include, at a minimum, the general appearance 
of the subject, height (screening only) and weight, and examination of the skin, eyes,
ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, nervous 
system, and lymphatic system.
Symptom-directed physical exams, including tumor assessments by [CONTACT_23302], will be 
done during the treatment period and at the safety follow-up visits.
Vital signs (blood pressure, heart rate, respi[INVESTIGATOR_697], and body temperature) will be 
assessed after the subject has rested in the sitting position.
4.1.8 Bone Marrow Aspi[INVESTIGATOR_127843]
A bone marrow aspi[INVESTIGATOR_475181] 30 days before the main screening procedures. Per the current response criteria (Rajkumar 2011), a bone 
marrow aspi[INVESTIGATOR_337]/biopsy will also be required at any time on study to confirm a complete 
response (CR). The baseline bone marrow aspi[INVESTIGATOR_337]/biopsy will used for 
immunohistochemistry and/or flow cytometry, cytogenetics, and FISH.  Testing will be performed at the study center’s local laboratory or other clinical laboratory listed on the 
investigator’s form FDA 1572.  De-identified copi[INVESTIGATOR_378122]/aspi[INVESTIGATOR_378123].
When available, any unused bone marrow tissue will be used for PD testing.  PD testing 
will be done by [CONTACT_456].
Acerta Pharma Confidential Page [ADDRESS_609229]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
4.1.9 Electrocardiogram
Subjects should be in supi[INVESTIGATOR_050] p RVLWLRQDQGUHVWLQJIRU [ADDRESS_609230] include complete blood count (CBC) with differential and platelet and reticulocyte counts.  Testing w ill be done by [CONTACT_2237].
4.1.[ADDRESS_609231], bicarbonate, 
blood urea nitrogen (BUN), bone-specific alkaline phosphatase, calcium, chloride, 
creatinine, C-terminal telopeptide, glucose, lactate dehydrogenase (LDH), magnesium, 
phosphate, potassium, sodium, total bilirubin, total protein, and uric acid.  If an 
unscheduled ECG is done at any time, then an electrolyte panel (ie, calcium, 
magnesium, and potassium) must be done to coincide with the ECG testing.  Testing w ill 
be done by [CONTACT_2237].
4.1.13 Urinalysis
Urinalysis includes pH, ketones, specific gravity, b ilirubin, protein, blood, N-terminal 
telopeptide, and glucose.  Testing will be done by [CONTACT_2237].
4.1.14 T/B/NK Cell Count
Flow cytometry testing will include CD3+, CD4+, CD8+, CD19+, and CD16/56+cells.  
Testing will be done by [CONTACT_2237].
4.1.15 Disease Markers
Testing for serum M-protein levels (by [CONTACT_159425] [SPEP] and serum 
immunofixation electrophoresis [SIFE]), serum free light chains (SFLC), urine M-protein 
levels (by [CONTACT_475226] [UPEP] and urine immunofixation electrophoresis [UIFE]), and serum ȕ-microglobulin will be done by [CONTACT_11378].
Acerta Pharma Confidential Page [ADDRESS_609232]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609233] lateral radiograph of the skull, anterioposterior and lateral views of the spi[INVESTIGATOR_050], 
and anterioposterior views of the pelvis, ribs, femora, and humeri are required at screening or baseline (ie, before the first dose of study drug).  Radiographic imaging and analysis will be performed at the study center’s local laboratory or other clinical 
laboratory listed on the investigator’s form FDA 1572. 
4.1.17 Pharmacodynamics
Blood samples and bone marrow, when available, w ill be used for PD testing (eg, Btk
occupancy and B-cell activation).  Refer to the laboratory binder for instructions on 
collecting and processing these samples. Testing will be done by [CONTACT_456].
4.1.18 Pharmacokinetics
Refer to the laboratory binder for instructions on collecting and processing these 
samples. Testing will be performed at the central clinical laboratory. Leftover plasma 
samples may be used for exploratory ACP-196 metabolite analyses.  The PK sampling timepoints are provided in Table 4-1 .
Table 4-1.  Pharmacokinetic Sample Schedule
HOURS POSTDOSE
Cycle Day Predose0.5
(±5 min)0.75
(±5 min)1
(±5 min)2
(±10 min)4
(±10 min)6
(±10 min)
11 XX XX XX X
8 X X
15 X X
22 XX XX XX X
28 X X
Note: These timepoints are relative to the morning dose.
4.1.[ADDRESS_609234] of:
ƔM-protein determination using both of the following procedures:
żserum protein electrophoresis (SPEP) and serum imm unofixation 
electrophoresis (SIFE)
Acerta Pharma Confidential Page [ADDRESS_609235]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
żUrine protein electrophoresis (UPEP) and urine immunofixation 
electrophoresis (UIFE), all using the same 24-hour urine collection 
ƔSFLC
ƔPlasmacytoma evaluation
ƔBone marrow to quantify percent myeloma cell involvement (aspi[INVESTIGATOR_475166])
ƔSkeletal survey: lateral radiograph of the skull, anterioposterior and lateral 
views of the spi[INVESTIGATOR_050], and anterioposterior views of the pelvis, ribs, femora, and humeri
Ɣȕ  -microglobulin
On-study myeloma assessments will consist of:
ƔSPEP and/or UPEP (if results were measurable at baseline); quantitative 
immunoglobulins if used to follow disease; immunofixation to confirm a complete response
ƔSFLC
ƔPlasmacytoma evaluation (if only measurable disease at baseline)
ƔBone marrow aspi[INVESTIGATOR_6706]/or trephine bone biopsy (to confirm a complete 
response or if clinically indicated).
4.1.20 Study Drug Accountability
See Section 7.7 .
4.2 INVESTIGATOR’S ASSESSMENT OF RESPONSE TO TREATMENT
Subjects will be evaluated by [CONTACT_475227] 1 (Rajkumar 2011) and European Group for Blood and Marrow Transplant (EBMT; Bladé 1998)as listed belowin .  Response categories include sCR, 
CR,  VGPR, PR, SD, and progressive disease. In addition, the number of subjects
achieving the response category of MR will also be evaluated and reported.  Subjects
will be considered evaluable for response if they have a baseline and t1 adequate on-
study myeloma assessment obtained t4 weeks from the start of therapy.
Acerta Pharma Confidential Page [ADDRESS_609236]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Table 4-2. Response Criteria (derived from Rajkumar 2011 and Bladé 1998)
Response Subcategory Response Criteriaa
Complete response (CR)xNegative immunofixation of serum and urine and
xDisappearance of any soft tissue plasmacytomas and
x< 5% plasma cells in bone marrowb.
Stringent complete 
response (sCR)xCR as defined above plus
xNormal FLC ratio and
xAbsence of clonal plasma cells by [CONTACT_128756] 2- to 
4-color flow cytometry.
Very good partial 
response (VGPR)xSerum and urine M-component detectable by [CONTACT_237472]
x90% reduction in serum M-component plus urine M-component 
< 100 mg per 24 h.
Partial response (PR)x50% reduction of serum M-protein and reduction in 24-h urinary 
M-SURWHLQE\ 90% or to < 200 mg per 24 h
xIf the serum and urine M-protein are not measurable D50% 
decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria
xIf serum and urine M-protein are not measurable, and serum free 
light assay is also not measurable 50% reduction in bone
marrow plasma cells is required in place of M-protein, provided 
EDVHOLQHSHUFHQWDJHZDV 30%
x,QDGGLWLRQWRWKHDERYHFULWHULDLISUHVHQWDWEDVHOLQH 50% 
reduction in the size of soft tissue plasmacytomas is also required
Minimal response (MR) xRequires all of the following:
ot25% to d49% reduction of serum M-protein and
o50% to 89% reduction in 24-hour urine M-protein and
oIf present at baseline, 25-49% reduction in the size of soft 
tissue plasmacytomas and
oNo increase in size or number of lytic bone lesions 
(development of compression fracture does not exclude 
response).
Stable disease (SD) xNot meeting criteria for CR, VGPR, MR, PR or progressive 
disease
Progressive disease Any of the following:
x,QFUHDVHRI 25% from lowest response valuecin:
oSerum M-component (abs ROXWHLQFUHDVHPXVWEH 0.5 g/dL)d
oUrine M-component (absolute increase must be 
200 mg/24 h)
Acerta Pharma Confidential Page [ADDRESS_609237]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
oOnly in subjects without measurable serum and urine 
M-protein levels: the difference between involved and 
uninvolved FLC levels (absolute increase must be > 10 mg/dL)
oOnly in subjects without measurable serum and urine M-
protein levels and without measurable disease by [CONTACT_475228] (absolute increase must 
EH 10%)
xDefinite development of new bone lesions or soft tissue 
plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas
xDevelopment of hypercalcemia (corrected serum calcium 
> 11.5 mg/dL) that can be attributed solely to the plasma cell 
proliferative disorder
Abbreviations: FLC = (serum) free light chains
Note: in subjects in whom the only measurable disease is by [CONTACT_128758], CR requires a
normal FLC ratio of 0.26-1.65 in addition to negative serum and urine immunofixation. VGPR in 
such subjects is defined as a > 90% decrease in the difference between involved and uninvolved 
free light chain FLC levels
a. All response categories (CR, sCR, VGPR, PR, and PD) require 2 consecutive assessments 
made at t4 weeks after the start of study therapy and any time before the institution of any 
new therapy after study therapy; CR, sCR, VGPR, PR, and SD categories also require no 
known evidence of progressive or new bone lesions if radiographic studies were performed. VGPR and CR categories require serum and urine studies regardless of whether disease at 
baseline was measurable on serum, urine, both, or neither. Radiographic studies are not 
required to satisfy these response requirements.
b. Bone marrow assessments need not be confirmed.
c. Lowest response value does not need to be a confirmed value.d. For progressive disease, serum M- FRPSRQHQWLQFUHDVHVRI 1 gm/dL are sufficient to define 
relapse if starting M- FRPSRQHQWLV 5 g/dL.
4.3 EARLY TERMINATION/SAFETY FOLLOW-UP VISIT
An early termination visit is required for any subjects who permanently discontinue study 
drug early for any reason including disease progression.  Each subject should be 
followed for 30 (±7) days after his or her last dose of study drug (ie, the “safety follow-upvisit”) to monitor for resolution or progression of AEs (see Section 6.2.5) and to 
document the occurrence of any new events; unless, the subject receives a new 
anticancer therapy within this timeframe.  Subjects who withdraw consent should st ill be 
encouraged to complete the safety follow-up assessments, but these assessments cannot be mandated once consent is withdrawn.  The Schedule of Assessments 
(Appendix 5) describes the procedures required for the safety follow-up. 
4.[ADDRESS_609238]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
investigator’s opi[INVESTIGATOR_1649], medically unnecessary or unsafe because it is too close in time to 
the next scheduled evaluation.  In that case, the missed evaluation should be 
abandoned.
5.0 STA TISTICA L METHODS OF A NA LYSIS 
5.1 GENERAL CONSIDERATIONS
Descriptive statistics (including means, standard deviations, and medians for continuous variables and proportions for discrete variables) w ill be used to summarize data as 
appropriate. Analyses will be done by [CONTACT_178359].
5.2 SAMPLE SIZE CONSIDERATIONS
This study will assess safety, PK, PD, and antitumor activity of ACP-196 alone or in 
combination with dexamethasone.  Subjects will be equally randomized into 1 of the 2 dosing regimens (ACP-196 monotherapy or ACP-196 + dexamethasone) as an 
efficient method for allocating patients into these regimens. The study is not formally 
designed to compare these regimens but rather to obtain descriptive information that can be used in support of further ACP-196 development.
While the primary objective of this study is to determine the safety in each of the 
2 dosing cohorts, the sample size has been determine to independently evaluate the 
activity of each dosing regimen. The trial seeks to exclude an uninteresting ORR of 
d15% (ie, the response rate that might be associated with single-agent dexamethasone 
therapy [Anderson 2013]) in favor a target response rate of t40%.  Considering a 
sample size of [ADDRESS_609239] the difference between a null-
hypothesis response rate of 15% and an alternative-hypothesis response rate of 40%
with a 0.025 one-sided significance level is 69% using a one-group, exact binomial test.  
A sample size of 19 subjects per cohort w ill also provide a 97.5% 1-si ded confidence 
interval centered around an expected ORR of 40% that excludes an ORR of 18.6% as a lower bound
.
5.3 DEFINITION OF ANALYSIS POPULATIONS
The following definitions will be used for the analysis populations:
xSafety population: $OOHQUROOHGVXEMHFWVZKRUHFHLYH 1 dose of study drug.
xIntent-to-treat (ITT) population : All subjects who have been randomized.
The safety population will be used for evaluating the safety parameters in this study.  
The ITT population will be analyzed for efficacy parameters in this study.
Acerta Pharma Confidential Page [ADDRESS_609240]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
5.4 MISSING DATA HANDLING
General Considerations: Subjects lost to follow-up (or who dropped out) will be 
included in statistical analyses up to the point of their last evaluation.
Duration of Response and Progression-free Survival: Data for subjects without 
disease progression or death will be censored at the date of the last tumor assessment and before the initiation of alternative anticancer therapy.
Safety: Missing or partial start and end dates for AEs and concomitant medications w ill 
be imputed according to prespecified, conservative imputation rules.  No other 
imputation of values for missing data will be performed.
5.5 ENDPOINT DATA ANALYSIS
5.5.1 Safety Endpoint
Safety summaries will incl ude summaries in the form of tables and listings.  The 
frequency (number and percentage) of treatment emergent AEs will be reported in each treatment group by [CONTACT_61121].  Summaries w ill 
also be presented by [CONTACT_475211] (per CTCAE, v4.03) and by 
[CONTACT_8792].
Laboratory shift tables containing counts and percentages w ill be pr epared by [CONTACT_11512], laboratory parameter, and time.  Summary tables will be prepared for each laboratory parameter.  Figures of changes in laboratory parameters over time will be 
generated.
Results of vital sign assessments and physical exams w ill be tabulated and summarized.  
5.5.[ADDRESS_609241] demographics, baseline 
characteristics, compliance, and concurrent treatments. Concomitant medications will be 
coded according to the World Health Organization (WHO) Drug Dictionary and 
tabulated.
5.5.3 Analysis of Efficacy Parameters
[IP_ADDRESS] Overall Response Rate
Tumor control will be documented at each assessment by [CONTACT_475229] (eg, CR, 
sCR, VGPR, PR, MR, SD, and disease progression) as defined for each response parameter, date that response is first documented, and date of MM disease progression.
Acerta Pharma Confidential Page [ADDRESS_609242]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
The overall response rate (ORR) will be defined as the proportion of subjects who 
achieve a CR, sCR, VGPR, or PR. ORR will be calculated and the corresponding 
95% two-sided confidence interval will be derived.
[IP_ADDRESS] Duration of Response
The duration of response (DOR) defined as the interval from the first documentation of 
CR, sCR, VGPR, or PR to the earlier of the first documentation of definitive disease 
progression or death from any cause.  Kaplan-Meier methods will be used to estimate 
event-free curves and corresponding quantiles (including the median). Data from surviving, nonprogressing subjects will be censored at the earliest of the time of initiation of anticancer treatment other than the study treatment or the last time that lack of 
definitive MM progression was objectively documented. Data from subjects who have 
MMSURJUHVVLRQRUGLHDIWHUFRQVHFXWLYHPLVVLQJWXPRUDVVHVVPH QWVZLOOEH
censored at the last time before the missing assessments that lack of MM progression 
was objectively documented.
[IP_ADDRESS] Clinical Benefit Rate
Clinical b enefit rate (CBR) will be defined as the proportion of subjects who achieve a 
CR, sCR, VGPR, PR, or MR.  CBR will be calculated and the corresponding 95% two-
sided confidence interval w ill be derived.
[IP_ADDRESS] Disease Control Rate
Disease control rate (DCR) will be defi ned as the proportion of subjects who achieve a 
CR, sCR, VGPR, PR, MR, or SD.  DCR will be calculated and the corresponding 
95% two-sided confidence interval will be derived.
[IP_ADDRESS] Progression-free Survival
Progression-free survival (PFS) is defined as the interval from the date of randomization
to the earlier of the first documentation of objective MM disease progression or death 
from any cause.  Kaplan-Meier methods will be used to estimate the event-free curves 
and corresponding quantiles (including the median). Data from surviving, non-
progressing subjects will be censored at the earliest of the time of initiation of anticancer
treatment other than the study treatment or the last time that lack of MM progression was objectively documented. Data from subjects who have MM progression or die after 
[ADDRESS_609243]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
5.5.4 Analysis of Pharmacokinetic/Pharmacodynamic Parameters
The plasma PK of ACP-196 and dexamethasone will be characterized using 
noncompartmental analysis. The following PK parameters will be calculated, whenever possible, from plasma concentrations of ACP-196:
xAUC
0-t Area under the plasma concentration-time curve calculated using linear 
trapezoidal summation from time [ADDRESS_609244] measurable concentration (C
t).
xAUC 0-12 Area under the plasma concentration-time curve from 0 to 12 hours, 
calculated using linear trapezoidal summation.
xAUC 0- Area under the plasma concentration-time curve from 0 to infinity, 
calculated using the formula: AUC 0-= AUC 0-t + C tȜzZKHUHȜ zis the 
apparent terminal elimination rate constant.
xAUC 0-24calc Area under the plasma concentration-time curve from 0 to 24 hours, 
calculated by [CONTACT_378152] 0-12.
xCmax Maximum observed plasma concentration
xTmax Time of the maximum plasma concentration (obtained without 
interpolation)
xt½ Terminal elimination half-life (whenever possible) 
xȜz Terminal elimination rate constant (whenever possible)
xCL/F Oral clearance
Missing dates or times may be imputed for PK and PD samples if the missing values can 
be established with an acceptable level of accuracy based on other information obtained 
during the visit in question. If PK and PD sampling for a given subject is not performed 
according to protocol instructions that subject may be excluded from the PK and PD analyses.
The PK parameters will be t abulated and summarized using descriptive statistics. 
For each PD variable, the concentration at each assessment will be descri bed.  The 
change from baseline to each assessment w ill be summarized.  The best c hange from 
baseline during the study will also be summarized.  As appropriate, the on-treatment 
values will be compared with the pretreatment baseline values using paired t-tests.  
5.5.[ADDRESS_609245]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609246] of monitoring and recording AEs and SAEs;
measurements of protocol-specified hematology, clinical chemistry, urinalysis, and other 
laboratory variables; measurement of protocol-specified vital signs; and other protocol-
specified tests that are deemed critical to the safety evaluation of the study drug(s).
6.1 DEFINITIONS
6.1.1 A dverse Events
An AE is any unfavorable and unintended sign, symptom, or disease temporally 
associated with the use of an investigational (medicinal) product or other protocol-
imposed intervention, regardless of attribution.
This includes the following:
xAEs not previously observed in the subject that emerge during the protocol-specified 
AE reporting period, including signs or symptoms associated with MM that were not 
present before the AE reporting period (see Section 6.2.1 )
xComplications that occur as a result of protocol-mandated interventions (eg, invasive 
procedures such as biopsies)
xPreexisting medical conditions (other than the condition being studied) judged by [CONTACT_170068]-specified AE reporting period.
Abnormal laboratory values should not be reported as AEs; however, any clinically 
significant laboratory values (defined as requiring treatment, discontinuation from study,
or dose modification) should be reported as AEs.
6.1.2 Serious A dverse Event
The terms “severe ”and “serious” are not synonymous.  Severity (or intensity) refers to 
the grade of an AE (see below).  “Serious” is a regulatory definition and is based on 
subject or event outcome or action criteria usually associated with events that pose a 
threat to a subject’s life or functioning.  Seriousness (not severity) serves as the guide for defining regulatory reporting obligations from the Sponsor to applicable regulatory authorities.
Acerta Pharma Confidential Page [ADDRESS_609247]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
An AE should be classified as an SAE if it meets any 1 of the following criteria:
xIt results in death (ie, the AE actually causes or leads to death).
xIt is life-threatening (ie, the AE, in the view of the investigator, places the subject at 
immediate risk of death.  It does not include an AE that, had it occurred in a more 
severe form, might have caused death).
xIt requires or prolongs in-patient hospi[INVESTIGATOR_059].
xIt results in persistent or significant disability/incapacity (ie, the AE results in 
substantial disruption of the subject’s ability to conduct normal life functions).
xIt results in a congenital anomaly/birth defect in a neonate/infant born to a mother 
exposed to the investigational product.
xIt is considered a significant medical event by [CONTACT_188212] (eg, may jeopardize the subject or may require medical/surgical intervention to prevent 1 of the outcomes listed above).
6.1.3 Severity
Definitions found in the CTCAE version 4.03 or higher will be used for grading the 
severity (intensity) of AEs. The CTCAE displays Grades [ADDRESS_609248] experience any AE not 
listed in the CTCAE, the following grading system should be used to assess severity:
xGrade 1 (Mild AE) – experiences which are usually transient, requiring no special 
treatment, and not interfering with the subject’s daily activities
xGrade 2 (Moderate AE) – experiences which introduce some level of inconvenience 
or concern to the subject, and which may interfere with daily activities, but are usually ameliorated by [CONTACT_475230] 3 (Severe AE) – experiences which are unacceptable or intolerable, 
significantly interrupt the subject’s usual daily activity, and require systemic drug 
therapy or other treatment
xGrade 4 (Life-threatening or disabling AE) – experiences which cause the subject to 
be in imminent danger of death
xGrade 5 (Death related to AE) – experiences which result in subject death
Acerta Pharma Confidential Page [ADDRESS_609249]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609250] be reported on the SAE/Product Complaint form (see Section 6.2.4 ).
6.2.[ADDRESS_609251] dose of 
study medication and ends with the safety follow-up visit (or last on-treatment visit if the 
safety follow-up visit is not done), or when the subject receives a new anticancer therapy.  An exception to this reporting period is any AE occurring due to a protocol-
defined screening procedure.  Fatal AEs occurring within [ADDRESS_609252]’s medical record and on the 
AE eCRF and, when applicable, on an SAE/Product Complaint form.
Disease progression itself is not considered an adverse event; however, signs and 
symptoms of disease progression may be recorded as AEs or SAEs.
Each recorded AE or SAE w ill be descri bed by [CONTACT_13662] (ie, start and end dates), 
severity, regulatory seriousness criteria, if applicable, suspected relationship to the study drug (ie, ACP-196, dexamethasone, or both; see following guidance), and any actions 
taken.  The relationship of AEs to the study drug will be assessed by m eans of the 
question: ‘Is there a reasonable possib ility that the event may have been caused by [CONTACT_50463]?’  Answer Yes or No. 
See Appendix [ADDRESS_609253]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
reported using the SAE report form, according to the usual timelines and directions for 
SAE reporting ( Section 6.2.4 ).
Any uncomplicated pregnancy that occurs in a subject or a partner of a treated subject 
during this study will be reported for tracking purposes only, if agreed to by [CONTACT_475231]. All pregnancies and partner pregnancies that are identified during or after this study, wherein the estimated date of conception is 
determined to have occurred from the time of consent to [ADDRESS_609254] interfered with the effectiveness of a contraceptive medication. Likewise, elective abortions without complications are not 
considered AEs. Any SAEs associated with pregnancy (eg, congenital 
abnormalities/birth defects/spontaneous miscarriages or any other serious events) must additionally be reported as such using the SAE/Product Complaint form. 
Subjects should be instructed to immediately notify the investigator of any pregnancies.  
Any female subjects receiving ACP-[ADDRESS_609255] be r eported within 24 hours of discover.  All initial SAE reports and follow-
up information will be reported using the protocol-specific electronic data capture 
system.  If electronic SAE r eporting is not available, paper SAE/Product Complaint forms 
must be emailed or faxed to Acerta Pharma Drug Safety, or designee. Acerta Pharma
may request follow-up and other additional information from the investigator (eg, hospi[INVESTIGATOR_15517]/discharge notes and laboratory results). 
All deaths should be reported with the primary cause of death as the AE term, as death 
is typi[INVESTIGATOR_36069], not the event itself. The primary cause of death on 
the autopsy report should be the term reported.  Autopsy and postmortem reports must be forwarded to Acerta Pharma Drug Safety, or designee, as outlined above.
If study drug is discontinued because of an SAE, this information must be included in the 
SAE report.
Acerta Pharma Confidential Page [ADDRESS_609256]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609257] and is not listed in the current 
Investigator’s Brochure (ie, an unexpected event). In this case, Acerta Pharma Drug Safety/Designee w ill forward a formal notification describing the SAE to all investigators. 
Each investigator must then notify his or her IRB/IEC of the SAE.
Drug Safety Contact [CONTACT_475215]:
Email:
6.2.[ADDRESS_609258] to follow-up or withdraws 
consent.
7.0 STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS
Acerta Pharma retains the right to terminate the study and remove all study materials 
from a study site at any time. Specific circumstances that may precipi[INVESTIGATOR_475167]: 
xUnsatisfactory subject enrollment with regard to quality or quantity
xSignificant or numerous deviations from study protocol requirements, such as 
failure to perform required evaluations on subjects and maintain adequate study 
records
xInaccurate, incomplete or late data recording on a recurrent basis
xThe incidence and/or severity of AEs in this or other studies indicating a potential 
health hazard caused by [CONTACT_104841]
7.1 REGULATORY AND ETHICAL COMPLIANCE
This clinical study was designed and will be implemented in accordance with the 
protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practices, 
applicable local regulations (including US Code of Federal Regulations Title [ADDRESS_609259]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
European Directive 2001/20/EC), and the ethical principles laid down in the Declaration 
of Helsinki.
7.[ADDRESS_609260] AND INDEPENDENT ETHICS 
COMMITTEE
The investigator will submit this protocol, the ICF, Investigator’s Brochure, and any other 
relevant supporting information (eg, all advertising materials) to the appropriate IRB/IEC
for review and approval before study initiation.  A signed protocol approval page; a letter 
confirming IRB/IEC approval of the protocol and informed consent; and a statement that 
the IRB/IEC is organized and operates according to GCP and the applicable laws and regulations; must be forwarded to Acerta Pharma before screening subjects for the 
study.  Additionally, sites must forward a signed FDA 1572 form (Statement of 
Investigator form) to Acerta Pharma before screening subjects for study enrollment.  Amendments to the protocol must also be approved by [CONTACT_1201]/IEC and local regulatory agencies, as appropriate, before the implementation of changes in this study.
7.[ADDRESS_609261] HEALTH 
INFO RM AT IO N AUT HO RIZAT IO N
A copy of the IRB/IEC-approved ICF must be forwarded to Acerta Pharma for regulatory 
purposes.  The investigator, or designee (designee must be listed on the Study Personnel Responsib ility/Si gnature Log, see Section 7.12 ), must explain to each subject 
the purpose and nature of the study, the study procedures, the possible adverse effects, 
and all other elements of consent as defined in § 21CFR Part 50, and other applicable 
national and local regulations governing informed consent.  Each subject must provide a signed and dated informed consent before enrollment into this study.  In the case of a 
subject who is incapable of providing informed consent, the investigator (or designee) 
must obtain a signed and dated informed consent form from the subject’s legal guardian.  Signed consent forms must remain in each subject’s study file and be available for 
verification by [CONTACT_9534].
In accordance with individual local and national subject privacy regulations, the 
investigator or designee must explain to each subject that for the evaluation of study 
results, the subject’s protected health information obtained during the study may be shared with Acerta Pharma and its designees, regulatory agencies, and IRBs/IECs.  As 
the study Sponsor, Acerta Pharma will not use the subject’s protected health information 
or disclose it to a third party without applicable subject authorization.  It is the investigator’s or designee’s responsibility to obtain written permission to use protected 
Acerta Pharma Confidential Page [ADDRESS_609262]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609263]’s legal guardian.  If a 
subject or subject’s legal guardian withdraws permission to use protected health 
information, it is the investigator’s responsibility to obtain the withdrawal r equest in 
writing from the subject or subject’s legal guardian andto ensure that no further data will 
be collected from the subject.  Any data collected on the subject before withdrawal will 
be used in the analysis of study results.
7.[ADDRESS_609264] that lists allsubjects considered for enrollment 
(including those who did not undergo screening) in the study.  For those subjects 
subsequently excluded from enrollment, record the reason(s) for exclusion.
7.5 CASE REPORT FORMS
Authorized study site personnel (see Section 7.12 ) will complete eCRFs designed for 
this study according to the completion guidelines that will be provided.  The investigator 
will ensure that the eCRFs are accurate, complete, legible, and completed within [ADDRESS_609265]’s visit (unless required earlier for SAE reporting).  The investigator w ill 
ensure that source documents that are required to verify the validity and completeness 
of data transcribed on the eCRFs are never obliterated or destroyed, in accordance with the record retention policies in Section 7.[ADDRESS_609266] to reviews or audits by [CONTACT_456], regulatory authorities, or ethics committees.
Every effort will be m ade to maintain the anonymity and confidentiality of all subjects 
during this clinical study.  However, because of the experimental nature of this treatment, the investigator agrees to allow the IRB/IEC, representatives of Acerta 
Pharma, its designated agents, and authorized employees of the appropriate regulatory 
agencies to inspect the fac ilities used in this study and, for purposes of verification, allow 
direct access to the hospi[INVESTIGATOR_147443]. This 
includes providing by [CONTACT_6791], email, or regular mail de-identified copi[INVESTIGATOR_134464], 
Acerta Pharma Confidential Page [ADDRESS_609267]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
pathology, and/or laboratory results when requested by [CONTACT_456].  A statement to this 
effect will be incl uded in the informed consent and permission form authorizing the use 
of protected health information.
7.[ADDRESS_609268] be maintai ned and readily available for 
inspection by [CONTACT_475232]. 
Each shipment of study drug will contain a Clinical Supplies Shippi[INVESTIGATOR_378128] 
(CSSF) that must be appended to the site’s drug accountab ility records. If it is used, the 
Drug Re-order Form (provided in the pharmacy binder) must also be included in the site’s drug accountab ility records.
Contents of each shipment must be visually inspected to verify the quantity and 
document the condition of study drug capsules.  Then the designated recipi[INVESTIGATOR_475169]. A copy of the signed CSSF must be faxed or emailed to 
Acerta Pharma at the fax number/emailing address listed on the form.
An Investigational Drug Accountab ility Log must be used for drug accountability.  For 
accurate accountab ility, the following information must be noted w hen drug supplies are 
used during the study:
1. study identification number (ACE-MY-001)
2. subject identification number
3. lot number(s) of ACP-[ADDRESS_609269]
At study initiation, the monitor will evaluate and approve the site’s procedure for 
investigational product disposal/destruction to ensure that it complies with Acerta 
Pharma’s requirements. If the site cannot meet Acerta Pharma’s requirements for disposal/destruction, arrangements will be made between the site and Acerta Pharma or 
its representative, for return of unused investigational product.  Before
Acerta Pharma Confidential Page [ADDRESS_609270]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
disposal/destruction, final drug accountability and reconciliation must be performed by 
[CONTACT_2037].
All study supplies and associated documentation w ill be r egularly reviewed and verified 
by [CONTACT_2037].
7.[ADDRESS_609271] RETENTION
The investigator and other appropriate study staff are responsible for maintaining all documentation relevant to the study. Mandatory documentation includes copi[INVESTIGATOR_475170], each FDA Form 1572, IRB/IEC approval letters, signed ICFs, drug accountab ility records, SAE forms transmitted to Acerta Pharma, subject files 
(source documentation) that substantiate entries in eCRFs, and all relevant 
correspondence and other documents pertaining to the conduct of the study.
An investigator shall retain records for a period of at least [ADDRESS_609272] 
marketing application is approved for the drug for the indication for which it is being 
investigated; or, if no application is to be filed or if the application is not approved for such indication, until [ADDRESS_609273] from the study site so that they can be returned sealed to the investigator for audit purposes.
7.9 PROTOCOL AMENDMENTS
Acerta Pharma will initiate any c hange to the protocol in a protocol amendment 
document. The amendment w ill be submitted to the IRB/IEC t ogether with, if applicable, 
a revised model ICF. If the change in any way increases the risk to the subject or 
changes the scope of the study, then written documentation of IRB/IEC approval must 
Acerta Pharma Confidential Page [ADDRESS_609274]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609275]. Additionally 
under this circumstance, information on the increased risk and/or change in scope must 
be provided to subjects already actively participating in the study, and they must read, understand, and sign any revised ICF confirming w illingness to remain in the trial.
7.[ADDRESS_609276]. The results may also be used for papers, abstracts, posters or other material presented at scientific meetings or published 
in professional journals or as part of an academic thesis by [CONTACT_2413]. The study is 
being conducted as part of a multicenter clinical trial. Data from all study centers shall be pooled and analyzed for publication in a final report (Primary Publication). The investigator agrees that the Primary Publication, which will be coordinated by [CONTACT_475217], will be the first publication to present the pooled study results. After the Primary 
Publication, or if the Primary Publication is not published within [ADDRESS_609277] matter and/or any 
inadvertent disclosure of its confidential information, which must be redacted from any final publication or presentation. If necessary, to permit the preparation and filing of 
patent applications, Acerta Pharma may elect an additional review period not to exceed 
60 days.
Authorship, in general, will follow the recommendations of the International Committee of 
Medical Journal Editors (International Committee of Medical Journal Editors 2014).  
7.[ADDRESS_609278] ensure that:
Acerta Pharma Confidential Page [ADDRESS_609279]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609280] their names included in the Study 
Personnel Responsib ility/Si gnature Log.
3. The study is conducted according to the protocol and all applicable regulations.4. The protection of each subject’s rights and welfare is maintained.
5. Signed and dated informed consent and, when applicable, permission to use 
protected health information are obtained from each subject before conducting nonstandard of care study procedures.  If a subject or subject’s legal guardian withdraws permission to use protected health information, the investigator w ill 
obtain a written request from the subject or subject’s legal guardian and w ill 
ensure that no further data be collected from the subject.
6. The consent process is conducted in compliance with all applicable regulations 
and privacy acts.
7. The IRB/IEC complies with applicable regulations and conducts initial and 
ongoing reviews and approvals of the study.
8. Any amendment to the protocol is submitted promptly to the IRB/IEC.
9. Any significant protocol deviations are reported to Acerta Pharma and the 
IRB/IEC according to the guidelines at each study site.
10. Electronic CRF pages are completed within [ADDRESS_609281]’s visit (unless 
required earlier for SAE reporting).
11. All IND Safety Reports/ Suspected Unexpected Serious Adverse Reaction 
(S[LOCATION_003]R) Reports are submitted promptly to the IRB/IEC.
12. All SAEs are reported to Acerta Pharma Drug Safety/Designee within 24 hours of 
knowledge and to the IRB/IEC per their requirements.
Acerta Pharma Confidential Page [ADDRESS_609282]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
8.0 REFERENCES
Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013;11:11-17. 
Bladé J, Samson D, Reece D, et al.  Criteria for evaluating disease response and 
progression in patients with multiple myeloma treated by [CONTACT_5019]-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular 
switches. Cell Signal 2010;22:1175-1184. 
Buggy JJ, Elias L. Bruton tyrosine kinase (Btk) and its role in B-cell malignancy. Int Rev 
Immunol 2012;31:119-132. Erratum in: Int Rev Immunol 2012;31:428.
By[CONTACT_9063], Furman RR, Coutre SE, Flinn IW, et al. Targeting Btk with ibrutinib in relapsed 
chronic lymphocytic leukemia. NEJM 2013;369:32-42.
By[CONTACT_9063], Brown JR, O’Brien S, et al.  Ibrutinib versus ofatumumab in previously treated 
chronic lymphoid leukemia.  NEJM 2014 May 31 [Epub ahead of print]
Cheson BD, By[CONTACT_9063], Rai KR, et al. Novel targeted agents and the need to refine clinical 
end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820-2820.
Cheson BD, By[CONTACT_9063], Rai KR, et al. Novel targeted agents and the need to refine clinical 
end points in chronic lymphocytic leukemia. J Clin Oncol 2012 30:2820-2822.
Edwards CM, BTK inhibition in myeloma: targeting the seed and soil.  Blood 
2012;120:1757-1759.  
FDA (US Food and Drug Administration). Guidance for industry. Food-Effect 
Bioavailability and Fed Bioequivalence Studies. 2002 Dec. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guida
nces/ucm070241.pdf.  Accessed January 19, 2015.
Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism
by [CONTACT_475218]. Metabolite identification and inhibition of 6-hydroxylation. J 
Pharmacol Exp Ther 1996;277:105-12.
Hallek M, Cheson BD, Catovsky D, et al.  Guidelines for the di agnosis and treatment of 
chronic lymphocytic leukemia: a report from the International Workshop on Chronic 
Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 
guidelines. Blood 2008;111:5446-5456.
Hellmann A, Rule S, Walewski J, et al. Effect of cytochrome P450 3A4 inducers on the
pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with 
multiple myeloma or non-Hodgkin's lymphoma. Clin Pharmacokinet 2011;50:781-791.
Honigberg LA, Smith AM, Sirisawad M, et al.  The Bruton tyrosine kinase inhibitor 
PCI-[ZIP_CODE] blo cks B-cell activation and is efficacious in models of autoimmune disease 
and B-cell malignancy. PNAS 2010;107:[ZIP_CODE]-[ZIP_CODE].
IMBRUVICA [package insert].  Horsham, PA: Janssen Biotech, Inc; 2014.
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals. 2014 Dec.  
Available from: http://www.ICMJE.org.  Accessed February 04, 2015.
Acerta Pharma Confidential Page [ADDRESS_609283]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton's tyrosine kinase (Btk): function, 
regulation, and transformation with special emphasis on the PH domain. Immunol Rev 
2009;228:58-73.
Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of 
action in multiple myeloma in 2013: a report from the International Myeloma Working 
Group (IMWG). Leukemia 2014;28:525-542.
Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop 
Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 5;117(18):4691-5. 
Rajkumar SV, Jacobus S, Callander NS, et a; Eastern Cooperative Oncology Group.
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose
dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37. Erratum in: Lancet Oncol
2010;11:14.
Romano A, Conticello C, Cavalli M, et al. Salvage therapy of multiple myeloma: the new 
generation drugs. Biomed Res Int 2014;2014:456037. Epub 2014 May 19.
Tai YT, Chang, BY, Kong SY, et al.  Bruton tyrosine kinase inhibition is a novel 
therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.  Blood 2012:120:1877-1887.
Vail DM, Thamm DH. Spontaneously occurring tumors in companion animals as models 
for drug development. In: Teicher BA, Anders PA, eds. Anticancer Drug Development 
Guide: Preclinical Screening, Clinical Trials, and Approval. 2nd Ed. Totowa, NJ: Human 
Press; 2004:259-284.
Vail DM, Michels GM, Khanna C, Selting KA, London CA; Veterinary Cooperative 
Oncology Group. Response evaluation criteria for peripheral nodal lymphoma in dogs 
(v1.0)—a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2010;8:28-37.
Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (Btk) in X-linked 
agammaglobulinemia (XLA). Front Biosci 2000;5:D917-D928.
Acerta Pharma Confidential Page [ADDRESS_609284]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609285]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Appendix 1. Performance Status Scores 
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without 
restriction
1 Restricted in physically strenuous activity but ambulatory and able 
to carry out work of a light or sedentary nature, eg, light house 
work, office work
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours
3 Capable of only limited self-care, confined to bed or chair more 
than 50% of waking hours
4 Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair
5 Dead
As published in Am J Clin Oncol:
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, 
P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin 
Oncol 5:649-655, 1982.
Credit: Eastern Cooperative Oncology Group Chair: Robert Comis, MD
Available at: http://www.ecog.org/general/perf_stat.html .  Accessed [ADDRESS_609286]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609287] been caused by [CONTACT_5349]?  
No___ Yes___
The descriptions provided below will help guide the principal investigator [INVESTIGATOR_378132] “yes” or “no”:
No = There is no reasonable possibility that the event may have been caused by [CONTACT_378159].
The adverse event:
xmay be judged to be due to extraneous causes such as disease or environment 
or toxic factors
xmay be judged to be due to the subject’s clinical state or other therapy being 
administered
xis not biologically plausible
xdoes not reappear or worsen when study drug is re-administered
xdoes not follow a temporal sequence from administration of study drug
Yes = There is a reasonable possibility that the event may have been caused by [CONTACT_378159].
The adverse event:
xfollows a temporal sequence from administration of study drug
xis a known response to the study drug based on clinical or preclinical data
xcould not be explained by [CONTACT_20612]’s clinical state, 
environmental or toxic factors, or other therapy administered to the subject
xdisappears or decreases upon cessation or reduction of dose of study drug
xreappears or worsens when study drug is re-administered
Acerta Pharma Confidential Page [ADDRESS_609288]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609289] John's wortf
indinavir
itraconazoleb
ketoconazoleb
lopi[INVESTIGATOR_054]/ritonavirb(combination drug)
mibefradild
nefazodone
nelfinavir
posaconazole
ritonavirb
saquinav ir
telaprevir
telithromycin
voric onaz ole
a. A strong inhibitor for CYP3A is defined as an inhibitor that increases the AUC of a substrate for CYP3A 
by 5-fold.
b. In vivo inhibitor of P-glycoprotein.c. The effect of grapefruit juice varies w idely among brands and is concentration-, dose-, and preparation-
dependent. Studies have show n that it can be classified as a “strong CYP3A inhibitor” w hen a certainpreparation w as used (eg, high dose, double strength) or as a “moderate CYP3A inhibitor” w hen another preparation w as used (eg, low  dose, single strength).
d. Withdraw n from the [LOCATION_002] market because of safety reasons.e. A strong inducer for CYP3A is defined as an inducer that results in 80% decrease in the AUC of a 
substrate for CYP3A.
f. In vivo inducer of P-glycoprotein.  
Note: The list of drugs in these tables is not exhaustive. Any questions about drugs not on this list 
should be addressed to the Medical Monitor of the protocol.
Source:
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Web link 
Accessed 21 January 2015: http://w w w.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#inVivo
Acerta Pharma Confidential Page [ADDRESS_609290]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Appendix 4. Dexamethasone Prescribing Information
The [LOCATION_002] label for dexamethasone tablets (Roxane Laboratories 2007) is
provided for reference.  The [LOCATION_002] label will also serve as the Reference Safety Information for dexamethasone for this study.  Country-specific labels will be provided to 
investigative sites as appropriate.
Acerta Pharma Confidential Page [ADDRESS_609291]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609292]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609293]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609294]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609295]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609296]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-[ADDRESS_609297]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Appendix 5.  Schedule of Assessments
Screeninga Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycles 5-12bET/Safety 
Follow Upc
Days (± 2) Days (± 2) Days (± 2) Days (± 2) Days (± 2)
1 8 15 22 28 15 28 28 28 28
Informed consent x
Confirm eligibility x
Medical history x
PEd/Vital signse/Weight x x x x x x x x x x x x
ECOG status x x x x x x x x x x x x
ECGfxx x
Lab assessments:
Urine pregnancy 
testgx x
Hematologyhxxqxx x x x x x x x x
Serum chemistryixxqxx x x x x x x x x
Urinalysisjxx x x x E v e r y  2  m o s
T/B/NK cell countkxqx x x x Every 6 mos
Disease markerslx x x x x x Every 2 mos x
Bone marrow
(aspi[INVESTIGATOR_337]/biopsy)
/Skeletal surveyp
xAs 
clinically 
indicated 
or to 
confirm a 
CRAs 
clinically 
indicated 
or to 
confirm a 
CRAs clinically 
indicated or
to confirm a 
CR
Pharmacodynamics xmxmxnxnx
Pharmacokineticsoxxxx x
AC P -196/
dexamethasone
dispensedxxxx x x x x x x
Study drug compliance x x x x x x x x x x
Tumor assessmentpxx x x x x
Concomitant 
medicationsxx x x x x x x x x x x
Adverse events x x x x x x x x x x x
Abbreviations: CR = complete remission; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; ET + early terminatio n; Ig = immunoglobulin; 
mos = months; PE = physical exam;
Acerta Pharma Confidential Page [ADDRESS_609298]: ACP-196
Date: 20 March 2015
Protocol: ACE-MY-001
Footnotes for ACE-MY-001 Schedule of Study Activities :
a. Screening tests should be performed w ithin [ADDRESS_609299] not progressed while receiving study drug treatment, may be eligible to enroll into a long-term follow  up study and continue to receive ACP-
196.
c. An early termination visit is required for any subjects who permanently discontinue study drug early for any reason including disease progression.  A 30-day (± 7 days) 
safety follow-up visit is required when subjects discontinue study drug unless they start another anticancer therapy within that  timeframe.
d. The screening physical examination w ill include, at a minimum, the general appearance of the subject, height (screening only) and w eight, and examination of the 
skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous syste m.  Symptom-directed physical exam s 
are done thereafter.  
e. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and temperature) will be assessed after the subject has rested in the sitting position.  
f. Subjects should be in supi[INVESTIGATOR_475182]DQGUHVWLQJIRU [ADDRESS_609300] be ruled out by [CONTACT_375842].
h. Hematology includes complete blood count w ith differential and platelet and reticulocyte counts. Cycle 1 Day 1 hematology does  not need to be repeated if screening 
hematology w as within 5 days.
i. Serum chemistry: albumin, alkaline phosphatase, bone-specific alkaline phosphatase, alanine transaminase (ALT), aspartate amin otransferase (AST), bicarbonate, 
blood urea nitrogen (BUN), calcium, chloride, creatinine, C-terminal telopeptide, glucose, lactate dehydrogenase (LDH), magnesi um, phosphate, potassium, sodium, 
total bilirubin, total protein, and uric acid. Cycle 1 Day 1 serum chemistry does not need to be repeated if screening serum chemistry w as within 5 days.
j. Urinalysis: pH, ketones, specific gravity, bilirubin, protein, blood, N-terminal telopeptide, and glucose. 
k. T/B/NK cell count (ie, CD3, CD4, CD8, CD19, CD16/56).  During Cycle 5-12, only done at end of Cycle [ADDRESS_609301] of myeloma disease markers.
m. Pharmacodynamic samples are draw n predose and 4 hours (±10 minutes) postdose on the days indicated. Note: These timepoints are  relative to the morning dose.
n. Pharmacodynamic samples are draw n predose on the days indicated.
o. Pharmacokinetic samples are draw n per Table 4-1 .
p Refer to Section 4-2. Bone marrow  aspi[INVESTIGATOR_337]/biopsy and skeletal survey are required at baseline (ie, before the first dose of st udy drug).  Thereafter they are required 
as indicated in the table above.
q. The indicated samples at this timepoint (Cycle 1 Day 1) must be draw n predose.
Acerta Pharma Confidential Page [ADDRESS_609302]: ACP-196
Date: 11 July 2014 
Protocol: ACE-MY-001
Acerta Pharma Confidential Page 1 of 64PROTOCOL
TITLE: An Open-label, Phase 1b Study of ACP-196 i n Subjects 
withMultiple Myeloma
PROTOCOL NUMBER: ACE-MY-001
STUDY DRUG: ACP-196
IND NUMBER: 118717
SPONSOR MEDICAL MONITOR:
Acerta Pharma BV
SPONSOR: Acerta Pharma BV
Molenstraat 110
5342 CC Oss
The Netherlands
PROTOCOL DATE: 11July [ADDRESS_609303] not be disclosed to  anyone other than the recipi [INVESTIGATOR_475183] d (IRB)/independent ethics commi ttee (IEC). This information 
cannot be used for any purpose other than the evaluation or conduct of the clinical 
investigation without the prior written consent of Acerta Pharma BV.
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 3 of 64 
 TABLE OF CONTENTS 
1.0 BACKGROUND INFORMATION ................................................................ 15  
1.1 Role of Btk in Lymphoid Cancers ................................................................. 15  
1.2 Preclinical Studies ....................................................................................... 15  
1.2.1  Chemistry ....................................................................................... 16  
1.2.2  Efficacy Pharmacology ................................................................... 16  
1.2.3  Safety Pharmacology ..................................................................... 17  
1.2.4  Drug-drug Interaction Potential....................................................... 18  
1.2.5  In Vivo General Toxicology ............................................................ 18  
1.3 Clinical Experience ...................................................................................... 19  
1.4 Summary and Conclusions .......................................................................... 22  
2.0 STUDY OBJECTIVES ................................................................................. 22  
2.1 Primary Objective ........................................................................................ 22  
2.2 Secondary Objectives: ................................................................................. 22  
3.0 STUDY DESIGN .......................................................................................... 23  
3.1 Description of Study ..................................................................................... 23  
3.2 Study Parameters ........................................................................................ 23  
3.2.1  Safety Parameters .......................................................................... 23  
3.2.2  Efficacy Parameters ....................................................................... 24  
3.2.3  Pharmacokinetic and Pharmacodynamic Parameters .................... 24  
3.3 Rationale for Study Design and Dosing Regimen ........................................ 24  
3.4 Selection of Study Population ...................................................................... 25  
3.4.1  Inclusion Criteria ............................................................................. 25  
3.4.2  Exclusion Criteria ........................................................................... 25  
3.4.3  Replacement of Subjects ............................................................... 26  
3.4.4  Enrollment and Randomization Procedures ................................... 26  
3.5 Study Drug ................................................................................................... 27  
3.5.1  Premedications ............................................................................... 27  
3.5.2  Formulation, Packaging, and Storage ............................................ 27  
[IP_ADDRESS]  ACP-196 .......................................................................... 27  
[IP_ADDRESS]  Dexamethasone............................................................... 28  
3.5.3  Administration of Study Drug .......................................................... 28  
[IP_ADDRESS]  ACP-196 .......................................................................... 28  
[IP_ADDRESS]  Dexamethasone............................................................... [ADDRESS_609304] Compliance......................................................... 29  
3.5.5  Study Treatment Regimen and Dose Modifications ....................... 29  
[IP_ADDRESS]  ACP-[ADDRESS_609305]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 4 of 64 
 [IP_ADDRESS]  Dexamethasone............................................................... 30  
3.6 Concomitant Therapy................................................................................... 31  
3.6.1  Permitted Concomitant Therapy ..................................................... 31  
3.6.2  Prohibited Concomitant Therapy .................................................... 31  
3.7 Precautions .................................................................................................. 31  
3.7.1  Dietary Restrictions ........................................................................ 31  
3.7.2  Drug-drug Interactions .................................................................... 31  
3.7.3  Reproductive Toxicity ..................................................................... 32  
3.7.4  Overdose Instructions .................................................................... 32  
3.8 Stoppi[INVESTIGATOR_1869] ............................................................................................ 33  
3.9 Data and Safety Monitoring ......................................................................... 34  
4.0 STUDY ACTIVITIES AND ASSESSMENTS ............................................... 34  
4.1 Description of Procedures ............................................................................ 35  
4.1.1  Informed Consent ........................................................................... 35  
4.1.2  Medical History ............................................................................... 35  
4.1.3  Adverse Events .............................................................................. 35  
4.1.4  Concomitant Medications and Therapy .......................................... 35  
4.1.5  Confirmation of Eligibility ................................................................ 35  
4.1.6  ECOG Performance Status ............................................................ 35  
4.1.7  Physical Examination, Vital Signs, Height & Weight ....................... [ADDRESS_609306] ..................................................................... 36  
4.1.11  Hematology .................................................................................... 36  
4.1.12  Serum Chemistry ............................................................................ 37  
4.1.13  Urinalysis ........................................................................................ 37  
4.1.14  T/B/NK Cell Count .......................................................................... 37  
4.1.15  Disease Markers ............................................................................ 37  
4.1.16  Skeletal Survey .............................................................................. 37  
4.1.17  Pharmacodynamics ........................................................................ 37  
4.1.18  Pharmacokinetics ........................................................................... 38  
4.1.19  Tumor Assessment ........................................................................ 38  
4.1.20  Study Drug Accountability .............................................................. 39  
4.2 Investigator’s Assessment of Respo nse to Treatment ................................. [ADDRESS_609307]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 5 of 64 
 5.2 Sample Size Considerations ........................................................................ 42  
5.3 Definition of Analysis Sets ........................................................................... 42  
5.4 Missing Data Handling ................................................................................. 43  
5.5 Endpoint Data Analysis ................................................................................ 43  
5.5.1  Safety Endpoint .............................................................................. 43  
5.5.2  Demographics and Baseline Characteristics .................................. 43  
5.5.3  Analysis of Efficacy Parameters ..................................................... 43  
[IP_ADDRESS]  Response Rate  ........................................................................ 43  
[IP_ADDRESS]  Duration of Response  ............................................................. 44  
[IP_ADDRESS]  Progression-free Survival  ....................................................... 44  
[IP_ADDRESS]  Time-to-Next Treatment  .......................................................... 44  
5.5.4  Analysis of Pharmacokinetic/Pharmacodynamic Parameters ........ [ADDRESS_609308]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 6 of 64 
 In–text Tables 
Table 1-1.  Assessment of ACP- 196 Active-site Occupancy in  Fine Needle Aspi[INVESTIGATOR_475149] (N=4) .......................................................................[ADDRESS_609309]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 7 of 64 
 ABBREVIATIONS 
 
AE(s) adverse event(s) 
ALT alanine aminotransferase 
ANC absolute neutrophil count 
  
AST aspartate aminotransferase 
AUC area under the curve 
BCR B-cell receptor 
BID twice a day (dosing) 
Btk Bruton tyrosine kinase 
BUN blood urea nitrogen 
CBC complete blood count 
CFR Code of Federal Regulations 
cGMP current Good Manufacturing Practices 
Cmax maximum concentration 
CLL chronic lymphocytic leukemia 
  
CR complete remission (response) 
CSSF Clinical Supplies Shippi[INVESTIGATOR_475150] P450 
DLBCL diffuse large B-cell lymphoma 
DLT dose-limiting toxicity 
ECG electrocardiogram 
  
ECOG Eastern Cooperative Oncology Group 
eCRF electronic case report form 
EGFR epi[INVESTIGATOR_475151]-in-human (trial) 
FLC (serum) free light chains 
GCP Good Clinical Practice 
GLP Good Laboratory Practices 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609310] 
LDH lactate dehydrogenase 
LTFU long-term follow up 
  
MCL mantle cell lymphoma 
MedDRA Medical Dictionary for Regulatory Activities 
MM multiple myeloma 
MR minor response 
NHL non-Hodgkin lymphoma 
NK natural killer (cells) 
ORR overall response rate 
PBMC(s) peripheral blood mononuclear cells 
PD pharmacodynamics 
PK pharmacokinetics 
PR partial remission (response) 
QD once a day (dosing) 
QTc corrected QT interval 
SAE(s) serious adverse event(s) 
SD stable disease 
SFLC serum free light chains 
SIFE serum immunofixation electrophoresis 
SPD sum of the products of the perpendicular diameters (of lymph nodes) 
SPEP serum protein electrophoresis 
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction (report) 
Tmax time to maximum drug concentration 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609311]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 10 of 64 
 STUDY SYNOPSIS  
Protocol Number: ACE-MY-001 
Study Drug:  ACP-196 
Protocol Title:  An Open-label, Phase 1b Study of  ACP-196 in Subjects with 
Multiple Myeloma  
Phase:  Phase 1 b 
Comparator:  None  
Background and 
Rationale for Study Clinical studies  have shown that targeting the B-cell receptor 
(BCR) signaling pathway by [CONTACT_475197] (Btk) 
produces significant clinical benefit in patients with non -Hodgkin 
lymphoma (NHL)  and chronic lymphocytic leukemia (CLL). 
Preclinical studies have shown that Btk in hibition significantly 
reduces in vivo multiple myeloma (MM) cell growth and MM cell-
induced osteolysis in a murine model (Tai 2012).  D ata on the 
utility of Btk targeted therapy in patients with MM is very 
preliminary, but suggests t here are subsets of patients with 
malignant plasma cell clones  in which Btk is active as evidenced 
by [CONTACT_475198] (p -Btk), and that these 
cancers may be particularly responsive to Btk inhibitor therapy.  
Acerta Pharma BV (Acerta  Pharma) has developed a novel second 
generation Btk inhibitor, ACP -196, that achieves significant oral 
bioavailability and potency in  preclinical models. ACP -196 
monotherapy  is currently in Phase 1 studies in subjects with 
chronic lymphocytic leukemia ( CLL) and in healthy volunteers.   
The purpose of this study is to evaluate the safety, 
pharmacokinetics (PK), pharmacodynamics (PD) , and activity of 
2 different schedules of ACP-196 ad ministration in subjects with  
relapsed  MM.  The study will explore the concept of whether 
biomarkers may help identify patien ts with MM that be particularly 
benefit from Btk inhibitor therapy.  
Study Design:  This study is a multicenter, open -label, randomized, parallel- group 
study.  Forty  subjects will be equally randomized (1:1 ratio) into  
2 cohorts to receive ACP- 196, without or without dexamethasone:  
x Cohort 1: ACP-196 100 mg twice per day (BID) continuously 
x Cohort 2: ACP-196 100 mg BID continuously and 
dexamethasone 40 mg once weekly  
Twenty -eight days of study drug ad ministration is 1 cycle.  
Treatment may be continued for > [ADDRESS_609312]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609313] a 
safety follow -up visit 30 (±7) days after the last dose of study drug 
unless they have started another cancer therapy within th at 
timeframe.  
All subjects will have hematology, chemistry, and urinalysis safety panels done at screening.  Once  dosing commences (Day 1), all 
subjects will be evaluated for safety, including serum chemistry 
and hematol
ogy, once weekly for the first 4 weeks , every 2 weeks 
in Cycle 2  and monthly thereafter.  PK/PD tes ting will be  done in 
Cycle [ADDRESS_609314] of study assessments 
and their timing.  
Study Objectives: Primary Objective:  
x To characterize the safety profile of ACP-196 with and without 
dexamethasone in subjects with relapsed or refractory MM 
Secondary Objective s: 
x To characterize the PK profile of ACP-196 with and without 
dexamethasone and the PK profile of dexamethasone with 
concomitant ACP-196 administration 
x To evaluate the PD effects of ACP-196 with and without 
dexamethasone 
x To evaluate the activity of  ACP-196 with and without 
dexamethasone as measured by [CONTACT_30530], duration of 
response, time-to-next tr eatment, and progression- free survival 
x To explore the relationship between biological markers in MM 
cells and response to therapy 
Safety Parameters: Type, frequency, severity, timing of onset, duration, and 
relationship to study drug  (ie, ACP- 196, dexamethasone, or both) 
of any adverse events (AEs) or ab normalities of laboratory tests; 
serious adverse events (SAEs); or  AEs leading to discontinuation 
of study treatment.  
Efficacy Parameters: x Overall response rate (ORR) 
x Duration of response 
x Progression-free survival 
x Time-to-next treatment 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 12 of 64 
 Pharmacokinetic 
Parameters:  The plasma  PK of ACP-196 will be characterized using 
noncompartmental analysis. The following PK parameters will be calculated, whenever possible, from 
plasma concentrations of 
analytes : 
x AUC (0-t):  Area under the plasma concentration-time curve 
calculated using linear trapezoidal summation from time [ADDRESS_609315] measurable concentration 
(Ct). 
x AUC (0-24):  Area under the plasma concentration-time curve 
from 0 to 24 hours, calculated using linear trapezoidal 
summation. 
x AUC (0-∞):  Area under the plasma concentration- time curve from 
0 to infinity, calculated using the formula: AUC (0-∞) = AUC (0-t) + 
Ct / λz, where λz is the apparent terminal elimination rate 
constant. 
x Cmax:  Maximum observed plasma concentration 
x Tmax:  Time of the maximum plasma concentration (obtained 
without interpolation) 
x t½:  Terminal elimination half-life (whenever possible) 
x λz:  Terminal elimination rate constant (whenever possible) 
x Cl/F:  Oral clearance 
Pharmacodynamic 
Parameters:  The occupancy of Btk by [CONTACT_408799]- 196 will be measured in peripheral 
blood mononuclear cells (PBMCs ) and in bone marrow, when 
available, with the aid of a biotin-tagged ACP- [ADDRESS_609316] of ACP -196 on biologic markers of B- cell function will 
also be evaluated.  
Samp le Size: Forty subjects with 20  subjects in each cohort. 
Inclusion Criteria: x Men and women ≥ 18 years of age . 
x A confirmed diagnosis of MM, which has relapsed after, or 
been refractory to ≥ 1 prior therapy for MM, and is progressing 
at the time of study entry. 
x Eastern Cooperative Oncology Group (ECOG) performance 
status of ≤ 2. 
x Agreement to use acceptable methods of contraception during 
the study and for [ADDRESS_609317] dose of study drug. 
x Willing and able to participate in all required evaluations and 
procedures in this study protocol including swallowing capsules 
without difficulty. 
x Ability to understand the purpose and risks of the study and 
provide signed and date d informed consent and authorization 
to use protected health information (in accordance with 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609318] privacy regulations). 
Exclusion Criteria: x Prior malignancy, except for adequately treated basal cell or 
squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for 
≥ 2 years or which will not limit survival to < 2 years. Note: 
these cases must be discussed with the Medical Monitor. 
x
 A life- threatening illness, medical condition or organ system 
dysfunction which, in the investigator’s opi[INVESTIGATOR_3078] n, could 
compromise the subject’s safety, interfere with the absorption 
or metabolism of ACP- 196, or put the study outcomes at undue 
risk. 
x Significant cardiovascular disease such as uncontrolled or 
symptomatic arrhythmias, cong estive heart failure, or 
myocardial infarction within [ADDRESS_609319] dose of study drug is 
< 5 times the half- life of the previously administered agent(s). 
x Relapsed or refractory to prior Btk inhibitor therapy. 
x Ongoing immunosuppressive therapy, including systemic or 
enteric corticosteroids for treatment of MM or other conditi ons. 
Note: Subjects may use topi[INVESTIGATOR_475176] . During study participation, 
subjects may receive systemic or enteric corticosteroids as 
needed for MM therapy or treatment-emergent comorbid 
conditions. 
x Grade ≥ 2 toxicity (other than alopecia ) continuing from prior 
anticancer therapy in cluding radiation. 
x Known history of human immuno deficiency virus (HIV) or 
active infection with hepatitis C virus (HCV) or hepatitis B virus 
(HBV) or any uncontrolled active systemic infection. 
x Major surgery within [ADDRESS_609320].  
x ANC < 0.75 x 109/L or platelet count < 50 x 109/L unless 
associated with >50% plasma cells in the marrow. 
x Creatinine > 2.5 x institutional upper limit of n ormal (ULN); total 
bilirubin > [ADDRESS_609321] (unless due to Gilbert’s disease); and 
aspartate aminotransferase (AST) or alanine aminotransferase 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 14 of 64 
 (ALT) > 2.[ADDRESS_609322] unless disease related. 
x Significant screening electrocardiogram (ECG) abnormalities 
including left bundle-branch block, 2nd-degree AV block type II, 
3rd-degree block, Grade t 2 bradycardia, or QTc > 480 m sec. 
x Breastfeeding or pregnant. 
x Concurrent participation in anot her therapeutic clinical trial. 
Dosage Form and 
Strength:  ACP-[ADDRESS_609323] phar maceutical grade excipi[INVESTIGATOR_840].  
Dose Regimen/Route 
of Administration: ACP-[ADDRESS_609324] omach defined as no food 2  hours 
before and 1 hour after dosing.  
Regimens:  
x Cohort 1 (BID): 100 mg ACP- 196 (1 x 100-mg capsule) 
administered 12 hours apar t (BID dosing = 200-mg total daily 
dose) 
x Cohort 2 (BID + dexamethasone): 100 mg ACP-196 
(1 x 100-mg capsule) administered 12 hours apart (BID dosing 
= 200-mg total daily dose) plus 40 mg dexamethasone (1 x 
40-mg capsule) administered once weekly (w eekly dosing = 
40-mg total weekly dose) 
Statistics:  Subjects meeting the stated eligibi lity requirements will be enrolled 
onto the study. Subjects will be equally randomized into  1 of 
2 regimens (ACP-196 with or wi thout dexamethasone).  With a 
sample siz e of [ADDRESS_609325] the 
difference between a null-hypot hesis response rate of 15 % and an 
alternative response rate of 40% with a 0.[ADDRESS_609326].  A sample size of 
19 subjects per cohort will al so provide a 97.5% one-sided 
confidence interval centered around an expected ORR of 40% that 
excludes an ORR of 18.6% as a lower bound. 
Descriptive statistics (including means, standard deviations, and 
medians for continuous variable s and proportions for discrete 
variables) will be used to summarize data, as appropriate.   
 
 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 15 of 64 
 1.0 BACKGROUND INFORMATION 
1.1 ROLE OF BTK IN LYMPHOID CANCERS 
Bruton tyrosine kinase (Btk) is a non-recepto r enzyme of the Tec kinase family that is 
expressed among cells of hematopoietic origin , including B cells, myeloid cells, mast 
cells and platelets, where it regulates multiple  cellular processes including proliferation, 
differentiation, apoptosis, and cell mi gration (Mohamed 2009, Bradshaw 2010). 
Functional null mutations of Btk in humans  cause the inherited disease, X-linked 
agammaglobulinemia, which is characterized by a lack of mature peripheral B cells 
(Vihinen 2000). Conversely, Btk activation is  implicated in the pathogenesis of several 
B-cell malignancies (Buggy 2012). Taken together, these findings have suggested that 
inhibition of Btk may offer an attractive strategy for treating B-cell neoplasms. Ibrutinib 
(IMBRUVICA™), a first -generation oral, small-molecule Btk inhibitor has been approved 
for the treatment for chronic lymphocytic le ukemia (CLL) and mantle cell lymphoma 
(MCL) and is being evaluated for activity in  other B-cell neoplasms including multiple 
myeloma (MM).  Preclinical studies have sh own that Btk inhibiti on with ibrutinib 
significantly reduces in vivo multiple myel oma (MM) cell growth and MM cell-induced 
osteolysis in a murine mode l (Tai 2012).  While current therapi[INVESTIGATOR_475184], MM remain s incurable; for patients who experience 
disease relapse after application of existing therapi[INVESTIGATOR_014], the prognosis is dismal and new 
drugs and therapeutic strategies are requ ired for continued disease control (Romano 
2014).  Inhibition of  Btk may simultaneously address the MM-related bone complications 
as well improve patient outc ome in MM (Edwards 2012). 
1.[ADDRESS_609327]: ACP-196
Date: 11 July 2014 
Protocol: ACE-MY-001
Acerta Pharma Confidential Page 16 of 64are provided below. For more detailed in formation please refer to the Investiga tor’s 
Brochure.  
1.2.1 Chemistry 
 ACP-196 is 
orally bioavailable in animals and is suitab le for formulating in capsules. For clinical 
testing, ACP-196 has been manufactured and formulated according to current Good 
Manufacturing Practices (cGMP). 
1.2.2 Efficacy Pharmacology 
Spontaneous canine B-cell lymphoma shar es many characteristics with human NHL, 
including diagnostic classifications and respon se to Btk inhibition (Honigberg 2010). The 
life expectancy in untreated animals with aggr essive disease is ~6 weeks, thus enabling 
rapid assessment of drug efficacy (Vail an d Thamm, 2004). ACP-196 is currently being 
evaluated in an ongoing dose-escalation stud y in canine spontaneous B-cell lymphoma.  
Fourteen dogs, all of which had diffuse large B-cell lymphoma (DLBCL) confirmed by [CONTACT_27183], have been treated with ACP-[ADDRESS_609328] ranged from 2.5 to 20 mg/kg once (QD) or tw ice (BID) per day.  To date, per Veterinary 
Cooperative Oncology Group criteria for a ssessment of response in peripheral nodal 
lymphoma (Vail 2010), partial responses (PRs ) been observed in 4 of 14 dogs (29%) 
and stable disease has been observed in 8 of 14 dogs (57%).  No ACP-196-related 
adverse events (AEs) have been reported to date in this study.  These findings are 
preliminary and similar to the clinical response s (ie, 1 dog with PR out of 5 dogs treated 
with suspected or confirmed DLBCL) observed  with ibrutinib in dogs with spontaneous 
B-cell lymphoma (Honigberg 2010). 
Preliminary results assessing Btk occupancy using a biotin-tagged analogue of ACP-196
show near complete Btk occupancy over 24  hours with both BID and QD dosing in 
canine tumor tissue ( Table 1-1 ). 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 17 of 64 
 Table 1-1.  Assessment of ACP-196 Active-site Occupancy in  
Fine Needle Aspi[INVESTIGATOR_475156] (N=4) 
Timing Dog Identification and ACP-196 Dosing Regimen 
DL-12 DL-14 DL-15 DL-16 
10 mg/kg BID 20 mg/kg QD 20 mg/kg QD 20 mg/kg QD 
Btk Occupancy (% versus predose) 
Day 1 (3 hours 
after morning 
dose) 99% 98% 87% 99% 
Day 7 (before 
morning dose) 98% 77% ND 93% 
BID = twice per day; Btk = Bruton tyrosine kinase; ND = not determi ned; QD = once per 
day 
These canine data provide nonclinical support for the ability of ACP-196 to target Btk in 
vivo. The role of Btk expression in driving the proliferation and survival of malignant plasma cells in multiple myeloma (MM) has been less clear than among other lymphoid 
cancers. However, emerging, unpublished, preclinical data from the laboratory of Sagar 
Lonial (Emory University) suggest that Btk and phosphorylated Btk (p-Btk) expression is 
present to varying levels in a standard panel of [ADDRESS_609329] the 
A3 adenosine receptor; follow-up dose -response experiments indicated a IC 50 of 2.7 μM, 
suggesting a low clinical risk of off-target effects.  ACP- 196 at 10 μM showed no 
inhibition of in vitro epi[INVESTIGATOR_226792] (EGFR) phosphorylation in an A431 
human epi[INVESTIGATOR_475158], whereas ibrutinib had an IC [ADDRESS_609330] of ACP- 196 on human ether-à-go-go-related gene (hERG) channel 
activity was investigated in vitro in human em bryonic kidney cells stably transfected with 
hERG. ACP-196 inhibited hERG ch annel activity by 25% at [ADDRESS_609331]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609332] in vivo Good Labora tory Practices (GLP) studies 
of pharmacologic safety. A functional observation battery in rats at doses of through 
300 mg/kg (the highest dose level) revealed no adverse effects on neurobehavioral effects or body temperature at any dose level. A study of respi[INVESTIGATOR_475159]-related adverse effect s at doses through 300 mg/kg (the highest 
dose level). In a cardiovascula r function study in awake telemeterized male beagle dogs, 
single doses of ACP-196 at dose levels through 30 mg/k g (the highest dose level) 
induced no meaningful changes in body temperature, cardiovascular, or 
electrocardiographic (ECG) (including QT inte rval) parameters.  The results suggest that 
ACP-196 is unlikely to cause serious off-targ et effects or adverse effects on critical 
organ systems. 
1.2.4 Drug-drug Interaction Potential 
In vitro metabolism studies using mouse,  rat, dog, rabbit, monkey, and human 
hepatocytes incubated with 14C-labelled ACP-196 indicated 2 mono-oxidized metabolites 
and a glutathione conjugate. No unique hu man metabolite was identified. Preliminary 
evaluations of metabolism in the plasma, bile, and urine of rats, dogs, and monkeys indicated metabolic processes of oxidation, glutathione binding, and hydrolysis. It was 
shown that ACP-196 binds to glutathione bu t does not deplete glutathione in vitro. 
In vitro experiments ev aluating loss of parent drug as catalyzed by [CONTACT_9058] P450 
enzymes (CYPs) indicated that ACP-196 is metabolized by [CONTACT_097]3A4. Drugs potentially altering activity of this isoenzyme may alter ACP-196 disposition (see Section 1.3 ).  
Nonclinical CYP interaction studies data indica te that ACP-196 is very unlikely to cause 
clinical drug-drug interactions through alte ration of the metabolism of drugs that are 
substrates for CYPs. 
1.2.5 In Vivo General Toxicology 
To date, the toxicology program has included  28-day GLP evaluations in rats and dogs. 
In the 28-day study in male and female Sp rague-Dawley rats, animals received oral 
gavage ACP-196 dosages of 30 , 100, and 300 mg/kg/day. In  the 28-day study in male 
and female beagle dogs, animals received  oral ACP-196 dosages of 3, 10, and 
30 mg/kg/day. Both studies had 28-day recovery periods. 
The no observable adverse effect level in  the dog was 30 mg/kg/day, which was the 
highest dose evaluated. In rats, 30 mg/kg/da y resulted in minimal inflammation of the 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 19 of 64 
 pancreas in some animals, with reversal, in dicating the rat to be the more sensitive 
preclinical species. The pancreatic effects were minimally increased at 100 mg/kg/day in 
the rat though there was no clinical evidence of toxicity. Hence, 100 mg/kg/day was selected to conservatively represent the high est nonseverely toxic dose (HNSTD).  In 
dogs at 30 mg/kg/day, no adverse effects on the pancreas were observed.  In rats and dogs, no adverse ECG or histopathologic cardiovascular effects were noted at the 
planned conclusion of the 28-day toxicology studies. However, in 5 of 6 rats from the 
300-mg/kg dose group that died early in the st udy, slight to moderate necrosis of the 
myocardium and/or white blood cell infiltra tion/inflammation of the myocardium were 
noted on microscopic examination of the hearts. These findings were most likely 
incidental postmortem changes. 
1.3 CLINICAL EXPERIENCE 
Table 1-2  lists the studies currently being co nducted with ACP-196 monotherapy.   
Table 1-2.  ACP-196 Clinical Studies 
Protocol Design Subjects 
Enrolled Status 
ACE-CL-001 
([STUDY_ID_REMOVED]) x First-in-human 
x Open label 
x Dose escalation (100- 450 mg QD) 
x Subjects with relapsed/refractory 
CLL [ADDRESS_609333] cohort (100 mg 
QD) enrolled and 
no DLTs observed.   
x 2nd cohort (175 mg 
QD) enrolled and 
no DLTs observed. 
x 3rd cohort (250 mg 
QD) enrolled and 
no DLTs observed. 
ACE-HV-001 x Open label 
x Single-dose escalation 
(2.5-50 mg BID and 100 mg QD)  
x Food effect (75 mg QD) 
x Drug- drug interaction (50 mg QD) 
x Healthy volunteers 59 x Enrollment 
completed. 
x No adverse 
laboratory, vital 
signs, or ECGs 
findings observed. 
x 1 event each of 
constipation, 
feeling cold, 
somnolence (e ach 
Grade 1) was 
reported as related 
to study drug. 
AE = adverse event; BID = twice per day; CLL = chronic lymphocytic leukemia; DLT = dose-limiting toxicity; QD = once per day 
 
ACE-CL-001 ([STUDY_ID_REMOVED]), an ongoing FIH st udy in subjects with relapsed/refractory 
CLL, has a sequential, dose-escalation desi gn. The starting dosage for ACP-196 is 
100 mg QD and the DLT observation period is 28 days (ie, 1 cycle of treatment).  To 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609334] 2 cohorts in this stud y show that Btk occupancy with ACP-196, in 
peripheral blood ce lls, is > 95% at 4 hours after dosi ng but decreases to < 90% 24 hours 
after QD dosing ( Table 1-3 ).  
Table 1-3.  Btk Occupancy in Peripheral  Blood of Subjects from ACE-CL-001 
 Percent Btk Occupancy Versus Day 1 Predose 
  100 mg QD 175 mg QD 
Timing Mean Std Dev N Mean Std Dev N 
Day 1: 4 h postdose 96.0 3.2 8 97.4 2.4 8 
Day 1: 24 h postdose 84.4 9.8 8 80.2 10.7 8 
Day 8: predose 87.6 5.0 8 87.0 10.5 7 
Day 8: 4 h postdose 98.0 1.8 8 96.6 5.1 7 
Btk = Bruton tyrosine kinase; std dev = standard deviation; QD = once per day 
 
To date, [ADDRESS_609335] been evaluated for tumor respon se in the 100- and 175-mg 
cohorts after 56 days of treatment; a response  rate of 81% (13 of 16 subjects) has been 
observed based on International Working Gr oup response criteria (Halleck 2008) as 
recently updated (Cheson 2012 ).  Of the 16 evaluable subjects, 15 (94%) have 
experienced reductions in lymphadenopathy, with 7 subjects achieving PRs, 6 subjects 
experiencing a ≥ 50% decrease in lymphadenopathy with lymphocytosis (ie, PR with 
lymphocytosis), and 3 subjects having stable disease (SD) ( Figure 1-1 ).  As shown in the 
figure, substantial response has been obser ved even among subjects with the adverse 
prognostic indicator of del17p in CLL cell s. ACP-[ADDRESS_609336]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609337] Scans 
(Evaluable CLL Subjects, N=16) 
 
CLL = chronic lymphocytic leukemia; CT= computed tomography; PR = partial response; 
PR+L = partial response with lymphocytosis;  SD = stable disease; SPD = sum of the 
products of the perpendicular diameters (of lymph nodes). 
 
ACE-HV-[ADDRESS_609338] ion study evaluating 
BID and QD dosing for 1 day in healthy volunt eers.  The starting dose for ACP-196 was 
2.5 mg BID.  The healthy volunteer study ha s completed and no adverse laboratory, vital 
signs, or ECG findings were observed (2.5 to  50 mg BID; 50 to 100 mg QD). Three AEs 
related to study drug were reported.  Ea ch AE was Grade 1 and resolved without 
treatment.  The AEs were constipation (2.5  mg BID), feeling cold (75 mg QD), and 
somnolence (75 mg QD). 
The food-effect evaluation indicated that ther e was no difference in area under the curve 
(AUC) between the fed and fasted states; ho wever, there was an approximately 3-fold 
decrease in the mean maximum concentration (C max) in the fed state. Therefore, 
ACP-[ADDRESS_609339]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609340] of this study is supported by [CONTACT_475204][INVESTIGATOR_378117]; knowledge of the activity and 
safety of the first-generation BCR inhibitor (e g, ibrutinib) in subjects with hematologic 
cancers; and the available nonclinical and clinical information regarding ACP-196. Preclinical studies are ongoing in parallel to identify biomarkers that may be evaluated in 
this clinical trial as correlates of response to Btk-directed therapy and that may permit selection of patients who are particularly likely to benefit from ACP-196 treatment for 
MM. 
2.0 STUDY OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
x To characterize the safety profile of ACP-196 with and without dexamethasone in 
subjects with relapsed or refractory MM 
2.2 SECONDARY OBJECTIVES: 
x To characterize the PK profile of ACP- [ADDRESS_609341]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609342] udy.  Forty subjects 
will be randomized 1:1 into the following 2 co horts to receive ACP-196, with or without 
dexamethasone: 
x Cohort 1: ACP-196 100 mg BID continuously  
x Cohort 2: ACP-196 100 mg BID contin uously and 40 mg dexamethasone once 
weekly  
Twenty-eight days of study drug administration  is 1 cycle.  Treatment may be continued 
for > [ADDRESS_609343] a safety follow-up visit 30  (±7) days after the last dose of study drug unless they 
have started another cancer ther apy within that timeframe.  
All subjects will have standard hematology, chemistry, and urinalysis safety panels 
performed at screening.  Once dosing commenc es (Day 1), all subjects will be evaluated 
for safety, including serum chemistry and hematology, once weekly for the first 4 weeks, 
every 2 weeks in Cycle 2 and monthly thereafter.  PK/PD testing will be done in Cycle 1. 
Tumor assessments will be done at 8- to 12-week intervals during the trial. 
Refer to Appendix [ADDRESS_609344] of study assessments and their timing. 
3.2 STUDY PARAMETERS 
3.2.1 Safety Parameters 
The safety of ACP-196 with and without dexamethasone will be characterized by [CONTACT_344412], frequency, severity, timing of onset, du ration, and relationship to study drug (ie, 
ACP-196, dexamethasone, or both) of any tr eatment-emergent AEs or abnormalities of 
laboratory tests; serious adverse events ( SAEs); or AEs leading to  discontinuation of 
study treatment.  
For consistency of interpretation, AEs will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA), and the seve rity of AEs and laboratory abnormalities 
will be graded using the Common Terminology Criteria for Adverse Events (CTCAE), 
Version 4.03. Standard definitions fo r seriousness will be applied (see Section 6.1 ). 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609345] been  established for MM (Durie 
2006); assessments of ACP-196 efficacy in th is study will be based on these criteria. 
Efficacy endpoint s will include: 
x Overall response rate (ORR) 
x Duration of response 
x Progression-free survival 
x Time-to-next treatment 
3.2.[ADDRESS_609346] PK parameters for ACP-196 and dexamethasone in plasma will be evaluated 
in this study.  A full description of the PK parameters is provided in Section 5.5.4 . 
The occupancy of Btk by [CONTACT_408799]-196 will be measured in peripheral blood mononuclear 
cells (PBMCs) and bone marrow, when avai lable, with the aid of a biotin-tagged 
ACP-[ADDRESS_609347] of ACP-19 6 on biologic markers of B-cell function 
will also be evaluated. 
3.3 RATIONALE FOR STUDY DESIGN AND DOSING REGIMEN 
As described in Section 1.3 , preliminary data from the ongo ing FIH study in subjects with 
relapsed/refractory CLL have shown that AC P-[ADDRESS_609348] full Btk occupancy (96% to 98%)  in peripheral blood is observed 4 hours 
after dosing but decreases to < 90% occupancy at 24 hours ( Table 1-3 ).  These data 
suggest that de novo synthesis of Btk can occu r within 24 hours in peri pheral blood cells.  
BID dosing may ensure Btk inhibition for the entire 24 hours and thus  may be beneficial 
in terms of increasing efficacy and/or decreasi ng development of resi stance to ACP-196.  
In addition, having information regarding the safety and pharmacology of a BID schedule 
may support future combination studies with other drugs that are administered BID.   
Evaluation of dexamethasone as a combin ation partner for ACP-196 builds on known 
antineoplastic activity of this drug in patients with MM. Dexamethasone therapy is commonly coadministered with targeted ag ents for MM (Ocio 2014).  The dosing 
regimen of 40 mg weekly to be used in this study has been established based on 
randomized trial data showing the superiority of this method of administration (Rajkumar 
2009). Combined use of ACP-[ADDRESS_609349]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 25 of 64 
 individual agents alone. While dexamethas one can increase CYP3A4 activity and thus 
might enhance ACP-196 metabolism, it is cons idered a weak inducer of this isoenzyme 
and has not substantially altered the disposition of other CYP3A4 substrates (eg, bortezomib) that are commonly used in the therapy of MM (Hellmann 2011). The 
randomized design of this pi [INVESTIGATOR_475161]-drug interactions 
between ACP-196 and dexameth asone to be assessed. 
3.4 SELECTION OF STUDY POPULATION 
3.4.1 Inclusion Criteria 
Eligible subjects will be considered for inclusion in this study if they meet all of the 
following criteria:  
1. Men and women ≥ 18 years of age . 
2. A confirmed diagnosis of MM, which has relapsed after, or been refractory to 
≥ 1 prior therapy for MM, and is progressing at th e time of study entry. 
3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. 
4. Agreement to use acceptable methods of  contraception during the study and for 
[ADDRESS_609350] dose of study drug. 
6. Willing and able to participate in all requir ed evaluations and procedures in this study 
protocol including swallowing capsules without difficulty. 
7. Ability to understand the purpose and ri sks of the study and provide signed and 
dated informed consent and authorization to  use protected health information (in 
accordance with national and local subject privacy regulations). 
3.4.2 Exclusion Criteria 
Subjects will be ineligible for this study if they meet any of the following criteria: 
1. Prior malignancy, except for adequately treated basal cell or squamous cell skin 
cancer, in situ cervical cancer, or other cancer from which the subject has been 
disease free f or ≥ 2 years or which will not limit su rvival to < 2 years. Note: these 
cases must be discussed with the Medical Monitor. 
2. A life-threatening illness, medical condition or organ system  dysfunction which, in the 
investigator’s opi[INVESTIGATOR_1649], could compromise the subject’s safety, interfere with the 
absorption or metabolism of ACP-196, or put the study outcomes at undue risk. 
3. Significant cardiovascular disease such as  uncontrolled or symptomatic arrhythmias, 
congestive heart failure, or myocardial infa rction within [ADDRESS_609351]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609352] dose of study drug is  < 5 times the half-life of the previously 
administered agent(s). 
7. Relapsed after or refractory to prior Btk inhibitor therapy. 
8. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids 
for treatment of MM or other conditions. Note: Subjects may use topi[INVESTIGATOR_475185]. During study participation, 
subjects may also receive systemic or en teric corticosteroids as needed for MM 
therapy or treatment-emergent comorbid conditions. 
9. Gra de ≥ 2 toxicity (other than alopecia ) continuing from prior anticancer therapy 
including radiation. 
10. Known history of human immunodeficiency  virus (HIV) or active infection with 
hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontroll ed active systemic 
infection.  
11. Major surgery within [ADDRESS_609353]. 
14. ANC < 0.75 x 109/L or platelet count < 50 x 109/L unless >50% marrow involvement 
with plasma cells are present. 
15. Creatinine > 2.5 x institutional upper limit of normal (ULN); total bilirubin > 2.[ADDRESS_609354] 
(unless due to Gilbert’s diseas e); and aspartate aminotransfera se (AST) or alanine 
aminotransferase (ALT) > 2.[ADDRESS_609355]-degree block, Grade t 2 bradycardia, or 
QTc > [ADDRESS_609356] into the study will  be performed according to the following 
procedure:  
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609357] has signed and dated the Informed Consent Form (ICF), all 
screening procedures have been completed, and eligibility has been confirmed, the 
subject can be officially enrolled in the study.  
x To enroll a subject, the study center will fax/email a completed Enrollment 
Confirmation Form to the sponsor.  The enrollment date will be the date that the form is faxed/emailed to the sponsor. 
x An Enrollment Confirmation Form will be  completed and faxed/emailed to the study 
center by [CONTACT_86622] [ADDRESS_609358] begin within the screening window ( Section 4.1 ) and after the site has 
received the cohort allocation from the sponsor.  Study treatment is not blinded on this study. 
3.5 STUDY DRUG 
3.5.1 Premedications 
No specific premedications or supporting me dications are required in conjunction with 
ACP-196 administration.  
3.5.2 Formulation, Packaging, and Storage 
[IP_ADDRESS] ACP-[ADDRESS_609359].   
ACP-196 capsules are available in 2 dose strengths: 25 and 100 mg. The 25-mg 
capsules are Swedish orange in color; the 100 -mg capsules are grey in color.  Capsules 
also include the following inactive excipi[INVESTIGATOR_38191]: microcrystalline cellulose, gelatin, and 
globally acceptable colorant.  ACP-196 will  be provided in white, high-density 
polyethylene bottles; each bot tle contains 30 capsules. 
If a drug shipment arrives damaged, or if  there are any other drug complaints, a 
SAE/Product Complaint Form shou ld be completed and emailed or faxed to the sponsor 
or the sponsor’s represen tative.   
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 28 of 64 
 Refer to the Investigator’s Brochure for ad ditional information. 
[IP_ADDRESS] Dexamethasone 
This study will use commercially availabl e dexamethasone.  Please refer to the 
appropriate dexamethasone package insert  for storage and handling instructions. 
3.5.3 Administration of Study Drug  
[IP_ADDRESS] ACP-[ADDRESS_609360] ensure that subjects receive 
ACP-196 only from personnel wh o fully understand the procedures for administering the 
drug. 
ACP-196 is intended to be administered orally  with 8 ounces (approximately 240 mL) of 
water.  Subjects should be instructed to take each dose of st udy drug on an empty 
stomach defined as no food [ADDRESS_609361] be returned to the site at the 
next scheduled visit. 
[IP_ADDRESS] Dexamethasone 
This study will use commercially available de xamethasone tablets for oral administration.  
At the time of weekly dexamethasone administration, the subject should take the dexamethasone tablets simultaneously with the ACP-196 capsules and with 8 ounces (approximately 240 mL) of water.  The de xamethasone tablets should be swallowed 
intact and subjects should not attempt to chew them or dissolve them in water.  
If a dexamethasone dose is missed, it can be  taken up to 3.5 days (84 hours) days after 
the scheduled time with a return to the no rmal schedule the following week.  If the 
interval of missed dosing has been > 3.5 days (84 hours), the dexamethasone dose 
should not be taken and the subject should take the next dose at the scheduled time in 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609362] Compliance 
During cycle 1, subjects will receive their Day 1, 8, 15, 22, and 28 doses (for Cohort 2 
this includes the dexamethasone dose)  in the clinic because predose PK/PD 
measurements are required.  For treatments that are taken in the clinic, subjects should take the dose from the drug dispensed for them  for that particular time period.  All other 
treatments will be taken at home.  Subjects will receive a diary to record the specific time 
each dose was taken and to record reasons for any missed doses.   
Subject compliance will be assessed at every visit.  The subject will be instructed to 
bring the diary and any remaining ACP-[ADDRESS_609363] number of AC P-196 capsules and dexamethasone tablets 
needed for use until the next visit. 
3.5.5 Study Treatment Regimen and Dose Modifications 
[IP_ADDRESS] ACP-[ADDRESS_609364] warrant a 
dose escalation for lack of response or for disease progression. 
Table 3-1.  ACP-196 Dose Levels  for Cohort 1 and Cohort 2 
Dose  
Level Dosage 
Twice per Day 
(mg) Capsule 
Strength 
(mg) Capsule 
Number per 
Dose Total Daily 
Dosage  
(mg) 
[PHONE_9944] [ADDRESS_609365]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 30 of 64 
 during the course of ACP-196 therapy, then study drug admi nistration should be held, as 
necessary, until the AE resolves or stabilizes to an acceptabl e degree.  As appropriate, 
certain laboratory abnormalities may warrant more frequent monitoring (eg, once per 
week) until abnormalities have recovered to Grade d 1. Thereafter, ACP-[ADDRESS_609366] tolerates a reduced dose of ACP-196 f or ≥ [ADDRESS_609367] the dose escalated, as outlined in the ta bles above, if the investigator feels that a 
dose escalation is medically warranted to ma ximize therapeutic bene fit (eg, for lack of 
response or for disease progression in a subj ect who is tolerating the current dose level 
of ACP-196 therapy).  In addi tion, subjects in Cohort [ADDRESS_609368] dexamethasone (40 mg once weekly) added to their treatment. 
Whenever possible, any dose adjustment of ACP-196, incl uding adding dexamethasone 
to subjects in Cohort 1, should be discu ssed between the investigator and the Acerta 
Pharma medical monitor before implementati on. The appropriate clinic staff should 
dispense the study drug for the new dose le vel and instruct the subject/caregiver about 
the change in dose level. 
[IP_ADDRESS] Dexamethasone 
This study will use commercially available dexamethasone.  Dosing of dexamethasone 
will be [ADDRESS_609369]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609370] supportive care medications 
are permitted as per institutional standards.   
For subjects considered at risk for tumo r lysis syndrome:  Administer appropriate 
hydration and allopurinol or rasburicase per institutional standards before initiating 
treatment. 
3.6.2 Prohibited Concomitant Therapy 
Any chemotherapy, immunotherapy, kinase in hibitors, bone marro w transplantation, 
experimental therapy, and radi otherapy are prohibited (see Section 3.4.2 ).   
3.7 PRECAUTIONS 
3.7.1 Dietary Restrictions 
There are no dietary restrictions on this protocol. 
Subjects should be encouraged to follow instru ctions relating to eating relative to study 
drug administration ( Section 3.5.3 ). 
3.7.2 Drug-drug Interactions 
At the systemic exposure levels expected in this study, ACP-19 6 inhibition of CYP-
mediated metabolism of other drugs is no t anticipated.  However, ACP-196 is 
metabolized in part by [CONTACT_097]3A4. In a cl inical drug-drug interaction study, 
coadministration of the potent CYP3A4 in hibitor, itraconazole, increased the mean 
plasma exposures of ACP-196 by > 4-fold (see Section 1.3 ). Dexamethasone is also 
metabolized by [CONTACT_097]3A4 (Gentile 1996). These data indicate that coadministration of 
inhibitors of CYP3A4 could increase AC P-[ADDRESS_609371] therapeutically equivalent drugs 
that do not inhibit these enzymes substi tuted if possible (particularly if the 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 32 of 64 
 coadministered agents are strong inhibitors or inducers).  If substitution is not possible, 
investigators should carefully monitor for to xicity or loss of ACP-196 activity and 
appropriately alter ACP-196 administration cons istent with protocol recommendations for 
dose modification in response to ACP-196-related adverse events (see Section 3.5.3 ). 
The study medical monitor should be consul ted if there are questions regarding the 
potential for drug-drug interactions with ACP-196. 
3.7.[ADDRESS_609372]’s  partner must be reported (see Section 6.2.3 ). Male subjects must agree 
to refrain from sperm donation during the study and for [ADDRESS_609373] experienci ng an ACP-196 overdose (administration of a dose 
≥ 1.[ADDRESS_609374] intended dose level in the clinical study protocol), observation for 
any symptomatic side effects should be in stituted, and vital signs, biochemical and 
hematologic parameters should be followed cl osely (consistent with the protocol or more 
frequently, as needed). Approp riate supportive management to mitigate adverse effects 
should be initiated. If the overdose ingestion is  recent and substantial, and if there are no 
medical contraindications, use of gastric lavage or induction of emesis may be considered. 
The Acerta Pharma Medical Monitor should be contact[CONTACT_35114] a study drug overdose 
occurs.  
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 33 of 64 
 3.8 STOPPI[INVESTIGATOR_475163]-196 in definitely as long as they are safely 
benefitting. However: 
x Any subject has the right to withdraw from the study at any time. 
x Any subject who has objective evidence of definitive MM progression while receiving 
study treatment at the highest individual to lerable dose level allowed in the protocol 
(total dose = 400 mg of ACP- 196 plus dexamethasone) (see Section 3.5.5 ) should 
be withdrawn from the stud y treatment.  Note: If there is uncertainty regarding 
whether there is MM progression, the subjec t should continue study treatment and 
remain under close observation (eg, evaluate d at 4- to 8-week intervals) pending 
confirmation of progression. In particular, worsening of constitutional symptoms in the absence of objective evidence of worseni ng MM will not be considered definitive 
disease progression; in such subjects, bo th MM-related and non-MM-related causes 
for the constitutional symptoms should be considered. Transient worsening of 
disease during temporary interruption of study therapy (eg, for intercurrent illness) 
may also not indicate definitive disease progression. In these instances, relevant 
clinical, laboratory, and/or radiograph ic assessment should be attempted to 
document whether definitive  disease progression has occurred. If subsequent 
evaluations suggest that the subject has ex perienced persistent definitive disease 
progression, then the date of progression will be the timepoint at which progression 
was first objectively documented. 
x Any subject is unable to tolerate a second  rechallenge with protocol-described, dose-
modified levels (see Section 3.5.5 ) should be withdrawn from the study treatment 
unless continued therapy is permitted by  [CONTACT_378147]. 
x Any subject whose medical co ndition substantially changes after entering the study 
should be carefully evaluated by [CONTACT_475233]. Such subjects should be withdrawn from study 
treatment if continuing wo uld place them at risk.  
x Any subject who becomes pregnant or begins breastfeeding should be removed from 
study treatment. 
x Any subject who becomes significantly nonc ompliant with study drug administration, 
study procedures, or study requirements sh ould be withdrawn from study treatment 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609375] from the study treatment, if, in the investigator’s opi[INVESTIGATOR_1649], it is 
not in the subject’s best interest to continue.  
Subjects who discontinue study therapy will continue on study for follow-up of safety 
(Section 4.3 ) and time-to-next therapy for MM unless they withdraw consent for further 
follow-up. Thus, all subjects receiving ≥ [ADDRESS_609376] is withdrawn 
from study treatment or from the study (inclu ding long-term follow-up) and the reason for 
discontinuation will be recorded and also  should be described on the appropriate 
electronic case report form (eCRF).   
3.9 DATA AND SAFETY MONITORING 
This trial will be monitored in accordance with the sponsor’ s Pharmacovigilance 
Committee procedures.  Adverse events and SA Es will be reviewed  internally on an 
ongoing basis to identify safety concerns .  Quarterly conference calls with the 
investigators will be conducted to discuss study progress, obtain investigator feedback 
and exchange, and discuss "significant safe ty events" (ie, AEs leading to dose 
reductions, related SAEs, and deaths).   
4.[ADDRESS_609377]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609378] read, understand and sign th e IRB/IEC approved ICF confirming his or 
her willingness to participate in this study befo re initiating any screening activity that is 
not standard of care.  Subjects must also  grant permission to use protected health 
information. 
4.1.[ADDRESS_609379]’s complete history  should be collected and recorded through review of 
medical records and by [CONTACT_30230]. Concurre nt medical signs and symptoms must be 
documented to establish baseline severities . A disease history, including the date of 
initial diagnosis and list of all prior anticanc er treatments, and resp onses and duration of 
response to these treatments, also will be recorded. 
4.1.[ADDRESS_609380] 
dose of study drug. 
4.1.6 ECOG Performance Status 
The ECOG performance index is provided in  Appendix 1 . 
4.1.7 Physical Examination, Vital Signs, Height & Weight 
The screening physical examination will includ e, at a minimum, the general appearance 
of the subject, height (screening only) an d weight, and examination of the skin, eyes, 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 36 of 64 
 ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, nervous 
system, and lymphatic system. 
Symptom-directed physical exams, including tumor assessments by [CONTACT_23302], will be 
done during the treatmen t period and at the sa fety follow-up visits. 
Vital signs (blood pressure, heart rate, respir atory rate, and body te mperature) will be 
assessed after the subject has rested in the sitting position.   
4.1.8 Bone Marrow Aspi[INVESTIGATOR_127843] 
A bone marrow aspi[INVESTIGATOR_475186] 30 days before the 
main screening procedures.  Per the current response criteria (D urie 2006), a bone 
marrow aspi[INVESTIGATOR_337]/biopsy will also be required at any time on study to confirm a complete response (CR).  The base line bone marrow aspi[INVESTIGATOR_337] /biopsy will used for 
immunohistochemistry and/or flow cytometry, cytogenetics, and FISH.  Testing will be performed at the study center’s local lab oratory or other clinical laboratory listed on the 
investigator’s form FDA 1572.  De -identified copi[INVESTIGATOR_475165]/aspi[INVESTIGATOR_378123].  
When available, any unused bone marrow tissu e will be used for PD testing.  PD testing 
will be done by [CONTACT_456]. 
4.1.9 Electrocardiogram 
Subjects should be in supi[INVESTIGATOR_378124] ≥ 10 minutes before study-related 
ECGs.  At screening, results from the sites ECG machine (12-lead; triplicates taken ≥ 1 minute apart) will be averaged to determine eligibility and must meet the eligibility 
criteria of QTc ≤ [ADDRESS_609381] be ruled out by [CONTACT_2207].  Te sting will be done by  a central laboratory 
as listed on the investigator’s form FDA 1572.  
4.1.[ADDRESS_609382] include complete blood count (CBC) with  differential and 
platelet and reticulocyte counts.  Testing will be  done by a central laboratory as listed on 
the investigator’s form FDA 1572.  
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609383], bicarbonate, 
blood urea nitrogen (BUN), bone-specific alkaline phosphatase, calcium, chloride, 
creatinine, C-terminal telopept ide, glucose, lactate dehydrogenase (LDH), magnesium, 
phosphate, potassium, sodium, total bilirubin , total protein, and uric acid.  If an 
unscheduled ECG is done at any time, th en an electrolyte panel (ie, calcium, 
magnesium, and potassium) must be done to coincide with the ECG testing.  Testing will 
be done by a central laboratory as listed on the investigator’ s form FDA 1572. 
4.1.13 Urinalysis 
Urinalysis includes pH, ketones, specific grav ity, bilirubin, protein, blood, N-terminal 
telopeptide, and glucose.  Testing will be done by a central laboratory as listed on the investigator’s form FDA 1572 .  
4.1.14 T/B/NK Cell Count 
Flow cytometry testing for CD3+, CD4+, CD8+, CD19+, and CD16/56+ cells.  Testing will 
be done by a central laboratory as listed on the investigator’s form FDA 1572 . 
4.1.15 Disease Markers 
Testing for serum M-protein levels (by [CONTACT_475207] [SPEP] and serum 
immunofixation electrophoresis [SIFE]), seru m-free light chains (SFLC), urine M-protein 
levels (by [CONTACT_475208] [UPEP] and urine immunofixation 
electrophoresis [U IFE]), and serum β2-microglobulin will be done by a central laboratory 
as listed on the investigator’s form FDA [ADDRESS_609384] lateral radiograph of the skull, ante rioposterior and lateral views of the spi[INVESTIGATOR_050], 
and anterioposterior views of the pelvis, ri bs, femora, and humeri are required at 
screening or baseline (ie, before the first do se of study drug).  Radiographic imaging and 
analysis will be performed at the study center’s  local laboratory or other clinical 
laboratory listed on the investigator’s form FDA 1572.   
4.1.17 Pharmacodynamics 
Blood samples and bone marrow, when availabl e, will be used for PD testing (eg, Btk 
occupancy and B-cell activation).  Refer to the laboratory binder for instructions on 
collecting and processing these samples.  Testing will be done by [CONTACT_456]. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 38 of 64 
 4.1.18 Pharmacokinetics 
Refer to the laboratory binder for instructions on collecting and processing these 
samples. Testing will be performed at a central clinical laboratory.  The PK sampling timepoints are provided in Table 4-1 . 
Table 4-1.  Pharmacokinetic Sample Schedule 
 HOURS POSTDOSE 
Cycle Day Predose 0.5 
(±5 min) 0.75 
(±5 min) 1 
(±5 min) 2 
(±10 min) 4 
(±10 min) 6 
(±10 min) 
1 1 X X X X X X X 
 8 X   X    
 15 X   X    
 22 X X X X X X X 
 28 X   X    
Note: These timepoints are relative to the morning dose. 
 
4.1.[ADDRESS_609385] of:  
● M-protein determination using both of the following procedures: 
○ SPEP and SIFE 
○ UPEP and UIFE (all using the same 24-hour urine collection)  
● SFLC 
● Plasmacytoma evaluation 
● Bone marrow to quantify percent myeloma cell involvement (aspi[INVESTIGATOR_475166]) 
● Skeletal survey: lateral radiograph of the skull, anteriopos terior and lateral 
views of the spi[INVESTIGATOR_050], and anterioposterior  views of the pelvis, ribs, femora, and 
humeri 
● β2-microglobulin 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609386] of:  
● SPEP and/or UPEP (if results were meas urable at baseline); quantitative 
immunoglobulins if used to follow di sease; immunofixation to confirm a 
complete response 
● SFLC 
● Plasmacytoma evaluation (if only  measurable disease at baseline) 
● Bone marrow aspi[INVESTIGATOR_6706]/or trephine  bone biopsy (to confirm a complete 
response or if clinically indicated). 
4.1.20 Study Drug Accountability 
See Section 7.6 . 
4.2 INVESTIGATOR’S ASSES SMENT OF RESPONSE TO TREATMENT 
Subjects will be evaluated by [CONTACT_475234] (IMWG; Durie 2006) and 
European Group for Blood and Marr ow Transplant (EBMT; Bladé 1998) criteria as listed 
below.  Response categories  include sCR, CR, nCR, VGPR, PR, SD, and progressive 
disease. In addition, the number of subjects achieving the response category of MR will 
also be evaluated and reported.   Subjects will be considered evaluable for response if 
they have a baseline and t1 adequate on-study anti-myeloma assessment obtained 
t4 weeks from the start of therapy.   
Table 4-1.  Response Criteria (incorporating EBMT [Bladé 1998] and IMWG [Durie 
2006]) 
Response Subcategory Response Criteria a 
Complete response (CR) x Negative immunofixation on the serum and urine and 
x Disappearance of any soft tissue plasmacytomas and 
x < 5% plasma cells in bone marrowb. 
Stringent complete 
response (sCR)  x CR as defined above plus 
x Normal FLC ratio and 
x Absence of clonal cells in bone marrowb by [CONTACT_475235]. 
Near complete response 
(nCR)  x Meeting the criteria for CR, except  that the persistence of original 
monoclonal protein by [CONTACT_475236]. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 40 of 64 
 Very good partial 
response (VGPR)  x Serum and urine M- component detectable by [CONTACT_237472] 
x ≥ 90% reduction in serum M-component plus urine M- component 
< 100 mg per 24 h. 
Partial response (PR) x ≥ 50% reduction of serum M-protein and reduction in 24- h urinary 
M-protein by ≥ 90% or to < 200 mg per 24 h 
x If the serum and urine M- protein are unmeasurable at baseline, a 
≥ 50% decrease in the difference between involved and 
uninvolved FLC levels is required in place of the M-protein crite ria 
x If serum and urine M- protein are unmeasurable at baseline, and 
serum free light assay is also unmeasurable, ≥ 50% reduction in 
plasma cells is required in place of M- protein, provided baseline 
bone marrow plasma cell percentage was ≥ 30% 
x In addition to the above listed cr iteria, if present at baseline, a 
≥ 50% reduction in the size of soft tissue plasmacytomas is also 
required 
Minor response (MR) x MR includes subjects in whom so me, but not all, criteria for PR are 
fulfilled providing the remaining crit eria satisfy the requirements for 
MR. 
x Requires all of the following: 
o t 25% to d 49% reduction in the level o f serum monoclonal 
protein for ≥ 2 determinations 6 weeks apart. 
o If present, a 50% to 89% reduction in 24-hour light chain 
excretion, which still exceeds 200 mg/24 h, for 
≥ 2 determinations 6 weeks apart. 
o 25- 49% reduction in the size of plasmacytomas (by [CONTACT_475237]) for ≥ 6 weeks. 
o No increase in size or number of lytic bone lesions 
(development of compression fracture does not exclude 
response). 
Stable disease - SD (not 
recommended for use as an indicator of response; stability of disease is best 
described by [CONTACT_475238]) x Not meeting criteria for CR, VGPR, MR, PR or progressive 
disease  
 
Progression 
Subcategory  Progression Criteriad  
Progressive diseasea —To 
be used for calculation of 
duration of response  and 
progression -free survival 
end points for all subjects 
including those in CR 
(includes primary 
progressive disease and 
disease progression on or 
off therapy)g Laboratory or biochemical relapse or  progressive disease: requires the 
occurrence of ≥ 1 of any of the following: 
x Increase of ≥ 25% from lowest response value in serum M-
component and/or (the abs olute increase must be ≥ 0.5 g/dL)e. 
x Urine M-component and/or (the absolute increase must be 
≥200 mg/24 h). 
x Only in subjects without measurable serum and urine M- protein 
levels: the difference between involved and uninvolved FLC levels. 
The absolute increase must be > 10 mg/dL. 
x Bone marrow plasma cell percentage: the absolute % must be 
≥ 10%c. 
x Definite development of new bone lesions or soft tissue 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 41 of 64 
 plasmacytomas or definite increase in the size of existing bone 
lesions or soft tissue plasmacytomas. 
 
Abbreviations:  EBMT = European Group for Blood and Marrow Transplant; IMWG = International 
Myeloma Working Group; FLC = (serum) free light chains Note: * Note clarification to IMWG criteria for co ding CR and VGPR in subjects in whom the only 
measurable disease is by [CONTACT_128758]: CR in such subjects a normal FLC ratio of 0.26-1.65 in addition to CR criteria listed above. VGPR in such subjects is defined as a > 90% decrease in 
the difference between involved and unin volved free light chain FLC levels 
a. All response categories require 2 consecutive assessments made at t4 weeks after the start 
of study therapy and anytime before the institution of any new therapy after study therapy; 
CR and PR and SD categories also require no known evidence of progressive or new bone 
lesions if radiographic studies were performe d. Radiographic studies are not required to 
satisfy these response requirements. 
b. Confirmation with repeat bone marrow biopsy not needed 
c. Presence/absence of clonal  cells is based upon the kappa/lambda ratio. An abnormal 
kappa/lambda ratio by [CONTACT_145170]/or immunofluorescence requires a 
minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an 
abnormal clone is kappa/lambda of > 4:1 or < 1:2.  
d. All relapse categories require 2 consec utive assessments made at anytime before 
classification as relapse or disease progression and/or the institution of any new therapy. 
e. For progressive disease, serum M- component increases of ≥ 1 gm/dL are sufficient to define 
relapse if starting M- component is ≥ 5 g/dL. 
f. Relapse from CR has the 5% cutoff versus  10% for other categories of relapse. 
g. For purposes of calculating time to progression and progression-free survival, CR subjects 
should also be evaluated using criteria listed above for progressive disease. 
 
4.[ADDRESS_609387] should be followed for 30 (±7) da ys after his or her last dose of study drug 
(ie, the “safety follow -up visit”) to monitor for resoluti on or progression of AEs (see 
Section 6.2.5)  and to document the occurrence of any new events; unless, the subject 
receives a new anticancer therapy within this timeframe.  Subjects who withdraw 
consent should still be encouraged to comp lete the safety follow-up assessments, but 
these assessments cannot be mandated once consent is withdrawn.  The Schedule of Assessments (Appendix 4) describes the proced ures required for the safety follow-up.  
4.4 MISSED EVALUATIONS 
Missed evaluations should be rescheduled an d performed as close to the original 
scheduled date as possible.  An exception is made when rescheduling becomes, in the 
investigator’s opi[INVESTIGATOR_1649], medically unnecessary or  unsafe because it is too close in time to 
the next scheduled evaluation.  In that case, the missed evaluation should be abandoned. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 42 of 64 
 5.0 STATISTICAL METHODS OF ANALYSIS  
5.1 GENERAL CONSIDERATIONS 
Descriptive statistics (including means, standard deviations, and medians for continuous 
variables and proportions for discrete vari ables) will be used to summarize data as 
appropriate.  Analyses will be done  by [CONTACT_178359]. 
5.2 SAMPLE SIZE CONSIDERATIONS 
This study will assess safety, PK, PD, and antitumor activity of ACP-196 alone or in 
combination with dexamethasone.  Subjects will be equally randomized into 1 of the 2 dosing regimens (ACP-196 monotherapy or ACP-196 + dexamethasone) as an 
efficient method for allocating patients into these regimens. The study is not formally 
designed to compare these regimens but rather  to obtain descriptive information that can 
be used in support of fu rther ACP-196 development. 
While the primary objective of this study is to determine the safety in each of the 
2 dosing cohorts, the sample size has been  determine to indepe ndently evaluate the 
activity of each dosing regimen. The trial seeks to exclude an uninteresting ORR of 
d 15% (ie, the response rate that might be associated with single-agent dexamethasone 
therapy [Anderson 2013]) in favo r a target response rate of t 40%.  Considering a 
sample size of [ADDRESS_609388] the difference between a null-
hypothesis response rate of 15% and an alternative-hypothesis response rate of 40% 
with a 0.025 one-sided significance level is 84% using a one-group, chi-square test and 
69% using a one-group, exact binomial test.  A sa mple size of 19 subjects per cohort will 
also provide a 97.5% 1-sided confidence inte rval centered around an expected ORR of 
40% that excludes an ORR of 18.6% as a lower bound
. 
5.3 DEFINITION OF ANALYSIS SETS 
The following definitions will be used for the efficacy and safety analysis sets. 
x Safety analysis set:  All enrolled subjects who receive ≥ 1 dose of study drug. 
x Per-protocol (PP) analysis set:  All enrolled subjects who receive ≥ [ADDRESS_609389] sufficient baseline measurements, and und ergo ≥ [ADDRESS_609390] (eg, response and PK/PD parameters) after treatment. 
The safety analysis set will be used for evaluating the safety and efficacy parameters in 
this study (with the exception of assessment of  duration of response ).  The PP analysis 
sets will be analyzed for efficacy and PK/PD parameters in this study. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609391] to follow-up (or drop out) will 
be included in statistical analyses to  the point of their last evaluation. 
5.5 ENDPOINT DATA ANALYSIS 
5.5.1 Safety Endpoint 
Safety summaries will include summaries in the form of tables and listings.  The 
frequency (number and percentage) of treatment emergent AEs will be reported in each 
treatment group by [CONTACT_61121].  Summaries will 
also be presented by [CONTACT_475211] (per CTCAE, v4.03) and by 
[CONTACT_8792]. 
Laboratory shift tables containing counts and percentages will be prepared by [CONTACT_11512], laboratory parameter, and time.  Summary tables will be prepared for each laboratory parameter.  Figures of changes in  laboratory parameters over time will be 
generated. 
Results of vital sign assessments and physical exams will be tabulated and summarized.   
5.5.2 Demographics and Baseline Characteristics 
Additional analyses will include summaries of subjec t demographics, baseline 
characteristics, compliance, and concurrent treatments. Concomitant medications will be 
coded according to the World Health Or ganization (WHO) Drug Dictionary and 
tabulated. 
5.5.3 Analysis of Efficacy Parameters 
[IP_ADDRESS] Response Rate 
The individual and composite endpoints of re sponse and progression will be determined. 
Tumor control will be documented at each assessment by [CONTACT_115188] (eg, CR, 
sCR, nCR, VGPR, PR, MR, SD, and disease pr ogression) as defined for each response 
parameter, date that response is first docu mented, and date of MM disease progression. 
ORR will be defined as the proportion of subjects who achieve a CR, sCR, nCR, VGPR, 
PR, or MR. ORR will be calculated and the corresponding 97.5% one-sided confidence 
interval will be derived. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 44 of 64 
 [IP_ADDRESS] Duration of Response 
The duration of overall response defined as the interval from the first documentation of 
CR, sCR, nCR, VGPR, PR, or MR to the earlier of the first documentation of definitive disease progression or death from any cause.  Kaplan-Meier methods will be used to estimate event-free curves and corresponding  quantiles (including the median). Data 
from surviving, nonprogressing subjects will be censored at the earliest of the time of initiation of antitumor treatment other than the study treatment or the last time that lack of definitive MM progression was objectively  documented. Data from subjects who have 
MM progres sion or die after ≥ [ADDRESS_609392] time before the missing assessments that lack of MM progression 
was objectively documented. 
[IP_ADDRESS] Progression-free Survival 
Progression-free survival is defined as the in terval from the start of ACP-[ADDRESS_609393] documentation of obje ctive MM disease progression or death from 
any cause.  Kaplan-Meier methods will be us ed to estimate the event-free curves and 
corresponding quantiles (including the median ).  Data from surviving, non-progressing 
subjects will be censored at the earliest of the time of initiation of antitumor treatment 
other than the study treatment or the last time that lack of MM progression was 
objectively documented. Data from subjects  who have MM progression or die after 
≥ [ADDRESS_609394] time prior to the 
missing assessments that lack of MM progression was objec tively documented. 
[IP_ADDRESS] Time-to-Next Treatment 
Time-to-next treatment defined as the time from start of ACP-196 therapy for MM on this 
protocol to the start of the next treatment for MM. Kaplan-Meier methods will be used to estimate the event-free curves and correspondi ng quantiles (including the median). Data 
from subjects who have not received subseque nt therapy for MM will be censored at the 
earliest of death or the last time that lack of administration of a new therapy for MM was 
objectively documented. 
5.5.4 Analysis of Pharmacokinetic/Pharmacodynamic Parameters  
The plasma PK of ACP-196 and dexameth asone will be characterized using 
noncompartmental analysis. The following PK parameters will be calculated, whenever 
possible, from plasma concentrations of ACP-196: 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 45 of 64 
 x AUC (0-t) Area under the plasma concentratio n-time curve calculated using linear 
trapezoidal summation from ti me [ADDRESS_609395] 
measurable concentration (C t). 
x AUC (0-24) Area under the plasma concentratio n-time curve from 0 to 24 hours, 
calculated using linear trapezoidal summation. 
x AUC (0-∞) Area under the plasma concentratio n-time curve from 0 to infinity, 
calculated using the formula: AUC (0-∞) = AUC (0-t) + C t / λz, where λz is the 
apparent terminal elimination rate constant. 
x C max Maximum observed plasma concentration 
x T max Time of the maximum plasma concentration (obtained without 
interpolation) 
x t ½ Terminal elimination half -life (whenever possible)  
x λz Terminal elimination rate constant (whenever possible) 
x Cl/F Oral clearance 
Missing dates or times may be  imputed for PK and PD samples if the missing values can 
be established with an acceptable level of ac curacy based on other information obtained 
during the visit in question. If PK and PD sampling for a given subject is not performed according to protocol instructions that su bject may be excluded from the PK and PD 
analyses. 
The PK parameters will be tabulated and su mmarized using descriptive statistics.  
For each PD variable, the concentration at each assessment will be described.  The 
change from baseline to each assessment will be summarized.  The best change from 
baseline during the st udy will also be summarized.  As  appropriate, the on-treatment 
values will be compared with the pretreatment  baseline values using paired t-tests.  
P-values of d 0.[ADDRESS_609396] of monitoring and recording AEs and SAEs; 
measurements of protocol-specified hematology , clinical chemistry, urinalysis, and other 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 46 of 64 
 laboratory variables; measurement of protocol-specified vital signs; and other protocol-
specified tests that are deemed critical to the safety evaluation of the study drug(s). 
6.1 DEFINITIONS 
6.1.1 Adverse Events 
An AE is any unfavorabl e and unintended sign, symptom, or disease temporally 
associated with the use of an investigatio nal (medicinal) product or other protocol-
imposed intervention, regardless of attribution. 
This includes the following: 
x AEs not previously observed in the subject that emerge during the protocol-specified 
AE reporting period, including signs or symptoms associated with MM that were not 
present before the AE reporting period (see Section 6.2.1 ) 
x Complications that occur as a result of pr otocol-mandated interven tions (eg, invasive 
procedures such as biopsies) 
x Preexisting medical conditions (other than the condition being studied) judged by [CONTACT_475212]-specified AE reporting period. 
Abnormal laboratory values should not be reported as AEs; however, any clinical 
consequences of the abnormality (eg, withdr awal from study) should be reported as 
AEs. 
6.1.2 Serious Adverse Event 
The terms “ severe ” and “serious” are not synonymous.  Se verity (or intensity) refers to 
the grade of an AE (see below).  “Serious” is  a regulatory definition and is based on 
subject or event outcome or action criteria usually associated with events that pose a 
threat to a subject’s life or functioning.  Se riousness (not severity) serves as the guide 
for defining regulatory reporting obligations from the Sponsor to applicable regulatory 
authorities. 
An AE should be classified as an SAE if it meets any 1 of the following criteria: 
x It results in death (ie, the AE actually causes or leads to death). 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 47 of 64 
 x It is life-threatening (ie, the AE, in the vi ew of the investigator, places the subject at 
immediate risk of death.  It  does not include an AE tha t, had it occurred in a more 
severe form, might ha ve caused death). 
x It requires or prolongs in-patient hospi[INVESTIGATOR_059]. 
x It results in persistent or significant disability/incapacity (ie, the AE results in 
substantial disru ption of the subject’s ability to conduct normal life functions).  
x It results in a congenital anomaly/birth de fect in a neonate/infant born to a mother 
exposed to the investigational product. 
x It is considered a significant medical ev ent by [CONTACT_188212] (eg, may jeopardize the subj ect or may require medical/surgical 
intervention to prev ent 1 of the outcomes listed above). 
6.1.3 Severity 
Definitions found in the CTCAE version 4.03 or higher will be used for grading the 
severity (intensity) of AEs. The CTCAE displays Grades [ADDRESS_609397] experience any AE not 
listed in the CTCAE, the following grading system should be used to assess severity: 
x Grade 1 (Mild AE) – experiences which are usually transient, requiring no special 
treatment, and not interfering wi th the subject’s daily activities  
x Grade 2 (Moderate AE) – experiences which introduce some level of inconvenience 
or concern to the subject, and which may interfere with daily activities, but are 
usually ameliorated by [CONTACT_475213] 
x Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, 
significantly interrupt the subject’s usual daily activity, and require systemic drug 
therapy or other treatment 
x Grade 4 (Life-threatening or disabling AE) – experiences which cause the subject to 
be in imminent danger of death 
x Grade 5 (Death related to AE) – experiences which resu lt in subject death 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609398] be reported on the SAE/Product Complaint form (see Section 6.2.4 ). 
6.2.[ADDRESS_609399]’s medical record and on the 
AE eCRF and, when applicable, on an SAE/Product Complaint form. 
Disease progression itself is not considered an adverse event; however, signs and 
symptoms of disease progression may be recorded as AEs or SAEs. 
Each recorded AE or SAE will be described by  [CONTACT_13662] (ie, start and end dates), 
severity, regulatory seriousness criteria, if ap plicable, suspected relationship to the study 
drug (ie, ACP-196, dexameth asone, or both; see following guidance), and any actions 
taken.  The relationship of AEs to the study drug will be assessed by [CONTACT_7859]: ‘Is there a reasonab le possibility that the event may have been caused by [CONTACT_50463]?’  Answer Yes or  No.  
See Appendix [ADDRESS_609400] 
be reported using the SAE report form, according to the usual timelines and directions 
for SAE reporting ( Section 6.2.4 ). 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609401] interfered with the effectiveness of a 
contraceptive medication. Likewise, elective abortions without complications are not considered AEs. Any SAEs associated with pregnancy (eg, congenital 
abnormalities/birth defects/spontaneous misca rriages or any other serious events) must 
additionally be reported as su ch using the SAE report form.  
Subjects should be instructed to immediately no tify the investigator of any pregnancies.  
Any female subjects receiving ACP-[ADDRESS_609402], discussing any 
risks of continuing the pregnancy and an y possible effects on the fetus.   
6.2.4 Expedited Reporting Requirements for Serious Adverse 
Events 
All SAEs (initial and follow-up information) w ill be reported on an SAE/Product Complaint 
form.  Paper SAE/Product Complaint forms must  be emailed or faxed to Acerta Pharma 
Drug Safety, or designee, within [ADDRESS_609403] follow-up and other additional 
information from the investigator (eg, hosp ital admission/discharge notes and laboratory 
results).  
All deaths should be reported with the prim ary cause of death as the AE term, as death 
is typi[INVESTIGATOR_36069], not th e event itself. The primary cause of death on 
Product: ACP-196
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609404] and is not listed in the current 
Investigator’s Brochure (ie,  an unexpected event). In th is case, Acerta Pharma Drug 
Safety/Designee will forward a formal notifica tion describing the SAE to all investigators. 
Each investigator must then notify his or her IRB/IEC of the SAE. 
Drug Safety Contact [CONTACT_475215]:
Email:
6.2.[ADDRESS_609405] to follow-up or withdraws 
consent. 
7.0 STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS 
Acerta Pharma retains the right to terminate  the study and remove all study materials 
from a study site at any time. Specific circumstances that may precipi[INVESTIGATOR_475187]: 
x Unsatisfactory subject enrollment wi th regard to quality or quantity 
x Significant or numerous deviations from  study protocol requirements, such as 
failures to perform required evaluations on subjects and maintain adequate study 
records 
x Inaccurate, incomplete and/or late data recording on a recurrent basis 
x The incidence and/or severity of AEs in this or other studies indicating a potential 
health hazard caused by [CONTACT_475239]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609406] AND INDEPENDENT ETHICS 
COMMITTEE 
The investigator will submit this protocol, the informed consent, Investigator’s Brochure, 
and any other relevant supporting informatio n (eg, all advertising materials) to the 
appropriate IRB/IEC for review and approval before study initiation.  A signed protocol 
approval page; a letter conf irming IRB/IEC approval of the protocol and informed 
consent;  and a statement that the IRB/IEC is orga nized and operates according to GCP 
and the applicable laws and regulations;  must  be forwarded to Acerta Pharma before  
screening subjects for the study.  Additi onally, sites must fo rward a signed FDA 1572 
form (Investigator Obligation Form) to Acer ta Pharma before screening subjects for 
study enrollment.  Amendments to the protocol  must also be approved by [CONTACT_1201]/IEC 
and local regulatory agency, as appropriate, before the implementation of changes in 
this study. 
7.[ADDRESS_609407] HEALTH 
INFORMATION AUTHORIZATION 
A copy of the IRB/IEC-approved informed consent must be forwarded to Acerta Pharma 
for regulatory purposes.  The investigator, or  designee (designee must be listed on the 
Study Personnel Responsibility/Signature [CONTACT_94618], see Section 7.11 ), must  explain to each 
subject the purpose and nature of the study,  the study procedures, the possible adverse 
effects, and all other elements of consent as defined in § 21CFR Part 50, and other 
applicable national and local regulations go verning informed consent.  Each subject 
must provide a signed and dated informed consent before enrollment into this study.  In the case of a subject who is incapable of prov iding informed consent, the investigator (or 
designee) must obtain a s igned and dated informed consent form from the subject’s 
legal guardian.  Signed consent forms must re main in each subject’s study file and be 
available for verification by [CONTACT_9534]. 
In accordance to individual local and national subject privacy regulations, the 
investigator or designee must  explain to each subject that  for the evaluation of study 
results, the subject’s protected health info rmation obtained during the study may be 
shared with Acerta Pharma an d its designees, regulatory agencies, and IRBs/IECs.  As 
the study Sponsor, Acerta Pharma will not use the subject’s protected health information 
or disclose it to a third party without appl icable subject authorization.  It is the 
investigator’s or designee’s  responsibility to obtain wr itten permission to  use protected 
health information from each subject, or if ap propriate, the subject’s legal guardian.  If a 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609408]’s legal guardian withdr aws permission to us e protected health 
information, it is the investigator’s responsibi lity to obtain the withdrawal request in 
writing from the subject or subject’s legal guardian and to ensure that no further data will 
be collected from the subject.  Any data coll ected on the subject before withdrawal will 
be used in the analysis of study results. 
7.[ADDRESS_609409] that lists all subjects considered for enrollment 
(including those who did not undergo screen ing) in the study.  For those subjects 
subsequently excluded from enrollment , record the reason(s) for exclusion. 
7.4 CASE REPORT FORMS 
Authorized study site personnel (see Section 7.11 ) will complete eCRFs designed for 
this study according to the completion guidelin es that will be provided.  The investigator 
will ensure that the eCRFs are accurate, complete, legible, and completed within [ADDRESS_609410]’s visit  (unless required earlier for SAE re porting).  The investigator will 
ensure that source documents that are requir ed to verify the validity and completeness 
of data transcribed on the eCRFs ar e never obliterated or destroyed. 
7.[ADDRESS_609411] to reviews or audits. 
Every effort will be made to maintain the anonymity and confidentiality of all subjects 
during this clinical study.  However, be cause of the experimental nature of this 
treatment, the investigator agrees to allo w the IRB/IEC, representatives of Acerta 
Pharma, its designated agents, and authorized  employees of the appropriate regulatory 
agencies to inspect the facilitie s used in this study and, for purposes of verification, allow 
direct access to the hospi[INVESTIGATOR_475168].  This 
includes providing by [CONTACT_6791], email, or regular mail de-identified copi[INVESTIGATOR_134464], 
pathology, and/or laboratory results when requ ested by [CONTACT_456].  A statement to this 
effect will be included in the informed consent and permission form authorizing the use 
of protected health information. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609412] be  maintained and readily available for 
inspection by [CONTACT_475240].  
Each shipment of study drug will contain a Clinical Supplies Sh ippi[INVESTIGATOR_378128] 
(CSSF) that must be appended to the site’s drug accountability records. Additionally a 
Drug Re-order Form for requesting more stud y drug is provided in the pharmacy binder. 
If it is used, then the Drug Re-order Form must also be included in the site’s drug 
accountability records.   
Contents of each shipment must be visual ly inspected to verify the quantity and 
document the condition of study drug capsules.  Then the designated recipi[INVESTIGATOR_475188]. A copy of the signed CSSF must be faxed or emailed to 
Acerta Pharma at the fax number/emailing address listed on the form. 
An Investigational Drug Accountability Log mu st be used for drug accountability.  For 
accurate accountability, the following inform ation must be noted when drug supplies are 
used during the study: 
1. study identification number (ACE-MY-001) 
2. subject identification number 
3. lot number(s) of ACP-[ADDRESS_609413] 
At study initiation , the monitor will evaluate and approve the site’s procedure for 
investigational product disposal/destruction to ensure that it complies with Acerta Pharma ’s requirements. If the site cannot meet Acerta Pharma ’s requirements for 
disposal/destruction, arrangements will be ma de between the site and Acerta Pharma or 
its representative, for return of unused investigational product.  Before 
disposal/destruction, final drug accountability and reconciliation must be performed by 
[CONTACT_2037]. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609414] RETENTION 
The investigator and other appropriate stud y staff are responsible for maintaining all 
documentation relevant to the study. Mandat ory documentation includes copi[INVESTIGATOR_475170], each FDA Form 1572, IRB/IEC approval letters, signed 
ICFs, drug accountability records, SAE forms tr ansmitted to Acerta Pharma, subject files 
(source documentation) that substantiate entr ies in eCRFs, all rele vant correspondence 
and other documents pertaining to the conduct of the study. 
An investigator shall retain records for a period  of at least [ADDRESS_609415] 
marketing application is approved for the drug  for the indication for which it is being 
investigated; or, if no application is to be f iled or if the application is not approved for 
such indication, until [ADDRESS_609416] from th e study site so that they can be returned 
sealed to the investigator for audit purposes. 
7.8 PROTOCOL AMENDMENTS 
Acerta Pharma will initiate any change to  the protocol in a protocol amendment 
document. The amendment will be submitted to the IRB/IEC together with, if applicable, 
a revised model ICF. If the change in any way increases the risk to the subject or 
changes the scope of the study, then writte n documentation of IRB/IEC approval must 
be received by [CONTACT_475241] e amendment may take effect. Additionally 
under this circumstance, informa tion on the increased risk and/or change in scope must 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609417]. The results may also be used for 
papers, abstracts, posters or other material pr esented at scientific meetings or published 
in professional journals or as part of an academic thesis by [CONTACT_2413]. The study is 
being conducted as part of a multicenter clinical  trial. Data from all study centers shall be 
pooled and analyzed for publication in a fi nal report (Primary Publication). The 
investigator agrees that the Primary Public ation, which will be coordinated by [CONTACT_475217], will be the first publication to presen t the pooled study results. After the Primary 
Publication, or if the Primary Publication is not published within [ADDRESS_609418] matter and/or any 
inadvertent disclosure of its confidential information, which must be redacted from any 
final publication or presentation. If necessary, to permit the preparation and filing of patent applications, Acerta Pharma may elect an additional review period not to exceed 
[ADDRESS_609419] provided significant intell ectual input into the study design, shall be 
listed as lead authors on manuscripts and reports of study results. The Medical Monitor, study director and/or lead stat istician may also be  included in the list of authors. This 
custom can be adjusted upon  mutual agreement of the authors and Acerta Pharma. 
7.[ADDRESS_609420]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609421] ensure that: 
1. He or she will personally conduct or supervise the study. 
2. His or her staff and all persons who assist in the conduct of the study clearly 
understand their responsibilities and hav e their names includ ed in the Study 
Personnel Responsibility/Signature [CONTACT_94618]. 
3. The study is conducted according to the protocol and all applicable regulations. 
4. The protection of each subject’s rights and welfare  is maintained. 
5. Signed and dated informed consent an d, when applicable, permission to use 
protected health information are obtained  from each subject before conducting 
nonstandard of care study procedures.  If a subject or subject’s legal guardian 
withdraws permission to use protected health information, the investigator will 
obtain a written request from the subjec t or subject’s legal guardian and will 
ensure that no further data be  collected from the subject. 
6. The consent process is conducted in co mpliance with all applicable regulations 
and privacy acts. 
7. The IRB/IEC complies with applicable  regulations and conducts initial and 
ongoing reviews and approvals of the study. 
8. Any amendment to the protocol is submitted promptly to the IRB/IEC. 
9. Any significant protocol deviations are reported to Acerta Pharma and the 
IRB/IEC according to the guidelines at each study site. 
10. Electronic CRF pages are completed within [ADDRESS_609422]’s visit  (unless 
required earlier for SAE reporting). 
11. All IND Safety Reports/ Suspected Unexpected Serious Adverse Reaction 
(S[LOCATION_003]R) Reports are submitted promptly to the IRB/IEC. 
12. All SAEs are reported to Acerta Pharma Drug Safety/Designee within 24 hours of 
knowledge and to the IRB/IEC per their requirements. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 57 of 64 
 8.0 REFERENCES 
Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma, version 1.2013. J Natl 
Compr Canc Netw 2013;11:11-17.  
Bladé J, Samson D, Reece D, et al.  Cr iteria for evaluating disease response and 
progression in patients with multiple myeloma treated by [CONTACT_5019]-dose therapy and 
haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European 
Group for Blood and Marrow Transplant.  Br J Haematol 1998;102:1115-1123. 
Bradshaw JM. The Src, Syk, and Tec family kinases: distinct types of molecular 
switches. Cell Signal 2010;22:1175-1184.  
Buggy JJ, Elias L. Bruton tyrosine kinase (Btk ) and its role in B-cell malignancy. Int Rev 
Immunol 2012;31:119-132. Erratum in: Int Rev Immunol 2012;31:428. 
Cheson BD, By[CONTACT_9063], Rai KR, et al. Novel target ed agents and the need to refine clinical 
end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820-2820. 
Durie BG, Harousseau JL, Miguel JS et al.  International uniform response criteria for 
multiple myeloma.  Leuk emia 2006;20:1467-1473. 
Edwards CM, BTK inhibition in myeloma:  targeting the seed and soil.  Blood 
2012;120:1757-1759.   
Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism 
by [CONTACT_475218]. Metabolite identifica tion and inhibi tion of 6-hydroxylation. J 
Pharmacol Exp Ther 1996;277:105-12. 
Hallek M, Cheson BD, Catovsky D, et al.  Guidelines for the diagnosis and treatment of 
chronic lymphocytic leukemia: a report from  the International Workshop on Chronic 
Lymphocytic Leukemia updating the Nation al Cancer Institute-Working Group 1996 
guidelines. Blood 2008;111:5446-5456. 
Hellmann A, Rule S, Walewski J, et al. Effect of cytochrome P450 3A4 inducers on the 
pharmacokinetic, pharmacodyna mic and safety profiles of bo rtezomib in patients with 
multiple myeloma or non-Hodgkin's lymp homa. Clin Pharmacokinet 2011;50:781-791. 
Honigberg LA, Smith AM, Sirisawad M, et al .  The Bruton tyrosine kinase inhibitor 
PCI-[ZIP_CODE] blocks B-cell activation and is e fficacious in models of autoimmune disease 
and B-cell malignancy. PNAS 2010;107:[ZIP_CODE]-[ZIP_CODE]. 
Mohamed AJ, Yu L, Bäckesjö CM, et al. Br uton's tyrosine kina se (Btk): function, 
regulation, and transformation with specia l emphasis on the PH domain. Immunol Rev 
2009;228:58-73. 
Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of 
action in multiple myeloma in 2013: a report from the International Myeloma Working 
Group (IMWG). Leukemia 2014;28:525-542.   
Rajkumar SV, Jacobus S, Callander NS, et a; Eastern Cooperative Oncology Group. 
Lenalidomide plus high-dose dexamethason e versus lenalidomide plus low-dose 
dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label 
randomised controlled trial. Lancet Oncol 2010;11:29-37. Erratum in: Lancet Oncol 
2010;11:14. 
Romano A, Conticello C, Cavalli M, et al. Salvage therapy of multiple myeloma: the new 
generation drugs. Biomed Res Int 20 14;2014:456037. Epub [ADDRESS_609423]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 58 of 64 
 Tai YT, Chang, BY, Kong SY, et al.  Bruton  tyrosine kinase in hibition is a novel 
therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple 
myeloma.  Blood 2012:120:1877-1887. 
Vail DM, Thamm DH. Spontaneously occurring tumors in companion animals as models 
for drug development. In: Teicher BA, Anders  PA, eds. Anticancer Drug Development 
Guide: Preclinical Screening, Clinical Trials, and Approval. 2nd Ed. Totowa, NJ: Human 
Press; 2004:259-284. 
Vail DM, Michels GM, Khanna C, Selting KA, London CA; Veterinary Cooperative 
Oncology Group. Response eval uation criteria for peripher al nodal lymphoma in dogs 
(v1.0) —a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet 
Comp Oncol 2010;8:28-37. 
Vihinen M, Mattsson PT, Smith CI. Bruton tyrosine kinase (Btk) in X-linked 
agammaglobulinemia (XLA). Front Biosci 2000;5:D917-D928. 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609424]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 60 of 64 
  
Appendix 1. Performan ce Status Scores  
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuou s activity but ambulatory and able 
to carry out work of a light or sedentary nature, eg, light house work, office work 
2 Ambulatory and capable of all self -care but unable to carry out any 
work activities. Up and about mo re than 50% of waking hours 
3 Capable of only limited self-care,  confined to bed or chair more 
than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair 
5 Dead 
As published in Am J Clin Oncol: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, 
P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982. 
Credit: Eastern Cooperative Oncology Group Chair: Robert Comis, MD 
Available at: http://www.ecog.org/general/perf_stat.html .  Accessed [ADDRESS_609425]: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-[ADDRESS_609426] been caus ed by [CONTACT_5349]?  
No___ Yes___ 
The descriptions provided below will help guide the principal investigator [INVESTIGATOR_378132] “yes” or “no”:  
No = There is no reasonable possibility that  the event may have be en caused by [CONTACT_378159]. 
The adverse event: 
x may be judged to be due to extraneous causes such as disease or environment 
or toxic factors 
x may be judged to be due to the subject’s clinical state or other therapy being 
administered 
x is not biologically plausible 
x does not reappear or worsen when study drug is re-administered 
x does not follow a temporal sequence  from administration of study drug 
Yes = There is a reasonable possibility that the event may have been caused by [CONTACT_378159]. 
The adverse event: 
x follows a temporal sequence from  administration of study drug 
x is a known response to the study drug based on clinical or preclinical data 
x could not be explained by [CONTACT_190377] c haracteristics of the subject’s clini cal state, 
environmental or toxic factors, or other therapy administered to the subject 
x disappears or decreases upon cessation or reduction of dose of study drug 
x reappears or worsens when study drug is re-administered 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
Acerta Pharma Confidential Page 62 of 64 
 Appendix 3.  Inhibitors of CYP3A4 
Inhibitors 
Strong ( tt5-fold  
Increase in AUC) Moderate (2- to 5-fold  
Increase in AUC) Weak (1.25- to  <2-fold 
Increase in AUC) 
Boceprevir 
Chloramphenicol  
Clarithromycin  
Cobicistat  
Conivaptan  
Indinavir  
Itraconazole  
Ketoconazole  
Lopi[INVESTIGATOR_475189] e 
Nelfinavir  
Posaconazole  
Ritonavir  
Saquinavir  
Suboxone  
Telaprevir  
Telithromycin  
Voriconazole  Amprenavir 
Aprepi[INVESTIGATOR_475190]1 
Imatinib  
Verapamil  Alprazolam 
Amiodaro ne 
Amlodipi[INVESTIGATOR_475191]1  
Goldenseal1  
Isoniazid  
Nilotinib  
Oral contraceptives  
Ranitidine  
Ranolazine  
Tipranavir  
Zileuton 
Inducers 
Strong ( tt80%  
Decrease in AUC) Moderate (50 to 80% 
Decrease in AUC) Weak (20 to 50% 
Decrease in AUC) 
Avasimibe 
Carbamazepi[INVESTIGATOR_475192]. John’s wort1 Bosentan 
Efavirenz  
Etravirine  
Modafinil  
Nafcillin  Amprenavir 
Aprepi[INVESTIGATOR_475193]1 
Pi[INVESTIGATOR_475194] 
1. Food or herbal product 
2. Primary reference: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Devel opmentResources/DrugInteractionsLabeling/ucm0
[ZIP_CODE].htm  
 
 
  
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
 
Acerta Pharma Confidential Page 63 of 64 Appendix 4.  Schedule of Assessments 
 Screeninga Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycles 5-12b Follow Upc LTFUq 
  Days (± 2) Days (± 2) Days (± 2) Days (± 2) Days (± 2) Days (± 2)  
1 8 15 22 28 15 28 28 28 28   
Informed consent x             
Confirm eligibility x             
Medical history x             
PEd/Vital signse/Weight x x x x x x x x x x x x  
ECOG status x x x x x x x x x x x x  
ECGf x x  
Lab assessments:              
 Urine pregnancy 
testg x           x  
 Hematologyh x xr x x x x x x x x x x  
 Serum chemistryi x xr x x x x x x x x x x  
 Urinalysisj x     x  x x x Every 2 mos   
 T/B/NK cell countk  xr x x  x  x   Every 6 mos   
 Disease markersl x  x  x  x x x Every 2 mos x  
Bone marrow 
(aspi[INVESTIGATOR_337]/biopsy) 
/Skeletal surveyp x       Bone 
Marrow 
only As 
clinically 
indicated 
or to 
confirm a 
CR As 
clinically 
indicated 
or to 
confirm a 
CR As clinically 
indicated or to 
confirm a CR   
 Pharmacodynamics  xm xm   xn  xn    x  
 Pharmacokineticso  x x x x x        
ACP-196/ 
dexamethasone  
dispensed  x x x x x x x x x x   
Study drug compliance  x x x x x x x x x x   
Tumor assessmentp x     x  x x x x   
Concomitant 
medications x x x x x x x x x x x x  
Adverse events x x x x x x x x x x x  
Time-to-next treatment             x 
Abbreviations: CR = complete remission; ECG = electrocardiogram, ECOG = Eastern Cooperative Oncology Group, Ig = immunoglobulin ; mos = months; PE = 
physical exam; LTFU = long-term follow up 
Product: ACP-196 
Date: 11 July 2014 
Protocol: ACE-MY-001 
 
 
 
Acerta Pharma Confidential Page 64 of 64 Footnotes for ACE-MY-001 Schedule of Study Activities : 
a.  Screening tests should be performed within [ADDRESS_609427] not progressed while receiving study drug treatment, may be eligible to enroll into a long-term follow  up study and continue to receive ACP-196. 
c. A 30-day (± 7 days) safety follow-up visit is required when subjects discontinue study drug unless they start another antica ncer therapy within that timeframe. 
d. The screening physical examinat ion will incl ude, at a minimum, the general appearanc e of the subject, height (screening only ) and weight, and examination of the skin, 
eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system.  Sy mptom-directed physical exams are done 
thereafter.   
e. Vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and temperature)  will be assessed after the subject has rested in the sitting position.   
f. Subjects should be in supi[INVESTIGATOR_475171] ≥ 10 minutes before study-related ECGs.  12- lead electrocardiogram (ECG) will be done in triplicate ( ≥ 1 minute apart) 
at screening.  The calculated QTc average of the [ADDRESS_609428] be ≤ [ADDRESS_609429] be ruled out by [CONTACT_375842]. 
h. Hematology includes complete blood count with differential and platelet and reticulocyte counts. Cycle 1 Day 1 hematology do es not need to be repeated if screening 
hematology was within 5 days. 
i. Serum chemistry: albumin, alkaline phosphatase, bone-specific alkaline phosphatase, alanine transaminase (ALT), aspartate am inotransferase (AST), bicarbonate, blood 
urea nitrogen (BUN), calcium, chloride, creatinine, C-terminal telopeptide, glucose, lactate dehydrogenase (LDH), magnesium, ph osphate, potassium, sodium, total bilirubin, 
total protein, and uric acid. Cycle 1 Day 1 serum chemistry does not need to be repeated if screening hematology was within 5 d ays. 
j. Urinalysis: pH, ketones, specific gr avity, bilirubin , protein, blood, N- terminal telopeptide, and glucose.  
k. T/B/NK cell count (ie, CD3, CD4, CD8, CD19, CD16/56).  During Cycle 5-12, only done at end of Cycle [ADDRESS_609430] of myeloma disease markers. 
m. Pharmacodynamic samples are drawn predose and 4 hours (±10 minutes) postdose on the days indicated. Note: These timepoints a re relative to the morning dose. 
n. Pharmacodynamic samples are drawn predose on the days indicated. 
o. Pharmacokinetic samples are drawn per Table 4-1 . 
p Refer to Section 4-2.  Bone marrow aspi[INVESTIGATOR_337]/biopsy and skeletal survey are required at baseline (ie, before the first dose of  study drug).  Thereafter they are required as 
indicated in the table above. 
q. Subjects who discontinue study therapy will contin ue on study for fo llow-up of safety and time-to-next therapy for myeloma u nless they withdraw consent for further follow-
up. 
r. The indicated samples at this timepoint (Cycle 1 Day 1) must be drawn predose. 
 